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ABSTRACT  
Significance: Oxidative stress is thought to play a key role in the development of intestinal damage in 
Inflammatory Bowel Disease (IBD), because of its primary involvement in intestinal cells’ aberrant 
immune and inflammatory responses to dietary antigens and to the commensal bacteria. Recent 
advances: During the active disease phase, activated leukocytes generate a wide spectrum of pro-
inflammatory cytokines, but also excess oxidative reactions, which markedly alter the redox 
equilibrium within the gut mucosa, and maintain inflammation by inducing redox-sensitive signaling 
pathways and transcription factors. Moreover, several inflammatory molecules generate further 
oxidation products, leading to a self-sustaining and auto-amplifying vicious circle, which eventually 
impair the gut barrier. Critical issues: The current treatment of IBD consists of long-term 
conventional anti-inflammatory therapy and often leads to drug refractoriness or intolerance, limiting 
patients’ quality of life. Immune modulators or anti-TNFα antibodies have recently been used, but all 
carry the risk of significant side effects and treatment poor response. Future Directions: Recent 
developments in molecular medicine point to the possibility of treating the oxidative stress associated 
with IBD, by designing a proper supplementation of specific lipids to induce local production of anti-
inflammatory derivatives, as well as developing biological therapies that target selective molecules 
(i.e. NF-B, NADPH oxidase, prohibitins or inflammasomes) involved in redox signaling. The 
clinical significance of oxidative stress in IBD is now becoming clear, and may soon lead to important 
new therapeutic options to lessen intestinal damage in this disease. 
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I. INTRODUCTION  
IBD comprises a group of idiopathic chronic inflammatory intestinal conditions of which 
Crohn’s disease (CD) and ulcerative colitis (UC) are the two main categories.  
IBD is considered to be a chronic intermittent inflammatory process, in which active disease 
alternates with variable periods of remission, the evidence of tissue lesions being differentially 
localized in CD and UC. 
Intestinal tissue in CD is characterized by patchy transmural inflammation, with the presence 
of lesions along the whole tract of the gut mucosa. Multiple granulomas, especially localized in the 
ileo-cecal or ileo-colic areas, and extra-intestinal complications are common features in these patients. 
UC patients show diffuse inflammation limited to the superficial layers of the colonic mucosa, and 
relapse at least once within ten years from diagnosis. In addition, they are prone to developing 
pancolitis with megacolon and colon carcinoma, as well as extra-intestinal complications. As far as 
the etiopathogenesis is concerned IBD appears to depend on the interaction between genetic 
alterations and environmental stressors that induce an aberrant response by innate, adaptive and 
tolerogenic immunity of the intestinal mucosa to dietary antigens and/or commensal bacteria. 
Chronic inflammation in IBD is characterized by massive leukocyte infiltration of the gut. 
Upon activation, these cells produce a wide spectrum of pro-inflammatory cytokines but also an 
excessive amount of reactive oxygen (ROS) and nitrogen (RNS) species. Importantly, the marked and 
sustained alteration of redox equilibrium within the gut mucosa towards an excess of oxidative 
reactions, i.e. a condition of oxidative stress, plays a pivotal role in the expression and the progression 
of IBD. Oxidative stress maintains active inflammation within the intestinal mucosa by inducing 
redox-sensitive signaling pathways and transcription factors. Conversely, several inflammatory 
reactions and molecules generate further amounts of ROS, leading to a self-sustaining and auto-
amplifying vicious circle that in turn leads to structural and functional impairment of the gut barrier, 
and affects its responsiveness to commensal flora and pathogens present in the lumen. 
The highest incidence rates and prevalence of IBD and UC have been reported in the United 
States and Northern Europe. The incidence of IBD is now also increasing in other regions of Europe 
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and Asia, in direct correlation to economic development and industrialization. Other factors that 
influence the incidence rate of the disease are gender, age and ethnicity. CD is more frequent in 
females, while UC is much more frequent in males. The age peak for CD is 20-30, while it is 30-40 
for UC. Different susceptibilities to IBD have been reported for the Jews, as well as for the whites and 
African Americans (high), Hispanic and Asian Americans (both increasing), but with marked 
variations induced by migration (49). Concerning the likely combination of genetic and environmental 
factors in IBD pathogenesis, variants of multiple genes involved in microbe recognition, lymphocyte 
activation, cytokine signaling and intestinal epithelial defense, could make a given population more 
susceptible to environmental attack (190). 
This review, after a rapid survey of the current understanding of the mechanisms that regulate 
intestinal barrier integrity and function, as well as its pathologic alterations during the development of 
IBD, focuses on the pathogenetic roles played by the multiple redox changes that occur during the 
development of this disease process. The main indications and suggestions for targeted therapy of 
IBD that arise from the recent molecular studies and in particular from the redox reconsideration of 
the disease are also examined and discussed.  
 
II. MOLECULAR MECHANISMS OF INTESTINAL BARRIER DYSFUNCTION IN IBD  
In IBD, both the structure and the function of the intestinal barrier are compromised, with a 
loss of tolerance to normal dietary components and/or excessive response to pathogens, which all 
contribute to amplify the overall inflammatory process. 
  
II A. Alteration of the Apical Junctional Complex  
The cytokines interferon γ (IFNγ) and tumor necrosis factor α (TNFα), which are central 
mediators of intestinal inflammation, are able to damage epithelial barrier functions independently of 
their pro-apoptotic action. These cytokines have been shown to disassemble tight junctions (TJs) of 
apical junctional complex (AJC) and to enhance paracellular permeability, by promoting 
internalization and cellular redistribution of their junctional adhesion molecule (JAM)-A, occludin 
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and claudins1, but not of zonula occludens-1 (ZO-1) or adherens junction (AJ) proteins in T-84 cells 
(32). 
A dramatic loss of JAM-A expression has been found both in CD and UC, and also in dextran 
sodium sulfate (DSS)-induced experimental colitis in mice. Consistently, JAM-A null mice, in which 
colitis was induced by DSS treatment, showed a marked increase in epithelial permeability and 
inflammatory cytokine production (272).  
Redistribution of claudins has also been observed in IBD: while claudins-3 and -4 seem to be 
reduced, or almost entirely redistributed to the basolateral surface of the epithelium, the expression of 
claudin-2 increased predominantly in cells along inflamed crypts of both UC and CD patients. 
Interestingly, claudin-2 was up-regulated in T-84 cells by Interleukin (IL)-13, which is a key effector 
of the T helper (Th)2 response and is produced in large amounts in the lamina propria of UC patients 
(205). In these individuals, IL-13 has been found to induce apoptosis of colonic epithelial cells and to 
lower transepithelial resistance by increasing paracellular permeability (92). 
It is still unclear whether damage to the transmembrane proteins that are components of 
junctions should be considered a cause or a consequence of intestinal inflammation. Under 
inflammatory conditions, as in IBD patients, endocytosis of junctional molecules increases, and 
intracellular redistribution may cause a breakdown of the protective barrier. This process may 
enhance production of inflammatory infiltrate and of cytokines, which further contribute to 
amplifying epithelial barrier damage.  
 
II B. Impairment of intestinal antimicrobial peptides  
The intestinal mucosa is covered by a thick layer of secreted mucus containing antimicrobial 
molecules, which protect the mucosal surface against microbial invasion. It has been suggested that a 
possible cause of IBD is a defect in mucus secretion that can expose the mucosa not only to 
pathogenic microbes, but also to assault by commensal bacteria that become pathogens, and 
contribute to chronic inflammatory response. Several mucin glycoproteins and antimicrobial peptides, 
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such as defensins, cathelicidins, lactotransferrin, and lysozymes, are highly effective in the host 
defense. 
Mucins (MUCs), trefoil factors (TFFs) and resistin-like molecule β (RELMβ), are produced 
by goblet cells in varying proportions throughout the human gastrointestinal tract. Up to 20 different 
mucin genes have been identified: MUC2 was the first human secretory mucin to be identified and 
widely studied. Mice with missense mutations in the MUC2 gene or MUC2-deficient animals 
spontaneously develop increased susceptibility to colitis (90, 270). 
A significant down-regulation of MUC2 in CD and MUC12 gene expression has been found 
in colon tissue in both CD and UC (171). MUC1, MUC3 and MUC19 have also been identified as 
possible susceptibility genes for IBD (165, 231).  
TFF3 interacts with MUC2 by enhancing the stability of the mucin layer, thus protecting 
epithelial cells from intestinal stressors (124). TFF3-deficient mice show a higher susceptibility to 
DSS-induced colitis. Conversely, TFF3 overexpression increases resistance to intestinal damage in 
mice (126). RELMβ is also strongly expressed in intestinal goblet cells by colonization with normal 
enteric bacteria, and in mice with gastrointestinal infections or IBD. It is involved in the induction of 
CD4
+
 T cell-dependent adaptive immune response (179). 
Paneth cells control bacterial attack of the host mucosa, regulating bacterial numbers by 
secreting various defensins, as well as lysozyme and secretory phospholipase A2 (Plase A2). Defensins 
provide an important antimicrobial function, because of their ability to regulate the adherence of 
specific bacteria to the intestinal epithelium. In humans, two α-defensins secreted under normal 
conditions by Paneth cells have been identified, namely human α-defensins (HD)-5 and HD-6 (130). 
Reduced expression of HD-5 and HD-6 by Paneth cells has been observed in ileal mucosa from CD 
patients, with no changes in lysozyme or secretory Plase A2 expression (283).  
The importance of human β-defensins (HBDs) in IBD pathogenesis is still unclear. HBD-1 is 
costitutively expressed in small amounts in normal colonic epithelial cells. HBD-1 has been found to 
be decreased in the inflammed mucosa of IBD patients. In contrast, HBD-2 was strongly induced in 
the inflamed mucosa of UC, but not CD, patients (210, 284). Defensin production is under the control 
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of the molecules involved in commensal and pathogenic bacteria recognition, namely nucleotide-
binding oligomerization domain (NOD)-like receptors and Toll-like receptors (TLRs) (see below). 
Alterations to HD and HBD expression are reported to be associated with caspase activation and 
recruitment domain 15 (CARD15)/NOD2 mutations, which in turn are thought to be responsible for 
an increased susceptibility to CD (278, 284).  
Cathelicidins are antimicrobial peptides, synthesised by neutrophils, macrophages and 
intestinal epithelial cells (IEC), which modulate microbial growth, wound healing, and inflammation; 
they counteract gastrointestinal pathogens, including several Helicobacter strains, Shigella, 
Salmonella and Candida albicans (102). It is unknown whether they are associated with IBD; 
however, recent experimental studies have revealed a new role for these peptides in UC therapy. 
Administration of a synthetic mouse cathelicidin significantly prevented the development of DSS-
induced ulcerative colitis in mice (249). 
The response to commensal and pathogens bacteria and viruses of this antimicrobial peptide is 
mainly mediated by selective activation of the TLR-nuclear factor-κB (NF-κB) pathway (124). In fact, 
MUC2 has been shown to have NF-κB binding sites in the promoter. A number of Lactobacillus 
strains up-regulate HBD-2 via induction of NF-κB, activator protein 1 (AP-1) and mitogen-activated 
protein kinase (MAPK) signaling pathways (224). Recently, because of TFF3 ability to inhibit TNFα 
production, TLR4 and NF-κB in a well-established model of trinitrobenzene sulfonic acid (TNBS)-
induced colitis in mice, TFF3 has been hypothesized to be a potent agent in controlling IBD (258). 
 
II C. Impairment of receptor-mediated microbial recognition  
The different dietary antigens are recognized by pathogen recognition receptors (PRRs), 
which discriminate among pathogenic bacteria, commensal bacteria, and nutrients. PRRs recognize 
conserved molecular motifs known as pathogen-associated molecular patterns (PAMPs) or microbe-
associated molecular patterns (MAMPs). PRRs include membrane bound TLRs, the RNA helicase 
family of receptors, i.e. retinoic acid inducible gene I (RIG-I)-like receptors (RLRs) and cytoplasmic 
NOD-like receptors (NLRs). TLRs recognize bacteria-derived lipopolysaccharide (LPS), flagellin or 
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unmethylated cytosine nucleotide next to guanine separated by a phosphate (CpG); RIG-I and the 
melanoma differentiation-associated gene 5 (MDA5) belong to the RNA helicase family of receptors, 
and are primary sensors of RNA viruses; NLRs recognize bacteria-derived peptoglycans (285). 
 
1) Toll-like receptors and activation of redox-sensitive transcription factors  
TLRs are expressed in different cell types of the gastrointestinal tract, including IEC, 
macrophages, Paneth and goblet cells, enteroendocrine cells, and immune cells, such as dendritic cells 
and CD4
+
 T cells. They selectively recognize different pathogens: lipopeptides are recognized by 
TLR2, viral-derived double-stranded RNA by TLR3, LPS is detected by TLR4, TLR5 recognizes 
flagellin derived from Salmonella species, and TLR9 is activated by CpG DNA dinucleotides. 
Most TLRs, except for TLR3, activate the major signaling pathway dependent on the common 
adaptor protein, known as myeloid differentiation primary response gene 88 (MyD88), which is 
recruited through its Toll-IL-1-resistance (TIR) domain, to interact with the TIR domain of TLRs. 
This process culminates in the activation of NF-B, a redox-sensitive transcription factor playing a 
major role in the inflammatory process. Alternatively, TLR3 and TLR4 may signal in a MyD88-
independent pathway, recruiting another adaptor molecule, TIR domain-containing adaptor-inducing 
IFNβ (TRIF); this adapter leads to activation of the transcription factor interferon regulatory factor 3 
(IRF3) and results in activation of type I IFNs, particularly IFNβ (290). Further, TLR2 and TLR4 
appear to be implicated in protecting the epithelial barrier against pathogens, stimulating the 
expression of intestinal cell HBD-2 by activating the c-Jun N-terminal kinase (JNK)-AP-1 pathway 
(277) and by activating autophagy processes; TLR2 and TLR4 accumulate on the autophagosome 
where they recognize microbial cell-wall components (5, 183). Notably, AP-1 is another transcription 
factor whose activation depends on the cellular and tissue redox state.  
Sustained hyper-activation of TLRs occurs in the tissue lesions of most inflammatory 
disorders, and thus dysregulated TLR-mediated cell signaling, often resulting in hyper-activation of 
NF-κB and other redox-sensitive transcription peptides, may also contribute to the pathogenesis of 
IBD (89). 
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2) Retinoic acid inducible gene I (RIG-I)-like receptors   
As far as RLRs are concerned, RIG-I and MDA5 are cytosolic receptors belonging to the 
RNA helicase family, which are primary sensors of RNA viruses in the early phase of infection, and 
are constitutively expressed in the IEC. Interestingly, it has been shown that RIG-I is closely 
associated with the actin cytoskeleton in cultured IEC, and localizes predominantly at the apical-
lateral cell junctions of both polarized human colorectal adenocarcinoma CaCo-2 cells and healthy 
human colon and small intestine. Besides playing a role in immune recognition, RIG-I has been 
suggested to be involved in regulating cellular motility and migration (176). 
RLRs induce IFN production in response to virus infection, through the common adaptor 
protein interferon-β promoter stimulator-1, which signals interferon regulatory factors IRF3, IRF7, 
and NF-κB. RLRs interact with different signal transduction pathways, such as just another kinase 
(JAK) and the signal transducer and activator of transcription (STAT), amplifying the IFN response, 
and they provide signaling crosstalk to enhance TLR expression and function (159). 
 
3) NOD-like receptors and their modulation by reactive oxygen species 
NLRs are emerging as crucial regulators of the inflammatory response to commensal 
microflora in the gut. NLRs are cytoplasmic proteins characterized by the presence of N-terminal 
protein-protein interaction domains (such as CARD, pyrin and baculovirus inhibitor of apoptosis 
protein repeat domains), a central conserved NOD domain, and the carboxy-terminal leucine-rich 
repeats (LRRs), which are involved in microbial sensing. Among the different NLRs (23 members in 
humans), NOD1 and NOD2 have been most widely studied in the intestine. NOD1 is ubiquitously 
expressed in intestinal cells, including IEC, whereas high levels of NOD2 are constitutively expressed 
in phagocytes and dendritic cells, and are induced in Paneth cells of the small intestine by 
inflammatory stimuli. These NLRs recognize distinct PAMPs: NOD1 recognizes γ-glutamyl-meso-
diaminopimelic acid, while NOD2 recognizes muramyl dipeptide. They are actively involved in the 
recognition and activation of inflammatory and immune responses against intestinal pathogenic 
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bacteria, such as Enterobacteriacee, Helicobacter pylori, and Listeria monocytogenes. Upon 
activation, NOD1 and NOD2 form cytoplasm platforms called “NOD signalosomes”, which activate 
MAPKs and NF-κB, by recruiting the receptor-interacting protein 2 (RIP2), and producing pro-
inflammatory cytokines (e.g. IL-8 and IL-1β) (74). NOD2-dependent NF-κB activity appears to be 
closely related to the perturbation of actin dynamics in cells (145). Through NF-κB activation, NOD2 
induces the release of antibacterial molecules produced in Paneth cells, such as HD.  
Another set of NLRs responds to different stimuli to form protein complexes known as 
inflammasomes, which are involved in the activation of pro-caspase-1. Caspase-1 is considered to be 
pro-inflammatory, because it activates immature forms of the IL-1 family (IL-1β, IL-18 and IL-33) 
and induces IL-1 secretion. There are different groups of inflammasomes, the main ones being 
nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain containing 1 and 3  
(NLRP1, NLRP3), and IL-1β converting enzyme-protease activating factor (IPAF). 
Of interest, ROS are crucial in up-regulating NLRP3 inflammasome activity. Most of the 
danger associated molecular patterns (DAMPs) listed above can activate phagocytic cells, with a 
consequent overproduction of ROS. For example, enhanced generation of ROS has been observed 
after macrophage-like THP1 cell exposition to asbestos and silica; NLRP3 activation is triggered by 
ROS produced by up-regulated NADPH oxidase (61) (See Sections VII B and C).  
Inflammasomes may play an important role in IBD, especially because of their ability to 
activate pro-inflammatory caspases. Recent reports have hypothesized a relationship between NLRPs 
dysregulation and IBD. Activation of NLRP1 has been observed in metaplastic Paneth cells in the 
colon of IBD patients (237). Furthermore, NLRP3 inflammasome has been found crucial in inducing 
experimental colitis in mice: NLRP3
-/-
 mice developed a markedly less severe clinical picture 
following DSS treatment (19). NLRP3 was found to be overexpressed both in the experimental model 
of TNBS-induced colitis in mice, and in the damaged mucosa of human CD patients. However, the 
precise role of NLRP3 inflammasome in IBD is still under debate. Recent reports have shown that 
NLRP3 inflammasome-induced cytokine production might, under specific conditions, confer 
protection against experimental colitis (95, 296). 
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In conclusion, consistently impaired signaling by TLRs and NLRs takes place during the 
development of IBD, with consequent enhancement and endorsement of inflammatory reactions 
within the gut wall (see the schematic representation in Figure 1).  
 
II D. The role of the endothelium in IBD progression  
IBD development comprises alternate phases of tissue damage and tissue repair. The latter 
process implies neoangiogenesis, then the synthesis of pro-angiogenic factors, such as vascular 
endothelial growth factor (VEGF) and fibroblast growth factor (FGF), by macrophages and 
lymphocytes recruited in the inflammatory areas. Endothelial cells of the inflamed capillaries also 
contribute to the production of angiogenic factors. 
Intestinal endothelial cells express CD40 and CD40L proteins, which belong to the TNF 
receptor superfamily, and which have co-stimulatory activity for immune cells, such as T cells, and 
for non-immune cells. CD40 pathway activation leads to the amplification of immune and 
inflammatory responses. In both ulcerative colitis and Crohn’s disease, CD40 and CD40L are 
overexpressed, especially in severely inflamed mucosa (52). 
Bacterial antigens that can penetrate the epithelial barrier may reach the endothelium, where 
they activate PRR signaling: various TLRs and both NOD1 and NOD2 have also been found 
expressed on the surface of endothelial cells, and are up-regulated by specific bacterial fragments. The 
possibility of hyper-activation of PRRs in inflammatory conditions suggests further function of 
endothelial cells as a second barrier against antigens (91). 
Expansion of the microvasculature in inflamed intestinal tissue stimulates the recruitment of 
pro-inflammatory mediators, thus further amplifying inflammation and tissue damage.  
 
III. PRO-INFLAMMATORY AND ANTI-INFLAMMATORY CYTOKINES IN IBD 
Under normal conditions, inflammatory reactions within the intestinal mucosa are 
quantitatively and temporally controlled by a delicate balance between pro-inflammatory (TNFα, 
IFNγ, IL-1, IL-6, IL-8, IL-17, IL-23) and anti-inflammatory (IL-4, IL-10, IL-11, TGFβ) cytokines. 
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The main hypothesis on the development and progression of IBD is based on impairment of 
immune tolerance to the gut commensal microbiota, thought to be due to a genetic predisposition of 
the host, which leads to chronic intestinal inflammation and mucosal damage. The chronic 
inflammation leads to massive gut infiltration by granulocytes and macrophages, with different 
features in CD and UC, as depicted in Figures 2 and 3. These cells produce large amounts of pro-
inflammatory cytokines, chemokines, and ROS/RNS intermediates, which the anti-inflammatory 
cytokines and antioxidant molecules are unable to counteract. 
Important is the role played by immune cells, which also mediate inflammatory reactions 
through the expression and synthesis of different cytokines. In IBD patients, the inflamed mucosa 
shows active infiltration of CD4
+
 T Th lymphocytes, which are responsible for maintaining chronic 
inflammation. In general, naïve CD4
+
 Th cells proliferate and differentiate into different subsets upon 
stimulation by specific cytokines: three different Th, i.e. Th1, Th2, and Th17, and a subpopulation of 
regulatory T lymphocytes (Tregs) are formed. Each T cell subset secretes specific cytokines able to 
differentially modulate inflammatory reactions. 
 
III A. Cytokines produced by T helper cells 
Lymphocytes Th1 are the main mediators of type1 immunity. They act against intracellular 
pathogens by means of intense phagocyte activity and produce IL-2, IFNγ, and TNFα; the same 
cytokines amplify this response by inducing macrophages to release further amounts of TNFα, IL-6, 
and IL-1β. Th1 cells and related cytokines are predominant in active CD. The histopathological 
features of CD are shown in Figure 4. The expressions of IL-1β, IL-6 and TNFα are increased in the 
affected mucosa of patients with active IBD. Conversely, the same patients showed decreased levels 
of IL-2 and IFNγ in the peripheral blood cells (209).  
Among the various cytokines produced during the Th1 response, the overexpression of TNFα 
undoubtedly plays a key role in the induction of intestinal damage, especially in CD patients. This 
molecule can trigger pro-inflammatory and survival pathways, as well as the apoptotic process. Its 
effect probably depends on the amount and time of cell exposure to the cytokine, the type of receptor 
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that binds TNFα, and the sequence of events that take place upon ligand binding. Regulation of NF-
κB activity appears to be fundamental in determining the specific cellular response to TNFα (211). 
Based on the extensive research that has been done into the biological activity of this molecule, the 
use of TNFα blockers in treating CD has recently generated considerable interest. 
Cytokines produced by Th2 cells are selectively increased in the inflamed mucosa of UC. 
These cells synthesize IL-4, IL-5, IL-10, and IL-13, and are required for humoral response (185). Th2 
lymphocytes support the synthesis of all types of immunoglobulins, by secreting IL-4 and IL-5, and 
inhibit Th1-activated macrophages by secreting IL-4, IL-10 and IL-13. IL-4 and IL-10 are considered 
anti-inflammatory cytokines. IL-4 secretion by dendritic cells is also a fundamental up-stream effector 
of Th2 differentiation. Conversely, IL-13 is considered a pro-inflammatory molecule mostly 
implicated in allergic inflammation. Mononuclear cells from intestinal lamina propria of UC patients 
show high levels of Th2-related IL-13 (92).  
The function of specific lymphocytes is more complicated. For example, both Th1 and Th2 
cells can increase transcription of MUC2, through NF-κB activation. Th2 cells utilize IL-4 and IL-13, 
which mediate NF-κB-dependent MUC2 transcription through MAPK signaling. On the other hand, 
Th1 cells up-regulate NF-κB-dependent MUC2 transcription through the TNFα-phosphatidylinositol 3 
kinase (PI3K)/Akt cell pathway (124). 
Lymphocytes Th17 secrete pro-inflammatory cytokines IL-17, IL-22, TNFα and IL-6, and 
have been identified as potent inducers of tissue inflammation because they recruit neutrophils and 
macrophages when Th1-type and Th2-type immunity fails to clear pathogens (156). Essential for 
maintaining Th17 response is the cytokine IL-23, and is characteristically associated with Th17 cell 
lineage differentiation and expansion. Furthermore, IL-23 counteracts anti-inflammatory pathways, by 
inhibiting the generation of inducible T regulatory cells, and reducing IL-10 secretion by other CD4
+
 
T cells (175). 
 
IIIB. Cytokines produced by T regulatory cells 
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Treg cell subsets are activated by the two anti-inflammatory cytokines IL-10 and transforming 
growth factor β (TGFβ), mainly those produced by dendritic cells (46). They are characterized by the 
expression of the transcription factor forkhead box protein 3 (FoxP3), and show the so-called 
CD4
+
CD25(high) phenotype in humans. They are thus also termed CD4
+
CD25(high)FoxP3
+
 cells. 
During the active phase of the disease, both CD and UC patients showed a decreased number of 
peripheral suppressive Tregs, whereas an expansion of the Treg population has been found in mucosal 
lymphoid tissues of these patients (20, 295).  
Tregs may indirectly control the production of pro-inflammatory TNFα, through the T-box 
transcription factor T-bet. T-bet deficient mice developing severe colitis showed a selective increase 
of TNFα production by colon dendritic cells. This finding suggests that colonic T-bet deficiency in the 
dendritic cells may confer genetic susceptibility to aberrant TNFα-related inflammatory response, by 
triggering strong apoptotic processes in the intestinal epithelium, which becomes more sensitive to 
pathogenic microbiota (79).  
IL-10 and TGFβ have long been known as the two main cytokines involved in the negative 
regulation of inflammation and immune response, thus contributing to the maintenance of gut 
homeostasis.  
The protective role of IL-10 in IBD had already been demonstrated in IL-10 knock-out mouse 
model of colitis, which required gut microbial intervention to develop inflammation. This gave rise to 
the idea that IL-10 could be involved in restricting the mucosal immune response to the enteric flora 
(138). IL-10 inhibits pro-inflammatory cytokine expression and nitric oxide (NO) generation in 
macrophages. It has been observed that IL-10 activates different cell signaling pathways in order to 
exert its anti-inflammatory action. In particular, it promotes proliferation in selected immune cells 
through JAK/STAT3 or PI3K⁄Akt pathways. IL-10 can also inhibit TNFα production and 
hemeoxygenase-1 induction in macrophages through the activation of p38 MAPK pathway (201). 
Impairment of IL-10 signaling has been reported in a pediatric group of IBD patients with granuloma-
positive colitis (20). These findings suggest IL-10 is a potential therapeutic target for IBD, although 
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no apparent beneficial effect of IL-10 therapy has yet been observed in a number of human clinical 
trials, probably due to IL-10 instability and its short half-life (114). 
The TGFβ cytokine family is recognized as a key regulator of cell proliferation, 
differentiation and apoptosis in the intestinal mucosa, as well as of the control of immunological self-
tolerance, inducing Treg activation by up-regulating FoxP3; high levels of the TGFβ1 isoform have 
been found to inhibit induction of Th17 cells (297). TGFβ1 is very probably implicated in organ 
fibrosis, and may be overexpressed by CD stricture fibroblasts. Tissue levels of this cytokine are 
transiently diminished in the early phases of IBD, whereas they increase at later disease stages 
(33,110). It has been hypothesized that the TGFβ1 cell signaling pathway is defective in IBD: up-
regulation of Smad7, the intracellular inhibitory molecule of the TGFβ1 signal, followed by a block of 
phosphorylation of the principal transduction molecule Smad3, have been reported to occur in murine 
IBD models (173). Finally, TGFβ1 has long been recognized to possess marked pro-angiogenic 
activity, so that the pleiotropic action of this cytokine appears to play a primary role in the 
chronicization of IBD (Figure 5). 
 
IV. THE MAIN GENETIC POLYMORPHISMS ASSOCIATED WITH IBD  
Although the precise etiology of IBD remains unclear, genome-wide association studies have 
identified more than 100 loci that are significantly associated with IBD, and that confer susceptibility 
to this disease. However, the contribution of genetic factors to IBD is complex: several putative 
susceptibility genes are involved in the pathogenesis of IBD and may interact with one another (271). 
Approximately 70 loci are associated with CD and 50 with UC, spanning pathways involved in the 
host defence (17, 76, 103, 236). Although CD and UC share some susceptibility genes, implicated in 
various different intestinal functions, they also have distinct association patterns. In this connection, 
CD is associated with NOD2 and with genes that regulate autophagy, whereas the predominant 
association in UC is with the human leukocyte antigen (HLA) class II genes (165), as well as with 
genes involved in the epithelial defense function, such as cadherin , laminin β1, and MUC19 (6, 165).  
Biasi 
18 
 
The first and most significant genetic variant reported to be associated with an increased 
susceptibility to CD, but not to UC, is CARD15/NOD2; this can lead to defective mucosal recognition 
of bacteria, with persistent activation of NF-κB and inflammatory reactions (191). However, advances 
in molecular genetics indicate that mutations in NOD2 alone are not sufficient to cause CD. The 
association of CARD15/NOD2 variants with genes encoding for autophagy process, in particular with 
autophagy-related protein (ATG16L), has been widely reported (17). Other essential genes for 
autophagy, i.e. immunity-related guanosine triphosphatase M (IRGM) (164) or leucine-rich repeat 
kinase 2 (LRRK2) (267) have also been associated to CD.  
Among HLA class II genes, which regulate interactions between host cells and pathogens, 
DRB1*0103 and DRB1*1502 have been reported to confer an increased risk of UC, whereas 
DRB1*0410 and DQB*0401 confer a risk for CD. Increased risk of UC has also been associated to 
B52 HLA class I gene, whereas Cw8 and B21 confer a risk for CD (68).  
Additional multiple variants have been observed in CD and/or UC, associated with the 
potential induction of defective innate immune pathways. A mutation of the D299G/TLR4 gene 
appears to be associated with some Caucasian CD and UC populations (75). A common variant in the 
NLRP3 region gene has been found to be closely associated with the risk of CD (273).  
IL-23R polymorphisms have been associated with CD (152). IL-23R and IL-17A variants have 
been linked to both UC and CD in part of the Korean population, and a significant polymorphism in 
the promoter region of IL-17A has been identified (123). Other susceptibility genes involved in the IL-
23 pathway, such as IL-12B, JAK2, and STAT3, have also been associated with CD (280). IL-22 has 
recently been named as a potential susceptibility gene in UC (236), and polymorphisms of IL-10 
receptor 2, which is shared by both IL-10 and IL-22, has been found in children affected by early-
onset enterocolitis (82).  
Different IBD-associated risk loci are reported to be shared by CD and UC; however, findings 
from human studies are still insufficient to draw any conclusions. 
 
V. REDOX IMBALANCE IN IBD  
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The application of modern molecular biology to the investigation of IBD pathogenesis, 
employing murine experimental models that mimic the disease’s pathophysiology and biopsies of 
patients’ affected mucosa, has provided new insights into an old problem: the actual role of redox 
imbalance in disease initiation and progression.  
 
V A. Antioxidant defenses in IBD 
  1) Alteration of redox couples in the IBD-affected intestinal tract 
The redox state of the intestinal epithelium plays a fundamental role in maintaining cell integrity 
and function, modulating signal transduction, absorbing nutrients, and interacting with luminal 
microflora. Key players in the intestinal redox biology appear to be three redox couples, namely 
reduced glutathione/glutathione disulfide (GSH/GSSG), cysteine/cystine (Cys/CySS) and reduced and 
oxidized thioredoxin (Trx/TrxSS). A recent review comprehensively analyzed their physiological role 
and function (42).  
The antioxidant system, represented by glutathione and glutathione-related molecules and 
enzymes, was probably the first to be investigated in depth in IBD patients and in relevant 
experimental models. In a cohort of 33 adult patients with active CD, Dröge’s group was the first to 
show substantial changes in GSH levels in the intestinal mucosa, namely of the ileum tract (234): 
whereas they found GSH and GSSG levels to be within the control range in red blood cells and 
circulating mononuclear cells, the GSH content of the inflamed ileum mucosa was markedly reduced, 
by about 40%. Very interestingly, the decreased GSH levels were not limited to the inflamed 
intestinal mucosa, but were also observed in bioptic samples of non-inflamed mucosa from the same 
patients (about 25% decrease). Moreover, GSSG levels were found to be very significantly increased 
only in inflamed areas, with a consequent net imbalance of the GSH/GSSG ratio. The same group 
found that γ-glutamylcysteine synthetase, the rate-limiting enzyme of GSH synthesis, was markedly 
inactivated, again showing an approximate 50% decrease in inflamed mucosa and 25% decrease in 
non-inflamed mucosa. Similar findings were obtained for γ-glutamyltransferase, an essential enzyme 
for GSH re-synthesis, which exhibited marked inactivation, with a consequent net GSH decrease, 
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especially in the inflamed mucosa (234). A net deficit in GSH synthesis was then demonstrated in the 
ileal mucosa of CD patients, which was at least in part independent of inflammation, and thus not a 
mere consequence of it. 
GSH depletion, most likely a crucial event in intestinal damage during IBD, has been fully 
confirmed by other research, both in patients and in experimental animals. In a smaller group of adult 
patients with active CD (n=18), several of whom were also malnourished, the amount of GSH 
recovered from the intestinal mucosa appeared to be diminished by about 70% versus controls. But 
again, a low concentration of GSH was observed both in inflamed and in non-inflamed mucosal 
samples. In addition, malnutrition significantly worsened the tripeptide deficiency (168). 
A decrease of GSH in the intestinal mucosa of IBD patients thus appears to be an early event 
in the natural history of the disease, not simply a consequence of overconsumption of antioxidants, 
due to the associated condition of oxidative stress. With the progression of the disease, impaired 
intestinal absorption of nutrients may accelerate and worsen the evolution of the disease process in 
many patients. This has been consistently confirmed by experimental attempts to replenish the GSH 
content of the intestinal mucosa in animal IBD models. In the case of TNBS/ethanol-induced colitis in 
rats, administration of the GSH precursor N-acetylcysteine (NAC) doubled the tripeptide pool in the 
intestinal mucosa, and reduced the extension of gut mucosa damage by 60-70% (8). A marked 
reduction of intestinal mucosa damage was also obtained in the TNBS model, both by supplementing 
the rats with a single dose of GSH before colitis induction (effect on disease onset) and by giving 
them repeated daily amounts of the tripeptide after colitis induction (effect on disease progression). In 
the first condition, GSH supplementation partly but significantly prevented lipid peroxidation and 
tissue damage; in the chronic model, daily GSH intraperitoneal injection completely restored the GSH 
loss and afforded good control of mucosal injury (158). In DSS-induced colitis in mice gut mucosal 
levels of GSH were improved by NAC treatment, and histological damage of the colonic mucosa was 
partially prevented (294). 
 With regard to the second redox couple mentioned above, i.e. Cys/CySS, again Dröge’s group 
reported a moderate decrease in plasma levels of the two amino acids, in both CD and UC patients, 
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before surgical removal of the inflamed tract, with a rapid return to normal plasma values after 
surgery. The latter finding appears to indicate that the decrease of Cys and CySS plasma levels 
observed in IBD patients was secondary to inflammation (234). IEC take up Cys, either as such from 
the diet, or through trans-sulfuration of dietary methionine. A significant proportion of the Cys 
absorbed by the gut leads to the formation of GSH. In addition, Cys is present in the functional motif 
of the major antioxidant enzymes, including Trx, and is a component of the regulatory and/or catalytic 
sites of a number of transcription factors, kinases, and phosphatases. Together with the GSH-GSSG 
couple, the Cys/CySS equilibrium regulates cell survival and function (34).  
Changes to another important redox couple, namely the reduced and the oxidized forms of 
Trx, have also been considered in the pathogenesis of IBD. Trx are small proteins containing a redox-
active disulfide/dithiol group within the conserved active site sequence Cys32-Gly-Pro-Cys35. Of the 
two main Trx found in mammals, Trx-1 has been studied more widely. It catalyzes the reversible 
reduction of disulfide bonds, deriving from oxidation of critical Cys residues in proteins. Perturbation 
of the Trx system in the intestinal mucosa of CD and UC patients has not as such yet been reported, 
and is thus still a matter of speculation. However, indirect indications of its occurrence in IBD come 
from recent findings of a marked increase of Trx-1 in the blood serum of CD and UC patients in the 
active disease phase, versus controls and versus IBD patients with inactive disease, who exhibited 
values consistently within the normal range (252). This group speculated that such a marked rise in 
serum Trx was evidence of a stimulated antioxidant host response, due to oxidative stress and 
inflammation in the gut mucosa, but the study did not provide direct proof of this. However, in a DSS 
mouse model of experimental colitis, they clearly demonstrated that preventive or therapeutic 
administration of recombinant human Trx to the affected animals resulted in a net amelioration of the 
disease state, and limited mucosal damage (252).  
Two findings support an increased level of Trx in the inflamed gut mucosa of IBD patients: i) 
expression of this protein can be induced by oxidative stress of moderate extent, an event already 
described for small intestine epithelial cells several years ago (94) and ii) the recent report of down-
regulated expression of the Trx negative regulator, known as thioredoxin interacting protein (Trxip), 
Biasi 
22 
 
within the inflamed mucosa of UC patients (251). Conversely, however, expression of Trxip has 
recently been reported to be significantly up-regulated by oxidative stress (121), but this controversial 
finding was in mice undergoing transient focal cerebral ischemia.  
 
2)  Impairment of enzymatic antioxidant defense in IBD 
IBD is characterized by marked but differing alterations of various enzymes involved in the 
oxidant/antioxidant homeostasis of IEC and mucosa. In terms of pathogenesis, important changes 
have been observed to occur in superoxide dismutase (SOD) and catalase (CAT) activities and/or 
levels in the intestinal mucosa of IBD patients. In a cohort of 19 CD and 15 UC patients, MnSOD 
level in inflamed gut mucosa increased by approximately 2.5 fold versus control mucosa, rather 
similarly in the two diseases. Notably, also in the non-inflamed IBD mucosa, MnSOD level showed 
an average increase of 56%. However, enzyme activity did not differ significantly versus controls. In 
the same group of patients, Cu/ZnSOD tissue levels increased 1.5 fold in the non-inflamed IBD 
intestinal mucosa, but not in inflamed areas. Extracellular SOD levels tended to decrease both in 
inflamed and in non-inflamed IBD mucosa (132). 
 Another study on lymphocytes, granulocytes and monocytes from peripheral blood of 20-25 
CD patients, both at disease onset and after remission, confirmed an increase in total SOD activity in 
the blood during the early clinical phases of the disease, with a return to control values after 
remission. Consistently, hydrogen peroxide H2O2 steady-state concentration in all three types of cells 
increased during the active phase of CD, returning within the control range in the inactive phase (21, 
101). All these findings indicate that total SOD activity is up-regulated in IBD patients as a reaction to 
oxidative stress and inflammation. However, the observed increase of MnSOD and Cu/ZnSOD 
protein levels in non-inflamed areas of CD and UC intestinal mucosa would suggest a possible 
increase in the generation of H2O2, i.e. the product of SOD activity, also during disease remission, and 
thus regardless of ongoing inflammatory reactions. 
In connection with the observed up-regulation of SOD in IBD, it is important to pinpoint both 
disease activity and levels of CAT, i.e. the enzyme converting 2H2O2 into 2H2O and O2. In the cohort 
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of CD patients studied by Beltran and colleagues, CAT activity measured in lymphocytes from 
patients with active disease was half that of controls. Moreover, this reduced enzyme activity 
persisted in the lymphocytes of the same patients after disease remission, and was also confirmed in 
CD patients with inactive disease (21, 101). The overall finding of an inhibited CAT activity in the 
lymphocytes of CD patients matches the evidence of reduced CAT activity in the erythrocytes of CD 
or UC patients in the active phase. On the other hand, in contrats to that observed in the lymphocytes, 
CAT activity showed normal values in the red blood cells of patients with inactive IBD (136).  
From the available literature, which indicates an increase in SOD and a decrease in CAT, at 
least in immunocompetent cells and erythrocytes from IBD patients, changes that are not strictly 
dependent on the inflammatory state of the disease, it might be hypothesized that inflammation-
independent changes of antioxidant enzymes may sustain an increased steady-state concentration of 
H2O2, and consequently of ROS, during remission of the disease process, and possibly also before its 
first clinical expression. 
Again concerning antioxidant enzymatic defenses, the observed decrease of GSH, an 
important intracellular antioxidant but also the substrate for a large family of selenium-containing 
enzymes with peroxidase activity (the glutathione peroxidases - Gpxs), might be crucial in the 
modulation of Gpxs’ role in counteracting oxidative damage, in CD and in UC. Gpx-1, a ubiquitous 
enzyme, and Gpx-2, which is gastrointestinal, recognize H2O2 as their main substrate, whereas Gpx-4, 
which is ubiquitous, shows much more affinity for lipid hydroperoxides. Of note, in the ex vivo 
evaluation of Gpx activity, the substrate GSH was added externally to perform the analytical test, 
meaning that any deficit in the mucosa was not taken into account. It would be of interest to know the 
actual levels of this enzyme within the IBD mucosa, during inactive and active disease phases. 
Despite inconsistency among different reports on Gpx activity in the peripheral blood of IBD patients 
(213), the conclusions drawn by a further study by Kruidenier and colleagues appear to be informative 
and reliable (132). This study measured activity and levels of Gpx and CAT, in the same colon 
biopsies that had been employed to analyze SOD isoenzymes. When total Gpx and CAT activity was 
evaluated in the whole IBD mucosa, both enzymes were up-regulated. In particular, in the lamina 
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propria of inflamed areas, an increased amount of CAT was detectable in phagocytes, which also 
express myeloperoxidase (MPO); on the contrary, the CAT level within the epithelium was very low, 
only a few cells expressing Gpx. These findings further point to hampered removal of H2O2 in the 
IBD colonic mucosa, particularly at the level of the epithelium. A more recent analysis of bioptic 
fragments of damaged mucosa from subjects affected by either UC or CD gave consistent results: the 
intestinal isoform of Gpx-2 was found to be up-regulated; conversely, aquaporin 8, one of the proteins 
forming pores in biomembranes and allowing the diffusion of H2O2, was found to be down-regulated 
(256). 
 
3) Antioxidant vitamins and antioxidant-related trace metals in IBD mucosa 
A number of reports are available on the level of β-carotene and vitamins A, C and E, in the 
plasma/serum of patients with CD or UC (213, 104). The large majority of these studies found a 
deficient blood content of antioxidant vitamins in IBD. In this connection, amelioration of the disease 
severity in patients supplemented with vitamin E, with or without vitamins A and C, has been 
reported (207, 2). Moreover, most reports relate to IBD in the active clinical phase, and do not 
discriminate between reduced dietary supply, due to gut malabsorption, and sacrificial consumption to 
counteract oxidative stress. Undoubtedly, both conditions may severely affect the antioxidant vitamin 
status of IBD patients, especially during activation of inflammatory and oxidative damage of the 
intestinal mucosa. For all these reasons, it would be of great interest to measure the various 
antioxidants in the blood of IBD individuals, during inactive and during remitted disease.  
In a cohort of 54 consecutive patients with CD, in remission for more than three months, Filippi 
and colleagues found that a large proportion of cases were characterized by low plasma levels of 
vitamin C (85% of patients); plasma levels of β-carotene and vitamin E were within the normal range 
in about one quarter of patients, while low levels of vitamin A were detected only in 4-5% of cases 
(70). 
More recently, antioxidant vitamins and pre-vitamins, as well as antioxidant-related trace metals, 
were measured comprehensively in a multicenter study on 132 IBD (CD and UC) patients in a 
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quiescent disease state, and in 35 patients with clinical symptoms. Of note, most of the patients with 
quiescent disease showed normal nutritional status, whereas the nutritional status of those with active 
disease was deficient. Versus healthy controls (n=45), quiescent IBD patients exhibited significantly 
lower plasma levels of vitamins E and C, as well as of several carotenoids, including β-carotene, 
lutein and lycopene. When quiescent versus active IBD patients were compared, plasma vitamin E 
levels appeared similar in the two groups, while vitamin C and the above carotenoids showed a further 
decrease during the active process (93). With regard to trace elements, plasma copper increased and 
selenium decreased in the active disease group. The latter finding confirms all previous related reports 
that consistently showed low concentrations of this mineral in the plasma of UC and CD patients 
(213). It may, also indirectly explain the repeated finding of impaired seleno-enzyme Gpx in IBD-
affected intestinal epithelium (132).  
More importantly, the significant deficit in plasma antioxidant vitamins and provitamins, in 
patients with quiescent IBD disease and normal nutritional status, did not appear to depend on either 
malabsorption or inflammation, but rather on specific dietary limitations (low intake of fruits and 
vegetables) undertaken by the patients (93).  
 
4) Dietary polyphenols and inflammation of the gut mucosa 
Besides tocopherols and tocotrienols, i.e. antioxidants bearing one phenolic ring, there are many 
other plant-derived phenols, with much stronger antioxidant power as tested in vitro, possibly due to 
their multiple phenolic rings; collectively these are termed polyphenols. Most of the compounds 
belonging to this large family are strong electron donors and metal chelators, thus able to quench or 
terminate free radicals chain reactions (149). Among the subclasses of polyphenols, those of high 
biomedical interest are the stilbenes (e.g. resveratrol), and the flavonoids. The flavonoids are further 
subdivided into anthocyanidins (e.g. malvidin), flavonols (e.g. quercetin), monomeric flavanols (e.g. 
catechin), polymeric flavanols (e.g. procyanidins), flavanones (e.g. naringenin), flavons (e.g. luteinin), 
and isoflavones (e.g. genistein, daidzein) (73, 24). In general, dietary polyphenols display poor in vivo 
bioavailability, mainly due to their scarce absorption and rapid metabolism in the gut. For this reason, 
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it is neither worth-while nor reliable to measure their concentrations in the peripheral blood; however, 
an increasing bulk of literature re-examines these compounds in terms of their possible contribution to 
the intestinal redox environment and strong anti-inflammatory potential. In IBD, the integrity of the 
intestinal mucosa and its barrier function are severely impaired, so that compounds such as 
polyphenols might more easily interact with attacking agents, and with inflammatory or immune cells. 
Based on epidemiological studies suggesting an important role of dietary flavonoids in helping to 
prevent disease processes sustained by inflammatory reactions (63, 56), a number of investigations 
have used in in vitro and in vivo experimental models to assess the effect of chronic consumption of 
polyphenols on soluble adhesion molecules and inflammatory cytokines. Using IEC lines derived 
from human colon cancer, most of the polyhenols examined, proved to significantly quench, at 
various levels, NF-B activation and nuclear translocation pathway, and also to down-regulate the 
synthesis and secretion of inflammatory cytokines including IL-6, IL-8, and monocyte chemotactic 
protein-1 (MCP-1). However, genistein and a few other flavonoids gave controversial results, and 
resveratrol even appeared to up-regulate IL-8 secretion by colonic cells (217). The findings of a large 
number of studies on animals with experimental colitis, concerning the anti-inflammatory and overall 
protective action of polyphenols, are more consistent. Almost all such reports showed that several 
polyphenols, given as single compounds or as a mixture (plant polyphenolic extracts), can 
significantly attenuate gut mucosal inflammation and related damage. Among the plant polyphenolic 
extracts, the most widely investigated ones were those deriving from green tea (217). 
Flavanol epigallocatechin gallate, a major component of green tea, was demonstrated to markedly 
down-regulate the expression of IL-17 and TNFα in a human T cell line (Kit 225) overproducing 
those cytokines (55). The same flavonoid had previously been shown to inhibit TNFα-induced 
increase of IL-8 and prostaglandin (PG) E2 production in human colonadenocarcinoma cell lines 
(204). 
Recently, using the database of the U.S. Nurses’ Health Study, which includes more than 100,000 
apparently healthy female nurses in the USA, Landberg and colleagues analyzed any possible 
relationship between dietary intake of flavonoids and plasma biomarkers of inflammation and 
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endothelial dysfunction. An inverse association was found between total intake of flavonoids and 
plasma levels of the pro-inflammatory cytokine IL-18, and between flavonols (catechins) and vascular 
adhesion molecule-1 (VCAM-1) (142). 
Table 1 reports the main alterations of antioxidant defenses observed in human inflammatory 
bowel diseases. 
 
V B. Oxidative insult in IBD 
A significant mass of data now points to a preponderance of ROS and RNS being the 
antioxidant defense affected in the inflamed areas of the gut of IBD. Quite recently, experimental and 
human studies on the steady-state of ROS and antioxidants in the inflamed colon mucosa have been 
nicely put together and analyzed (213). IBD is a classic chronic disease process in which 
inflammatory cells, cytokines, chemokines, and intestinal flora interact, until they induce a net 
imbalance of the redox equilibrium of colonic mucosa, with the consequent development of an “oxy-
radical overload” (181, 202, 269). ROS levels have been correlated to the clinical and endoscopic 
assessment of IBD severity (134). Of note, RNS and ROS have been demonstrated to up-regulate a 
number of different genes involved in adaptive and innate immune responses in the gastrointestinal 
tract.  
 
1) RNS in IBD progression 
Nitric oxide steady-state levels in the bowel mucosa during the development of inflammatory 
diseases may be significantly altered because of marked changes in both the synthesis and the 
disposition of this reactive chemical species. Enhanced recruitment of phagocytic cells, followed by 
the increased inducible nitric oxide synthase (iNOS) concentration, which occur in IBD affected 
intestinal mucosa, are accompanied by peculiar modifications of the local endothelium, expressing 
both iNOS and endothelial nitric oxide synthase (eNOS).  
The marked expansion of the microvasculature in the chronically-inflamed intestinal mucosa 
magnifies the harmful effects to the altered endothelium in IBD. The affected intestinal endothelium 
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generally shows a diminished amount of eNOS versus its normal counterpart (72). Markedly reduced 
NO-dependent vasodilation was demonstrated by in vitro videomicroscopy in human submucosal 
arterioles that had been dissected from IBD intestinal specimens (88). Moreover, the lack of 
expression of eNOS in the intestinal mucosa, as experimentally achieved in eNOS
-/- 
mice, led to a 
marked reduction of plasma nitrite versus wild-type animals and, in addition, severe exacerbation of 
colitis induced by DSS (221).  
Another very important source of NO in intestinal endothelial cells is iNOS, which, unlike the 
inducible isoform present in leukocytes, appears to play a physiological role protecting against 
leukocyte adhesion (28). In agreement with this evidence, DSS-induced inflammation of colonic 
mucosa was found to be more severe in iNOS
-/- 
mice than in DSS-treated wild-type mice (131). As in 
the case of eNOS, levels of iNOS were also found to be consistently decreased in intestinal 
endothelial cells isolated from surgical samples of IBD mucosa, from both CD and UC patients (28). 
Importantly, despite the fact that both the inducible and the constitutive forms of NO synthases 
present in normal intestinal microvasculature are markedly reduced in IBD, the overall amount of NO 
in this chronically-inflamed gut mucosa has clearly been shown to be significantly increased due to 
tissue invasion by inflammatory cells, which increase local concentrations of iNOS (128, 131). That 
excessive generation of NO, mainly sustained by iNOS activity, is implicated in the pathogenesis of 
IBD as supported by the finding that in mice lacking STAT-6 challenged with DSS the resulting 
colitis is much more severe. Significantly, STAT-6
-/-
 mice showed increased levels of iNOS, 
suggesting a regulatory role of STAT-6 on iNOS activity (62). Moreover, continuous cytokine 
exposure during chronic inflammation, and excessive consumption of nitrite- and nitrate-rich foods, 
may induce DNA deamination and cause strand breakage and mutations (225). Peroxynitrite (ONOO
-
) 
produced via iNOS during chronic inflammation can cause nitrative DNA damage by forming 8-
nitroguanine, in both animals and humans with inflammatory diseases, included intestinal diseases 
(113). 
Taking all available findings together, it might be concluded that, during the development of 
IBD, a net derangement of NO synthesis by the endothelial cells occurs, which is apparently directly 
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related to the severity/exacerbation of the inflammatory process. The physiological protective role of 
endothelial NO is lost, overwhelmed by an excess of NO of leukocyte derivation; this NO, in addition, 
shows localization and likely diffusion rates that differ significantly from those of the constitutive 
chemical species (279). 
 
2) ROS in IBD progression  
The primary activity of ROS in defense against invading microbes is the well-known 
respiratory burst induced in phagocytic cells. In particular, stimulated macrophages generate high 
concentrations of ONOO
-
 and H2O2, acting as bactericidal agents. ROS comprise many species, i.e. 
superoxide (O2
-.
), hydroxyl radical (HO
-
) and H2O2. Various studies have demonstrated that ROS are 
implicated in determining mucosal injury in UC (206). Gene expression profiles in the three different 
mouse models of colitis revealed alterations in the expression of important genes involved in the 
regulation of H2O2 production in the intestinal tissue (256). Furthermore, the mucosal barrier 
dysfunction has been related to disorganization of the cytoskeleton in epithelial cells, due to excessive 
ROS generation (14). 
An excess of ROS causes massive DNA damage to accumulate. Reaction of the hydroxyl 
radical at the C-8 position of deoxyguanosine induces formation of 8-hydroxy-2′-deoxyguanosine (8-
OHdG), which is considered a marker of oxidative DNA damage in biological systems (83). 
Oxidative DNA lesions are relevant to mutagenesis, producing several base modifications such as 
G:C to T:A transversions, which have been associated to TP53 mutations in UC (100). The colonic 
mucosa concentration of 8-OHdG has been found to be doubled in rats treated with DSS. The role of 
inflammation in inducing DNA oxidative damage, in terms of 8-OHdG production, has been verified 
in colonocytes by using the cyclooxygenase (COX)-2 inhibitor nimesulide (253, 254). It is widely 
thought that chronic inflammation is actively involved in intestinal tumorigenesis via the induction of 
DNA mutations by ROS (58, 67, 166). 
An important source of oxidative DNA damage is the mitochondria, because of the central 
role they play in energy oxidative cell metabolism. Mitochondrial DNA is particularly exposed to 
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ROS attack, due to its localization, close to the intracellular electron transport chain in the inner 
mitochondrial membrane, and to the absence of protective histones. Polymerase chain reaction 
analyses to detect large deletions in the mitochondrial DNA, and 8-OHdG tissue concentrations, were 
measured in mucosal specimens from patients affected by UC. The increased gene instability of 
mitochondrial DNA in UC patients has been related to the high development rate of colorectal cancer 
(188). 
However, owing to their short half-life and high reactivity, direct detection of ROS in vivo is 
difficult. Oxidative epithelial-cell injury has been indirectly evaluated in the mucosa of IBD patients, 
in whom the production of oxidants was excessive if compared to their antioxidant defenses (134). 
The assessment of oxidative and/or nitrative modifications of proteins has long been one of the few 
methods available to detect ROS/RNS generation in vivo. Inflamed mucosa of UC patients with active 
disease shows increased cytoskeletal protein oxidation and nitration (116). Direct evidence of in vivo 
ROS production in IBD has been provided using chemiluminescence methods (192, 247) or 
fluorescent probes (see Figure 6) detecting O2
-.
, H2O2, and NO in lymphocytes, monocytes, and 
granulocytes isolated from the peripheral blood of both CD and UC patients (21).  
Recent studies, aimed at evaluating the therapeutic effect of probiotics, have demonstrated 
abnormal intestinal bacterial colonization in IBD, which often causes damage by inducing 
exaggerated oxidative reactions. Certain bacteria, such as Bacteroides, Clostridium and Enteroccocus, 
can be considered detrimental, whereas Bifidobacterium and Lactobacillus may be beneficial (65). 
Enterococcus faecalis has been implicated in tissue damage in IBD because of its ability to induce 
high concentrations of H2O2 and of inflammatory cytokines, such as TNFα and IL-12p70 (161). ROS 
production is critical for efficient autophagic targeting of Salmonella enterica serovar Typhimurium 
in phagocytes (98). Conversely, Lactobacillus strains may ameliorate IBD severity, by activating 
antioxidant enzymes and anti-inflammatory cytokines, both in experimental animal models and in 
children (37, 153). 
The importance of ROS has been stressed in terms of their bactericidal effect, as regulators of 
molecules involved in the recognition and processing of intestinal pathogens. ROS are essential for 
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autophagosomal degradation of proteins: in particular, H2O2 specifically inactivates ATG4, most 
likely activating PI3K signaling, thereby promoting ATG8 lipidation, and resulting in enhanced 
autophagy (223). Conversely, another in vitro study has shown that ATG16L1 dysfunction, which has 
been observed in CD patients, results in an overproduction of ROS, which diverts cells away from 
autophagy, to activating NLRP3-related IL-1β production (219).  
ROS generation is closely related to TLR and NLR recognition aimed at killing the pathogen 
directly. ROS are reported to be involved in the NF-B pathway activation mediated by TLR4 in 
neutrophils (12). Autophagy induced by the LPS is mediated by TLR4-induced signaling. Generation 
of ROS with consequent recruitment of autophagy light chain peptide LC3 to phagosomes during 
phagocytosis of TLRs has been shown in the murine macrophage Raw 264.7 cell line (289). Various 
stressors, such as asbestos and silicas, activated NLRP3 to secrete IL-1β in macrophages through ROS 
generation mediated by ATP. ROS can activate the PI3K transduction pathway, which in turn is 
required to activate pro-caspase-1 and to secrete pro-inflammatory IL-1 and IL-18 (50, 61). ROS may 
either directly activate inflammasomes, or indirectly interact with other molecules able to modulate 
inflammasome activity (162). 
 
3) The role of lipid oxidation end-products in IBD 
Most studies determined the presence of a condition of oxidative stress in experimental colitis 
and/or human IBD in terms of increased lipid oxidation products, measuring thiobarbituric acid 
reacting substances or aldehydic end-products, such as 4-hydroxynonenal (HNE) and 
malondialdehyde (213). Dietary lipids, in particular ω6-polyunsaturated fatty acids (PUFAs) and their 
oxidative modifications are undoubtedly crucial in promoting chronic inflammation: they provide the 
main substrates for PGs and leukotrienes (LTs) formation through COXs and lipoxygenases (LOXs) 
activity and, for reactive aldehyde production, by non-enzymatic breakdown. 
As far as COX activity is concerned, phagocytes of the lamina propria produce high levels of 
ω6-arachidonic acid (AA) metabolites through inducible COX-2. The eicosanoids PGE2 and LTB4 
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may activate Th cells to synthesize either pro- or anti-inflammatory mediators of the response to 
dietary antigens, by selectively triggering different signal transduction pathways (87). 
A large body of literature is now available on cell-damaging effects of aldehydes deriving 
from non-enzymatic degradation of ω6-PUFA; some of these carbonyl derivatives appear likely to be 
involved in chronic inflammatory processes characterized by excessive fibrogenesis, especially in 
atherosclerosis and neuronal diseases (184). 
The aldehyde HNE is considered a crucial molecule in cell signaling activation, because of its 
strong reactivity with biomolecules containing amino and thiol groups. High concentrations of HNE 
exert necrogenic and genotoxic effects, whereas at low concentrations HNE appears to act as second 
messenger of free radical-mediated reactions. HNE appears to be involved in regulating a number of 
cell signals, especially in apoptosis- and inflammation-related signaling pathways. There is growing 
evidence of increased HNE tissue/blood levels in a wide variety of human diseases characterized by 
inflammation, pointing to the implication of this molecule in their pathogenesis (203). 
Diet may influence tissue levels of HNE, which derives from arachidonic and linoleic ω6-
acids, which are often abundant especially in Western diets (246). However, HNE levels can be also 
affected by antioxidant intake, as well as by intestinal microbiota. HNE and its urinary metabolites 
have been found to be reduced as a response to improved plasma antioxidant concentrations in 
humans. In diabetic rats, dietary supplementation with the antioxidant α-lipoic acid reduced plasma 
levels of HNE and prevented the progression of diabetes mellitus complications, by inhibiting 
oxidative DNA damage of the peripheral lymphocytes. An in vitro model of dietary fiber fermentation 
decreased HNE-induced DNA damage and increased glutathione-S-transferase in IEC (13, 139, 222). 
High levels of HNE have been consistently detected in the intestinal mucosa and in the 
plasma of CD patients (25, 26). An increase in etheno-modified DNA bases, generated by the reaction 
of DNA with HNE, has been found in inflamed pancreatic tissue of patients with chronic pancreatitis, 
and in the colon mucosa of IBD patients (178).  
In male Sprague-Dawley rats, in which colitis was induced by LPS injection, a transient 
increase of HNE in colonic mucosa was shown to modify IgA molecules, thus resulting in a reduction 
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of bactericidal activity at the level of the intestinal epithelial layer (125). In other experimental models 
of colitis, induced by DSS or TNBS in C3H/HeN and C3H/HeJ mice, high levels of HNE and 
malonaldehyde, together with reduced antioxidant defenses (i.e. GSH content, SOD and CAT 
activities) have been detected in inflamed colon mucosa (144). The consistent evidence of HNE 
overproduction during inflammatory disease processes, together with HNE’s strong reactivity with 
important functional biomolecules, point to this molecule being an effector of oxidative damage in 
IBD. 
Besides lipid peroxidation-derived aldehydes, other lipid oxidation products might impact not 
only on IBD’s progression and perpetuation, but also on its initiation. At least in the case of high 
dietary consumption of animal fats, several oxidation products of cholesterol, termed oxysterols, have 
recently been demonstrated to exert a strong pro-inflammatory effect on human colonic cells (163). 
The pathogenetic role of dietary cholesterol and oxysterols in several inflammatory diseases, 
mainly atherosclerosis, has been established unequivocally (197, 241). Oxysterols belong to a family 
of 27-carbon cholesterol derivatives, which originate from the diet through non-enzymatic reactions, 
or endogenously through the activity of specific hydroxylases, cytochrome P450-dependent or -
independent enzymes. Dietary oxysterols derive from cholesterol-rich food by autoxidation reactions, 
promoted either by incorrect food processing and storage, or by increased ROS steady-state levels 
(30). The addition of oxygen to the cholesterol molecule gives the resulting metabolite hydrophilic 
properties and much higher mobility than the parent compound within the cell membrane, with 
consequent changes in structure and function of the phospholipid bilayer. Dietary oxysterols are 
absorbed completely from the bowel, cleared from plasma into lipoproteins, and taken up by different 
tissues more rapidly than cholesterol (78). The principal dietary oxysterols formed upon non-
enzymatic cholesterol oxidation are found in a mixture; they comprise 7α-hydroxycholesterol, 7β-
hydroxycholesterol, 7-ketocholesterol, 5α,6α-epoxycholesterol, and 5β,6β-epoxycholesterol. Their 
concentrations are in the 10-100 µM range in processed and/or stored cholesterol-rich foods (111).  
Oxysterols perform important physiological activities that include sterol and bile acid 
biosynthesis and reverse cholesterol transport. However, the tissue accumulation of oxysterols has 
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been found to be potentially more pro-inflammatory and more toxic than cholesterol accumulation for 
different cell types, including IEC. The main cell pathways activated by oxysterols are summarized in 
Figure 7. A mixture of dietary oxysterols has recently been demonstrated to interfere with the 
homeostasis of the human digestive tract, promoting and sustaining inflammatory processes and 
inducing apoptosis of enterocyte-like CaCo-2 cells. In these cells oxysterols increased the expression 
of IL-1β (see Figure 8), IL-6, IL-8, IL-23 and MCP-1, but also up-regulated mRNA levels of the 
recognition receptors TLR2 and TLR9. The NADPH oxidase isoform 1 (NOX1) appears to contribute 
to the pro-inflammatory and pro-apoptotic effects of oxysterols, since these events can be prevented 
by cell pre-treatment with the NADPH oxidase inhibitor diphenyleneiodonium (DPI). Among the 
oxysterols studied, 7β-hydroxycholesterol and 7-ketocholesterol displayed the highest cytotoxicity. 
However, in food they are mixed with other oxysterols and do not elicit the same strong response, 
suggesting a partial competition with other oxysterols for the same cell functional sites (27, 163). 
Table 2 shows the main inflammatory molecules involved in IBD that are induced by lipid oxidation 
products. 
In the mechanism by which ROS propagate inflammation a key role is certainly played by the 
activation of NF-B, which is involved in the regulation of several immune and inflammatory genes.  
 
VI. REDOX STATE–RELATED TRANSCRIPTION FACTORS IN THE 
ETIOPATHOGENESIS OF IBD 
 
VI A. Nuclear factor-κB  
The transcription factor NF-κB is a major regulator of multiple important physiological 
processes. At the intestinal epithelium, NF-κB is involved in the immune homeostasis of IEC, and in 
modulating intestinal barrier permeability (200). However, chronic NF-κB activation may play a major 
role in exacerbating chronic inflammation of intestinal epithelium. This is supported by the aberrant 
NF-κB activation consistently found in IBD (7, 215, 274). Furthermore, chronic NF-κB activation and 
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the resulting inflammation are associated with a general risk for most cancer types (1), the link 
between IBD and colorectal cancer being paradigmatic (53, 66). 
Transcription factor NF-κB is composed of homodimers and heterodimers of the Rel/NF-κB 
family of proteins (c-Rel, RelB, p65 [RelA], p50/p105 and p52/p100). NF-κB normally resides in the 
cytosol, forming an inactive complex with the inhibitor of B (IB). Its activation via the canonical 
pathway involves IB kinase (IKK)-mediated phosphorylation of two IBα serine residues (S32 and 
S36). IB kinase consists of two regulatory subunits, IKK1 (IKKα) and IKK2 (IKKβ), plus the NF-
B essential modulator (NEMO or IKKγ) regulatory subunit. IBα phosphorylation triggers its 
subsequent ubiquitination and degradation by the proteasomes, and translocation of the active NF-κB 
dimer to the nucleus. NF-κB binds to DNA κB sites and regulates the expression of many genes that 
can be grouped into those that modulate the immune and stress response, cell proliferation, and cell 
survival (288). 
NF-κB activation is a down-stream pathway in microbial recognition by IEC. Upon activation 
by different PAMPs, TLRs react with adaptor proteins MyD88 and TRIF, which in turn activate NF-
κB. Furthermore, recognition of the bacteria-derived peptoglycan by NLRs results in the recruitment 
of RIP2/RIP-like interacting caspase-like apoptosis regulatory protein kinase (RICK) and the 
subsequent activation of NF-κB (3). Altered NF-κB expression led to the dysregulation of 
antimicrobial peptides, which influenced the proliferation of pathogenic bacteria in the intestinal 
epithelium of Drosophila melanogaster, leading to the host’s death (218). 
NF-κB is a redox-sensitive transcription factor. Increases in ROS tissue may partly explain the 
chronic activation of NF-κB in IBD. ROS disrupt the redox interaction between the dynein light chain 
LC8 peptide and IκBα, which prevents IκBα phosphorylation by IKK (109). TNFα activates NF-κB, 
which involves NADPH oxidase activation, increased ROS production, release of LC8, and IκBα 
phosphorylation (107). In support of a role of oxidative stress in IBD-associated NF-κB activation, 
phenyl-N-tert-butylnitrone, an oxidant-trapping compound known to inhibit NF-κB, ameliorates DSS-
induced inflammation by inhibiting the expression of NF-κB-regulated proteins, i.e. TNFα, IFNγ, and 
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iNOS (180). Consistently, this model of UC is associated with high levels of colonic mucosa oxidation 
and luminal nitrite/nitrate content (180). 
Although the etiology of IBD is probably multifaceted, NF-κB activation is a common finding 
in this disease. Administration of the NEMO-binding domain peptide, which blocks the association of 
NEMO with IKKβ subunit, was found to inhibit IKK activation and reduce the severity of colon 
inflammation in different mouse models of colitis (232). High levels of p65 are found in macrophages, 
endothelial cells and lamina propria fibroblasts from IBD patients (80, 215). Hyper-activation of NF-
κB can cause an increased transcription of various genes that are central to IBD pathogenesis: a) pro-
inflammatory cytokines: IL-1β, IL-6, IL-8, IL-16 and TNFα (198), which are crucial in the IBD 
sustained cycle of intestinal barrier disruption by furthering the NF-κB-dependent release of pro-
inflammatory mediators (43, 255); b) genes regulating cell proliferation and survival: a NF-κB-
dependent increased expression of the pro-apoptotic p53 upregulated modulator of apoptosis (PUMA) 
protein contributes to colitis in humans and mice (208), while increased expression of certain NF-κB-
regulated genes may be involved in the proliferation and survival of transformed epithelial cells 
leading to tumorigenesis (43); c) genes regulating the permeability of the intestinal barrier: in this 
connection, TNFα induces the partial permeabilization of the intestinal barrier through NF-κB-
dependent up-regulation of myosin light chain kinase (292); d) metalloproteinases, which may degrade 
the extracellular matrix and mucosal cells (212); e) enzymes (e.g. COX-2 and iNOS), which by 
participating in the metabolism of ROS and RNS may contribute to NF-κB activation and to the 
disruption of the barrier integrity (7) (Figure 9).  
The relevance of NF-κB dysregulation in IBD pathogenesis is supported by the evidence that 
drugs widely used in treating patients with IBD (i.e. sulfasalazine, steroids, TNFα antibodies) are 
capable of inhibiting NF-κB (193, 265, 282). Furthermore, in support of a role of NF-κB, induced 
IBD in mice was successfully treated with NF-κB decoy oligonucleotides (69). 
In summary, although NF-κB has relevant physiological functions within the intestinal 
mucosa, its sustained activation accompanies the chronic inflammatory processes in IBD, and may 
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play a major role in both the etiopathogenesis of IBD and the IBD-associated higher risk for 
colorectal cancer development (193). 
 
VI B. Nuclear factor-erythroid 2-related factor 2 
In recent years, accelerating research has drawn attention to another redox-sensitive transcription 
factor, namely nuclear factor-erythroid 2-related factor (Nrf2), known to play a key role in the 
regulation of several genes coding for primary antioxidant and/or type 2 detoxifying enzymes (127, 
172). Nrf2 may contribute to maintaining the homeostasis of the intestinal mucosa, by preventing 
and/or counteracting excess production of ROS within the intestinal epithelium and the lamina propria, 
as occurs in IBD. Further, Nrf2 appears to negatively modulate pro-inflammatory reactions occurring 
in the gut mucosa, through antioxidant and, possibly, non-antioxidant mechanisms. A number of in 
vivo experimental studies, most of which focused on lung inflammation and sepsis, have clarified the 
significant role of this transcription factor in regulating innate immunity and inflammatory processes 
(106, 266). 
Direct evidence of the Nrf2-dependent negative regulation of gut inflammation was obtained in 
the DSS-induced mouse model of colitis using Nrf2 wild-type and knock-out (KO) animals. Colitis 
induced in Nrf2
+/+
 mice after 6-7 days of 1% DSS oral administration (in the drinking water), caused 
the loss of about one/third of mucosal crypts. When Nrf2 KO mice underwent the same treatment, the 
loss of crypts was significantly greater at about two thirds. This increased vulnerability of Nrf2
-/-
 mice 
was associated with a net lower expression of antioxidant/phase II detoxifying enzymes, such as 
hemeoxygenase-1 and glutathione-S-transferase Mu-1. But, even more importantly, the expression of 
genes coding for key pro-inflammatory molecules, such as IL-1, IL-6, TNFα, iNOS and COX-2, was 
significantly increased in the colonic mucosa of Nrf2
-/-
  mice versus the wild-type mice (119). 
The in vitro and in vivo experimental findings of Osburn and colleagues further strengthened the 
evidence of negative regulation exerted by Nrf2 on the expression of inflammatory molecules and on 
intensity of inflammatory reactions also in the gut mucosa. The group’s main aim was to investigate 
the contribution of colonic inflammation in inducing colonic pre-neoplastic lesions after a single 
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initiating dose of azoxymethane, using Nrf2
+/+ 
and Nrf2
-/-
 mice. Two weeks after intraperitoneal 
injection of azoxymethane, mice were given 1% DSS in the drinking water, for six or seven days. 
Inflammation was only characterized at the end of DSS treatment, while the possible onset of pre-
neoplastic lesions was evaluated three weeks later. DSS-induced colitis was much more severe in 
Nrf2
-/-
 mice than in wild-type mice, with particularly marked damage to the mucosa, which was 
extensively infiltrated by leukocytes, mainly macrophages and neutrophils (194).  
Consistently, at the end of DSS treatment, significantly higher transcription of the pro-
inflammatory genes IL-1β, TNFα and IL-12p40 was detectable in the colonic mucosa of Nrf2 KO 
mice than in those with active Nrf2. The morphological evidence of colonic wall infiltration by 
professional phagocytic cells in Nrf2
-/-
 mice was biochemically confirmed when a net increase of 
MPO was found in the colon of these animals. Other relevant findings were a net rise of 3-
nitrotyrosine-positive macrophages and of lipid peroxidation products in the colonic mucosa of Nrf2
-/-
 
mice versus Nrf2
+/+
 mice (194).  
Besides confirming and expanding the finding of a more marked inflammatory reaction in the 
colon from Nrf2 KO mice versus wild-type mice, the same study reported that Nrf2-deficient mice 
were also more susceptible to inflammation-associated pre-invasive colorectal carcinogenesis versus 
wild-type mice. In fact, three weeks after having stopped DSS treatment, the number of aberrant crypt 
foci in the colon of azoxymethane plus DSS Nrf2
-/-
 mice was three times higher than it was in 
azoxymethane plus DSS treated wild-type mice (194). Subsequently, adopting the same cancer 
initiation treatment, i.e. intraperitoneal injection of a single dose of azoxymethane, two weeks 
interval, then one week of DSS, but in this case with a follow-up of a further 17 weeks (20 weeks in 
total), Khor and colleagues were able to evaluate the incidence of colon tumors in Nrf2 KO and wild-
type mice, and found a marked difference in the tumorigenesis rate: only 53% of wild-type mice 
versus 92% of KO mice, showed macroscopic tumor. Of note, while in Nrf2
+/+ 
tumor-bearing mice, 
80% were adenomas and 20% were adenocarcinomas, in the Nrf2
-/-
 mice, incidence of benign versus 
malignant colon tumors was the converse, i.e. 20% were adenomas and 80% were adenocarcinomas 
(119). 
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With regard to oxidative stress, a biochemical condition that significantly exacerbates the expression 
of IBD, NOX is considered to be one of the main cellular sources of ROS; using a mouse model of 
LPS-induced sepsis, Nrf2 has recently been shown to be essential for the physiological regulation of 
this enzyme’s activity. According to the researchers involved, the transcription factor down-regulates 
the activity of protein kinase C (PKC), which is a redox-sensitive kinase, as well as reducing the 
consequent activation of NOX, by increasing intracellular levels of antioxidants, in particular of GSH. 
This would at least partly explain why Nrf2 deficient mice display increased generation, as well as 
increased steady-state-levels, of ROS (129). 
The overall primary function of Nrf2 in moderating and controlling the expression and extent of 
inflammatory processes has been carefully analysed in a recent review (122). Disruption of Nrf2 
activity was shown to allow an exaggerated production of pro-inflammatory cytokines, such as IL-1β, 
IL-6, and TNFα, to take place; on the contrary, activation of this transcription factor efficiently down-
regulated the expression of key chemokines, like MCP-1 and IL-8, adhesion molecules, like VCAM-
1, metalloprotease-9, as well as down-regulating COX-2-dependent inflammatory reactions (122). 
On the basis of the available literature, it might be concluded that NF-kB up-regulation initiates 
and sustains a variety of pro-inflammatory reactions, whereas Nrf2 orchestrates a number of 
antioxidant-related biochemical events; together these might provide a fundamental quenching and 
negative regulation mechanism of inflammation itself.  
 
VII. THERAPEUTIC CONSIDERATIONS  
It is now widely accepted that intestinal damage in IBD is caused by an altered immune 
response to the luminal environment. This alteration results in a loss of tolerance and therefore the 
establishment of a chronic inflammatory response. Based on the latest findings, the treatment of IBD 
patients focuses on counteracting this exaggerated inflammatory response. 
The primary aim of IBD treatment is to induce and maintain remission and to prevent relapse. 
The classical therapeutic approach entails conventional anti-inflammatory agents, such as 5-
aminosalicylates and corticosteroids, which usually provide significant suppression of inflammation 
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and rapid relief of symptoms. However, IBD management requires long-term treatments that often 
bring side effects, or may even lead to drug refractoriness or intolerance. Furthermore, these anti-
inflammatory drugs do not prevent intestinal fibrosis, stricture formation, and consequent need for 
surgical intervention, especially in CD (44). These patients often respond inadequately to commonly-
used steroids, a condition which leads to a poor quality of life.  
Immune modulators, namely thiopurines, cyclosporin A or methotrexate, are currently widely 
used in treating IBD, in an attempt to induce immunosuppression. However, these drugs do have 
cytotoxic effects and increase the risk of adverse hematological, hepatic, and gastrointestinal events, as 
well as the susceptibility to highly infectious diseases. Although immunosuppressive therapy is 
commonly used, together with anti-inflammatory drugs, it requires close monitoring and personalized 
application (41, 117). 
Because of the growing incidence of IBD world-wide, a more targeted therapeutic approach is 
increasingly demanded by the medical profession. Recent pathophysiological studies have led to more 
specific drugs being used, including many biological drugs, which have revolutionized the treatment 
of IBD, showing clinical benefits in maintenance therapy.  
Biological therapy is focused on the inflammatory response, and aims to antagonize pro-
inflammatory molecules. Inflammatory cytokines are thus the most logical targets in IBD treatment, 
and many studies have been designed to synthesize specific cytokine inhibitors. In this connection, the 
two cytokines TNFα and IL-1β have been widely studied. Currently, the use of TNFα blockers is the 
only licensed biological therapy for IBD, in particular for CD. Figure 10 shows the stages of today’s 
therapeutic approaches to IBD management. 
However, new targeted therapeutic approaches are now being suggested by the rapidly 
improving knowledge of the pathogenesis of IBD, as it becomes clear that a primary contribution to 
the disease progression is made by exaggerated and dysregulated NF-B signaling and overproduction 
of ROS. Indeed, studies on both in vivo and in vitro models of intestinal inflammation have strongly 
implicated oxidative reactions in the mucosal barrier injury. Modulating NF-B signaling and 
targeting ROS overproduction sites, in particular plasma-membrane NADPH oxidase and 
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mitochondria, may soon provide important new therapeutic options to lessen intestinal damage. Lastly, 
recent clinical trials have outlined the potential efficacy of chronic dietary supplementation of 
polyphenols, which markedly down-regulate the expression of inflammatory cytokines and adhesion 
molecules, as well as that of nutritional diets including the antioxidant vitamins, which prevent the 
reacutization of IBD. Thus a diet rich in certain polyphenols and in the vitamins A, C, and E, may be 
recommended to IBD patients, not only during active disease, but particularly in the remission state.  
 
VII A. TNFα-mediated NF-κB signaling  
TNFα plays a key role in the induction of intestinal inflammation, through regulating NF-κB. 
The use of anti-TNFα antibodies in the IBD therapy has recently generated considerable interest. 
Several TNFα blockers are currently licensed for IBD treatment, namely infliximab, adalimumab, and 
certolizumab, which have been approved by the US Food and Drug Administration for the treatment 
of moderate-to-severe CD, with inadequate response to standard medications (23). Infliximab is a 
chimeric monoclonal IgG1 antibody, which binds with high affinity both the soluble and the 
transmembrane forms of human TNFα in the intestinal mucosa, thereby neutralizing its effect. 
Adalimumab is a complete human immunoglobulin G1, which specifically blocks interactions with 
TNFα receptors. Certolizumab is a monoclonal antibody, with the Fab fragment of human anti-TNFα 
combined with polyethylene glycol.  
Infliximab appears to be the most effective of these various TNFα blockers, especially in 
fistulizing active CD. A Crohn's disease Clinical study Evaluating infliximab in a New long-term 
Treatment regimen (ACCENT I) performed from 1999 to 2000, on 573 CD patients from 55 sites in 
North America, Europe, and Israel, provided the first significant evidence of the efficacy and safety of 
repeated infusions of infliximab, in patients who responded after an initial infusion of this compound 
(86). A second ACCENT II study demonstrated the efficacy of infliximab in sustaining fistula 
closure, in patients with active fistulizing CD (who had single or multiple draining fistulae) with a 
higher likelihood of abscess development (220). More recently, a randomized, double-blind Study of 
Biologic and Immunomodulator Naïve Patients in Crohn's Disease (SONIC) trial, conducted in 92 
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centers from March 2005 to November 2008, in 508 adult patients with moderate-to-severe Crohn's 
disease (who were naïve to both agents) treated with infliximab and/or azathioprine, showed that the 
combination therapy was more effective at inducing remission and mucosal healing (45). 
However, infliximab therapy brings the risk of significant side effects or refractory disease, 
especially in patients treated with infliximab who also receive concomitant immunomodulators, such 
as azathioprine or mercaptopurine, as well as corticosteroid therapy (57, 135). Combined therapy has 
been associated with significant toxicity, especially with an increased risk of serious infections. Thus, 
patients with latent infections, such as tuberculosis or hepatitis B, should be excluded or treated before 
starting biological therapy (268). In addition, long-term exposure to infliximab has been per se 
associated with a loss of response, due to a dysregulation of T cell subsets’ activation (239). 
Treatment with infliximab for a long period can result in the development of antibodies by the host 
against this molecule, reducing the duration of response to treatment, and increasing the risk of 
adverse events (54). A multicenter study on corticosteroid-refractory UC patients, in whom 
cyclosporin had failed, showed that the use of infliximab avoids colectomy in a relatively high 
percentage of patients, although 23% developed adverse events (38). 
Recently, numerous studies using anti-TNFα agent adalimumab as therapy have provided 
evidence of clinical improvement in CD patients in whom previous infliximab therapy had failed (47). 
Adalimumab therapy showed a sustained steroid-free remission and fistula healing in Canadian 
patients with moderate-to-severe Crohn's disease (199). 
TNFα signals initiate through binding to its surface receptors, TNF-R1 (ubiquitously 
expressed), and TNF-R2 (mainly found in immune cells). Many cell types co-express the two TNF 
receptors. TNFα induces their trimerization and results in the activation of apoptosis or inflammation. 
The induction of different processes depends on the recruitment of signal transducers, which activate 
three distinct down-stream effectors: Fas-associated death domain (FADD) protein, which is 
responsible for apoptosis recruiting and activating caspase 8, RIP1, which appears to be a key effector 
in the TNF-R1 dependent NF-κB activation, and the TNF-receptor-associated factor 2 (TRAF2), 
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which is activated by both TNF-R1 and TNF-R2, and leads to activation of their common cell signals 
IKK, JNK and p38 MAPK. (18). 
The key factor in regulating the balance between apoptosis and inflammation is the redox 
transcription factor NF-κB. Upon TNFα stimulation, the different components of TNFα signaling 
undergo post-translational modifications, namely ubiquitination and phosphorylation, which activate 
and amplify the inflammatory response mediated by NF-κB, which in turn suppresses the apoptotic 
cascade. Conversely, the duration of NF-κB activation is negatively controlled by the induction of 
different inhibitors associated to the TNFα signal. Among the NF-κB negative regulators identified, a 
TNF-R2a site located in the carboxyl terminus of TNF-R2 has been found to block TNFα signaling, 
binding TRAF2 (300). Furthermore, ubiquitin ligase A20, which is also called TNFα-induced protein 
3, is said to play an important role in the down-regulation of TNFα-NF-κB axis. A20 appears to block 
the recruitment of RIP and TNF-R1-associated death domain (TRADD) to TNF-R1 complex; RIP 
itself may be degraded by A20 (150). Interestingly, A20 has recently been found to be up-regulated 
by TLR signaling during inflammation, attenuating TLR response in a negative feedback loop (195). 
These findings suggest the potential clinical importance of A20, as a new target molecule playing a 
crucial role in the management of intestinal inflammation. The treatment of IBD patients with TNFα 
antibodies is indeed capable of inhibiting NF-κB (193). 
Recently, several attempts to reduce NF-κB and inflammatory cytokines have been made 
using anti-oxidant compounds such as phenolic acids. For instance, sylimarin was found to reduce 
TNFα and NF-κB activation in experimental colitis (169), and black tea restored adhesion molecule 
activation, by blocking NF-κB and the JNK cell pathway in IEC treated with LPS (238). 
Mitochondrial prohibitin (PHB) (for details see below) has been shown to decrease TNFα and NF-κB, 
both in IEC and in colonic mucosa of prohibitin transgenic mice (with a two fold increase in PHB 
expression in colon mucosa), suggesting this molecule may be protective against intestinal injury in 
IBD (262). 
It has been reported that TNFα potently activates NOX1, inducing transactivation of the 
NOXO1 gene in human colon epithelial cells; hence, this oxidase is a potential target in treating colon 
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inflammation (140). Furthermore, TNFα was also found to influence NF-κB, by enhancing ROS 
production mediated by another NADPH oxidase isoform, NOX2 (151). 
Future perspectives in IBD therapy involving TNFα signaling should focus on the various 
molecules that lead to induction of NF-B activity, rather than using antibodies directed against TNFα 
itself. 
 
VII B. The IL-1 family and inflammasomes as ROS-dependent targets  
Different members of the IL-1 family, such as IL-1α, IL-1β, IL-1 receptor antagonist (IL-
1Ra), IL-18 and IL-33, are known to be actively involved in innate and adaptive immune responses. 
In particular, IL-1β and IL-18 appear to be of great interest in the pathogenesis of intestinal 
inflammation. IL-1β has been widely investigated for its strong pro-inflammatory effects, which in 
many cases overlap those of TNFα, in terms of cell type and signaling molecules involved, despite the 
fact that there is no homology with any group of proteins activated by TNFα. IL-1β has an anti-
microbial function and regulates systemic reactions, i.e. fever and septic shock, as well as local 
inflammatory response. IL-18, like IL-1β, must be processed by caspase-1 in order to be activated.  
The concept that intestinal inflammation induced by IL-1β and IL-18 is only a contributory 
factor in tissue damage is now being revisited, based on recent reports on DSS- and TNBS-induced 
colitis-associated tumorigenesis, which suggest that the NLRP3 inflammasome and IL-1-related 
signaling are critically involved in protection against colorectal tumor development (4, 296). 
However, an altered response to luminal agents, with excessive inflammatory reactions, could 
maintain the inflammasome response harmfully active, which in turn might influence the activity of 
IL-1β and IL-18. High levels of these interleukins have, indeed, been detected in the inflamed mucosa 
of numerous IBD patients. Increased expressions of IL-18 and of its binding protein have recently 
been observed in the chronically-inflamed mucosa of children with CD, and in the serum of adults 
with active CD, but not in UC patients (143, 177). The levels of IL-1β have been found to be 
increased in macrophages of DSS colitic mice, in which ROS generation was necessary for p38 
MAPK and ERK1/2 activation, and consequently for IL-1β production. Furthermore, IL-1β release 
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and caspase-1 activity induced by DSS treatment were significantly inhibited by MAPK kinase 
inhibitors, and by NAC, a precursor of the antioxidant GSH (141). Extra-intestinal complications, 
such as thrombosis, have been related to IL-1β enhancement in mice with DSS-induced colitis (293). 
As discussed at length above, the implication of IL-1β in the pathogenesis of IBD gained new 
importance with the discovery of the NLRP3 inflammasome.  
ROS are crucial for the secretion of IL-1β via inflammasome activation. The experimental 
model of DSS-induced colitis in mice, both wild type and deficient in different components of 
NLRP3, showed that ROS signaling is indispensable to activate the inflammasome-dependent IL-1β 
production by macrophages (19). Mitochondria are important cellular sites actively involved in ROS 
generation, which leads to NLRP3 inflammasome activation (240). It has been proposed that exposure 
to stressors may activate NLRP3-IL-1β, either through NF-κB induction or through the interaction 
between ROS and a Trxip. ROS can be generated by direct exposure to PAMPs or DAMPs, but also 
in response to ATP-dependent potassium efflux and phagosomal or lysosomal damage. Trxip may 
directly interact with the redox domain of antioxidant Trx, and might function as a negative regulator 
of Trx reductase. In the presence of oxidative stress, Trxip dissociates from Trx and binds to NLRP3, 
which then undergoes conformational changes and activation (298). In UC, the mucosal production of 
IL-1β, H2O2, and NO may contribute to the impaired Ca
2+
 release, decreasing sigmoid smooth-muscle 
contractility (36). 
The intestinal epithelium thus appears to be highly sensitive to both decreased and increased 
expression of the inflammasome effectors, IL-1β and IL-18, which can culminate in severe mucosal 
injury. In this connection, synthetic antibodies against IL-1β and IL-18 have been developed, in an 
attempt to reduce the severity of colitis in animal models (118, 232, 293). 
The IL-1Ra is considered to be an important cytokine, whose action comprises competitive 
inhibition of the binding of IL-1β to its receptor. A low ratio between IL-1Ra and IL-1β has been 
found in explant cultures of colonic biopsies from both UC and CD (60). Different polymorphisms in 
gene sequences of IL-1β and IL-1Ra have been identified in IBD populations (48, 291). IL-1Ra has 
been shown to have beneficial effects in experimental models of colitis (77, 214), and has been 
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considered for use in managing intestinal inflammation. At present, sIL-1R, a non-glycosylated 
recombinant analogue of secreted IL-1Ra known as Anakinra, has been used in human rheumatoid 
arthritis and other rheumatic disorders, but solid evidence regarding its application in the therapy of 
IBD is yet to be obtained (16). 
 
VII C. NADPH oxidase as target of the pathogen recognition pathway 
The recent findings concerning the involvement of different NADPH oxidase isoenzymes, in 
inducing ROS in NLRP3, suggest that NOXs may be possible targets of IBD therapy (162, 174).  
Efficient bacterial recognition, processing and killing require a discrete production of 
bactericidal ROS, via NADPH oxidase enzyme complexes. These are complex enzymes consisting of 
cytosolic and membrane subunits, which assemble variously to form tissue-specific isoforms of NOX 
and Dual Oxidase (DUOX). In particular, NOX1 and DUOX2 are present in epithelial cells, whereas 
NOX2 is mainly found in phagocytes. Notably, NOX and DUOX have been shown to regulate the 
number of bacteria in response to commensal and infectious microbes in the intestine of Drosophila 
melanogaster (112). These enzymes are closely involved in the autophagy mechanisms activated by 
ROS generation. NOD2 signaling involves ROS generation via DUOX2 and the activation of down-
stream inflammasomes and NF-κB: colon tissue levels of ROS in wild-type mice stimulated with 
muramyldipeptide were increased, while in muramyldipeptide-stimulated NOD2
–/–
 mice, ROS 
generation was abrogated (154).  
Hyper-activation of different NOX/DUOX isoforms, highly expressed in mucosal cells, may 
inflict damage to the host tissue. The association between susceptibility to develop gastrointestinal 
diseases and altered function of phagocytic and non-phagocytic NADPH oxidase isoforms, has 
recently been hypothesized (40, 163, 216). Lymphocytes present in the mucosal lesions of CD and 
UC were also found to be strongly positive for NOX1 (248). A significant increase of DUOX2 mRNA 
expression was found in colonic biopsies from both CD and UC patients (154). 
NOX family stands as a promising target for new IBD therapeutic strategies, despite the fact 
that presently available NOX inhibitors are not fully specific. In relation to this, a recent study has 
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identified a potent, highly selective inhibitor of NOX1, namely the compound ML090 (CID-616479) 
(31). 
 
VII D. The mitochondrial target prohibitin 
Mitochondria are another primary site of ROS generation in the immune response against 
dietary antigens. The recent characterization of a mitochondrial antiviral signaling protein, which 
mediates NF-B and IRF3 activation, supports the evidence of active involvement of the 
mitochondria in microbial defense (229). TLR1, TLR2 and TLR4 can also increase ROS production 
in phagosome mitochondria (286). Intact mitochondria with intense respiratory activity are necessary 
for NLRP3 induction, in order to control bacterial recognition and immune response (115, 240). 
Furthermore, mitochondrial DNA may play an active role by contributing to the secretion of IL-1β 
and ATP in NLRP3 activation (182, 240).  
Mitochondrial derangement may be involved in intestinal inflammatory diseases. 
Interestingly, a complex regulating network has been hypothesized between mitochondrial machinery 
and NLRP3: NLRP3 is suggested to efficiently sense high concentrations of ROS produced by 
malfunctioning mitochondria, thus causing excessive activation of the inflammatory response. This 
points to an important role of mitochondrial derangement in the development of IBD (299). Marked 
mitochondrial damage in IEC and mucosal injury in terms of increased protein oxidation, have been 
found in IBD patients (64). In addition to that, increased TNFα expression, with transient 
enhancement of ROS production leading to mitochondrial derangement, has been observed 
throughout all the intestinal layers of neonates with necrotizing enterocolitis, and in rat IEC treated 
with TNFα; the possible role of TNFα-induced ROS in the activation of mitochondrial autophagy was 
stressed (15). An increase in mitochondrial respiratory chain complex IV, with an enhancement of 
lipid peroxidation-end products, was shown in the colon of DSS-treated rats (51).  
Recently, functional alterations of PHB, which are evolutionarily-conserved and ubiquitously-
expressed membrane proteins mainly localized in the mitochondria, have been suggested in various 
pathological processes characterized by oxidative modifications (187). PHB levels are decreased in 
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IEC during oxidative stress, and in the IBD inflamed mucosa (97, 260). Low levels of the PHB 
complex, with changes in PHB mitochondrial expression and localization, resulted in increased ROS 
generation and sensitivity to free radicals (242, 264).  
The eukaryotic mitochondrial PHB complex comprises two subunits, PHB1 and PHB2, which 
assemble into a ring-like complex, and anchor to the inner mitochondrial membrane through N-
terminal hydrophobic regions present in both PHB1 and PHB2. PHB1 appears to be present in larger 
amounts than PHB2 in mitochondria, and is mainly involved in maintaining mitochondrial 
morphology and distribution. PHB complex contributes to the stabilization of the mitochondrial 
genome (281); it is implicated in regulating membrane protein degradation by the mitochondrial m-
AAA protease (244), and can function as a holdase/unfoldase chaperone that holds and stabilizes 
unassembled membrane proteins (186). PHB complex plays a role in mitochondrial morphogenesis 
(167), functioning as a scaffold that recruits membrane proteins to a specific lipid environment; this 
function ensures the integrity and functionality of the mitochondrial inner membrane (11, 196). 
PHBs are also present in other cellular compartments, including nucleus and plasma-
membrane, the specific location depending on cell type and situation. PHB complex has been 
identified as a component of the cell-surface-associated molecular complex in human intestinal Caco-
2 cells, binding to Vi. The interaction of Vi with this complex makes Salmonella typhi resistant to 
phagocytosis and to the action of serum complement. PHB complex thus inhibits the inflammatory 
response to Salmonella typhi in the intestine. In addition, this interaction on Caco-2 cells causes a 
reduction in IL-8 secretion by involving the MAPK pathway (230). This finding suggests that cell-
surface-bound PHB complex might be an important target for the modulation of the inflammatory 
response by various molecules. In this connection, it may be hypothesized that small molecules, 
peptides or monoclonal antibodies, which interact with the PHB complex on intestinal cells, might 
play a therapeutic role in a variety of gastrointestinal diseases, including IBD, by reducing or 
inhibiting the inflammatory responses (170).  
Since IBD is associated with increased oxidative stress and mitochondrial dysfunction, PHB1 
could play a role in combating oxidative stress in the gut, in particular by inhibiting GSH depletion. 
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Indeed, IEC overexpressing PHB have been found to show an increase in GSH levels and an 
induction of glutathione-S-transferase  expression (260).  
Furthermore, TNFα (96) may contribute to decreasing PHB1 mucosal levels: TNFα has been 
found to reduce PHB1 levels in cultured IEC and in animals (262). TNFα activates the transcription 
factor NF-B, which decreases PHB expression. Overexpression of PHB1 in these cells protects 
against the deleterious effects of TNFα and NF-B on the intestinal barrier function by inhibiting 
TNFα-induced NF-B (262). This finding suggests that PHB1 may be crucial in modulating intestinal 
inflammatory processes. 
Contrary to TNFα, IL-6 has been shown to up-regulate PHB expression in IEC and in the 
intestine; cytokine increases PHB mRNA and protein and induces PHB promoter activation. The IL-6 
response element site in the PHB promoter is required for maximal basal promoter activity and 
responsiveness to IL-6 (261). Thus, IL-6 may protect intestinal mucosa from oxidative stress and 
inflammation by increasing PHB levels and inducing antioxidant defenses. In support to this 
observation, IL-6
-/-
 mice show reduced PHB expression in the colon compared to wild-type mice 
(261), and suffer more severe erosion of the intestinal epithelium during experimental colitis (257). 
PHB1 levels in the IEC of transgenic mice overexpressing PHB1 can be restored during 
inflammation (263); in these mice, it has been observed that prohibitin acts as an antioxidant, by 
decreasing oxidative stress and regulating the antioxidant response. Indeed, PHB has been shown to 
sustain activation of the transcriptional regulator of antioxidant responses Nrf2, and to protect from 
inflammation-associated oxidative stress (263). 
To demonstrate the therapeutic efficacy of PHB restoration for human IBD, adenovirus 
infection and nanoparticle delivery of biologically-active PHB1 have been tested in mice during 
experimental colitis: both methods of delivery have resulted in increased PHB1 levels in colon 
epithelial cells and in reduced severity of induced colitis (264).  
Taken together, all these in vivo and in vitro experimental studies consistently indicate that the 
PHB complex tends to protect IEC from inflammation-associated oxidative stress, thereby 
counteracting the mucosal barrier disruption induced by increasing steady-state levels of oxidants. On 
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these bases, the restoration of physiological levels of PHB1 in the intestinal mucosa affected by IBD 
appears to be a very promising and interesting approach (259). 
 
VII E. Suitable dietary regimens in IBD patients.  
 Over recent years, a small number of clinical trials have been carried out to evaluate the 
efficacy of special nutritional regimens in preventing relapse in patients with quiescent IBD. The only 
study thus far performed in a randomized, multicenter, placebo-controlled manner, which employed 
polyphenols to prevent IBD reactivation, showed that chronic dietary administration of curcumin plus 
sulfasalazine for six months, to patients (n=45) with ulcerative colitis, significantly reduced the 
percent incidence of disease relapse (5%) versus a similar group of patients (n=44) receiving only the 
anti-inflammatory drug (20%). The two groups of UC patients were then followed for six further 
months, during which only the anti-inflammatory therapy was administered, without curcumin. At the 
end of this second period, the number of relapses was quite similar in the two groups (84).  
More recently, other clinical trials have used polyphenols as a dietary supplement to 
counteract or prevent overexpression of inflammatory cytokines and adhesion molecules, not in IBD 
patients but in individuals with a high risk of developing atherosclerosis. In 67 male high-risk 
volunteers, who drank a standardized amount either of ethanol or of dealcoholized red wine, the 
phenolic extract from red wine was shown to down-regulate expression of certain adhesion molecules 
and cytokines in blood mononuclear cells, in particular intercellular adhesion molecule (ICAM)-1, E 
selectin and IL-6 (39). 
 Another type of so-called “nutritional therapy” employed a comprehensive mixture of 
aminoacids and vitamins, including the antioxidant vitamins A, C, and E (elemental diet patented as 
Elental), for home treatment of quiescent IBD, with the aim of delaying disease reactivation. Fifty CD 
patients in remission where randomly divided into two subgroups, one receiving a free diet and the 
other receiving a diet supplemented with the aminoacids/vitamins. After two years’ follow-up, the 
number of cases of disease reactivation was reduced to half in patients receiving nutritional therapy 
(34% relapses) versus those on a free diet (64% relapses) (250). Use of the same elemental diet has 
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recently been compared to the frequently-used drug 6-mercaptopurine, as maintenance therapy of CD 
in remission. After two years’ follow-up, the number of patients (n=32) receiving the elemental diet, 
rich in vitamins and aminoacids, showed a relapse rate (51%) quite similar to that of CD patients 
(n=30) receiving 6-mercaptopurine instead (40%). The researchers concluded that suitable nutritional 
therapy could achieve comparable efficacy to purine antimetabolites in preventing reactivation of CD 
(85). 
 
VII F. Lipoxins and resolvins: new drug candidates for IBD treatment 
There is considerable interest in the relation between fatty acids and gut inflammation. During 
acute inflammation, resident cells in the injured tissue produce soluble pro-inflammatory mediators, 
such as eicosanoids deriving from ω6-AA. This regulates early events in the inflammatory response, 
promoting the influx of neutrophils from the blood and their phagocytic activity. The resolution of 
acute inflammation is an active programmed process with a self-limited response of leukocytes, which 
provides a temporal switch in lipid mediator production within the family of eicosanoids, from pro- to 
anti-inflammatory PGs and LTs, and also their fatty acid precursors. Indeed, during the latter phase of 
inflammation, changes occur in the quantity and quality of the leukocyte infiltrate. In this phase, 
neutrophil numbers decrease, dying by apoptosis, while lymphocytes and monocytes/macrophages 
predominate, and combine to resolve inflammation by means of the endogenous generation of specific 
ω3- and ω6-PUFA derivatives with anti-inflammatory and pro-resolving activity, including lipoxins 
(LXs) and resolvins (Rvs) (227). 
Chronic inflammation is now believed to be the evolution of unresolved acute inflammation 
that can no longer be controlled. To prevent chronicization, it appears to be more important to 
improve the resolution of the process, rather than inhibiting inflammation by using anti-inflammatory 
glucocorticoids (226). 
Endogenous LXs and Rvs have aroused interest, because of their ability to promote the 
clearance of apoptotic cells by macrophages, and to limit the infiltration of pro-inflammatory 
leukocytes, which eventually leave the inflamed site. LXs and Rvs are also generated after acetyl 
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salicylic acid treatment, providing a basis for understanding a novel mechanism of action of both 
nonsteroidal anti-inflammatory drugs (NSAIDs) and dietary ω3-PUFA supplementation. 
Their function in mediating the resolution of inflammation makes them new promising 
candidates for regulating inflammation-associated disorders like IBD.  
LXs are generated through transcellular biosynthesis, in which cell-cell interactions activate 
15-LOX in different cell types at the inflammation site, to produce 15(S)-hydroperoxyeicosatetraenoic 
acid from AA. This compound is rapidly incorporated in leukocytes, and converted by 5-LOX and 
hydrolase into LXA4 or LXB4. 
Endogenous LX analogs are also produced after exogenous administration of aspirin (but not with 
other NSAIDs), which irreversibly acetylates COX-2 in endothelial cells or leukocytes, switching AA 
derivatives from pro-inflammatory PGs and LTs to LXs. Acetylated COX-2 is still active, but 
generates 15(R)-hydroxyeicosatetraenoic acid that, in turn, in endothelial or epithelial cells is 
converted by 15-LOX into the potent anti-inflammatory 15-LXA4 epimer, known as 15-epi-LXA4 or 
aspirin-triggered lipoxin (ATL) (226, 243).  
LXs limit the number of neutrophils in inflamed areas: they stimulate macrophages to ingest 
and clear neutrophilic apoptotic bodies, and promote only the infiltration of non-inflammatory 
monocytes, which produce anti-inflammatory and pro-fibrogenic cytokines. In particular, the widely 
studied LXA4 signals, through a G protein-coupled receptor, to inhibit chemotaxis and 
transmigration, and down-regulates pro-inflammatory pathways, such as ERK and p38 MAPK; it 
limits the activity of AP-1 and NF-B transcription factors, NOX-dependent ROS production, and 
inhibits the expression of inflammatory cytokines such as IL-8 and TNFα (9, 108,  137). Synthetic 
metabolically-stable LX analogs have been made to mimic anti-inflammatory LX actions, and prolong 
its active effect. A stable LXA4 analog has been found to down-regulate IL-8 mRNA expression via 
NF-B suppression T84 polarized IEC infected by S. typhimurium, which can be considered an in 
vitro model of inflammation (81). The therapeutic anti-inflammatory effect of LXA4 analogs has been 
verified on the DSS-induced murine colitis model, in which oral administration of this active analog 
led to the attenuation of colitis and down-regulation of pro-inflammatory gene expression (81). 
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Similar effects are reported for a synthetic analog of ATL examined in TNBS-induced experimental 
colitis. Oral administration of this analog decreased mucosal mRNA level of COX-2, macrophage 
inflammatory protein-2 (MIP-2), TNFα, IL-2 and IFNγ, showing anti-inflammatory efficacy similar to 
that observed with prednisolone (71). 
Studies in animal models of colitis, in which exogenous LX analogs resolve inflammation, 
support the hypothesis that LX deficiency plays a role in IBD. Mangino and colleagues found a 
decrease of LX production in colonic mucosal tissue from UC patients, compared to both organ 
donors and patients affected by slow-transit-time constipation. They found a decrease of epithelial 15-
LOX in UC biopsies, suggesting defective biosynthesis of LXs in these patients (160). 
These findings were strengthened by a recent study on humans that found elevated LXA4 
biosynthesis in mucosal biopsies from UC patients in medically-induced remission, confirming the 
hypothesis that LXA4 exerts protective and/or reparative action in human intestinal inflammation 
(276). 
Resolvins are potent bioactive compounds, which exert their anti-inflammatory function by 
blocking trans-endothelial leukocyte migration and infiltration. They derive from the degradation of 
eicosapentanoic (EPA) and docosahexaenoic (DHA) ω3-PUFAs through COX-2 and LOX enzymes. 
RvE-series has been identified in endothelial cells expressing COX-2 treated with aspirin: as in the 
case of LXs, Rvs are generated by acetylated COX-2, which converts EPA to 18(R)-
hydroxyeicosapentanoic acid, and eventually to RvE1 or RvE2, by leukocyte 5-LOX. RvD-series is 
generated from DHA by 15-LOX or aspirin-derived acetylated COX-2, and 5-LOX, through 
intermediates 17(S)-hydroxydocosahexaenoic acid or 17(R)-hydroxydocosahexaenoic acid (in the 
presence of aspirin). Notably, biosynthesis of RvE1 can be also initiated by P450-like enzymes in 
bacteria (228). 
Resolvins may provide the molecular means underlying ω3-PUFA's beneficial effects in IBD. 
Exogenous RvE1 administration protects against the development of TNBS-colitis in mice. 100 ng of 
RvE1 reduced leukocyte peritoneal infiltration by 50%, and increased survival and histological scores. 
Notably, a significant reduction in TNFα, IL-12-p40 subunit, iNOS, and COX-2 was observed in mice 
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that had received RvE1 (10). It has recently been reported that RvE1 treatment in mice with DSS-
induced colitis led to less severe histological features of colitis, with a reduction in body-weight loss. 
In this experimental model, RvE1 administration reduced NF-κB phosphorylation and expression of 
the NF-κB-dependent pro-inflammatory mediators TNFα, IL-1β, and IL-6. (105). Anti-inflammatory 
effects of the aspirin-triggered RvD1, of its precursor 17-hydroxy-DHA, and of RvD2 were 
demonstrated in DSS- or TNBS-induced colitis, reducing colonic cytokine levels as well as mRNA 
expression of NF-B and adhesion molecules (22).  
Elucidating the molecular basis of ω3-PUFA action in generating local mediator Rvs, and 
their effectiveness in clinical applications as anti-inflammatory therapy in IBD, are still major issues; 
data currently available only concern experimental models. Transgenic fat-1 mice with high tissue 
levels of ω3-PUFA, because they have been engineered to express C. elegans fat-1 gene encoding for 
ω3 fatty acid desaturase, showed a significant production of Rvs. Further, the same experimental 
model was protected against DSS-induced colitis, leading to a manifest reduction in tissue injury 
inflammation, with significantly low amounts of TNFα, IL-1β cytokines, as well as reduced NF-κB 
activity (99). 
A diet involving the intake of the recommended ω6/ω3-PUFA ratio could undoubtedly help to 
delay or prevent the progression of IBD. However, clinical and epidemiological studies on the role of 
PUFA supplementation in dampening inflammation in IBD, through the local production of anti-
inflammatory lipid derivatives, still do not afford conclusive results (35, 287). 
 
VIII. CONCLUSIONS 
This review has examined the current understanding of the mechanisms regulating intestinal 
barrier integrity, as well as its pathologic alterations during IBD development, with special emphasis 
on the pathogenetic role played by the multiple redox changes occurring during development of these 
diseases. The main indications and suggestions for targeted therapy of IBD arising from recent 
molecular studies have been examined and discussed. 
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The experimental studies carried out in recent years on the pathogenesis of IBD, together with 
the observational studies carried out so far on human patients, have defined the main cellular and 
molecular events underlying the onset and development of this frequent disease, whose incidence is 
increasing world-wide.  
In IBD, the host’s impaired ability to properly recognize and process the molecular signals 
activated by luminal antigens results in a chronic disease process, in which phagocytes and lymphoid 
cells are the key players. Together, these cells overproduce cytokines, inflammatory eicosanoids, and 
reactive oxidant species that, in turn, decrease cell and tissue antioxidant defenses, provoking a net 
imbalance of the local redox state toward oxidation. In addition, unbalanced ROS and RNS 
production exacerbates the inflammatory process, because of the marked pro-inflammatory properties 
of these products and their derivatives, in particular the highly-diffusible lipid oxidation products. A 
vicious circle then occurs between inflammation and oxidant species, amplifying the overall 
pathological process and hampering its resolution. 
With regard to the markedly altered cell signaling that characterizes molecular and cellular 
interactions in the affected intestine, a pivotal role is now known to be played by redox-sensitive 
transcription factor NF-B, because of the many inflammatory cytokines this factor stimulates at the 
transcriptional level. 
Interestingly, the modern approach to IBD pathogenesis, together with the recent progress in 
molecular medicine, point to treatment of the oxidative stress associated with IBD not by means of 
simple (and often ineffective) supplementation with antioxidants, but rather by designing a proper 
dietary intake of specific lipids with molecular modulation of the main sources of reactive species, i.e. 
NOXs, NOSs, mitochondria and inflammasomes. 
Treatment of IBD with biological drugs is a new and promising therapeutic frontier, 
notwithstanding the fact that only TNFα blockers have yet been approved for the management of 
patients with moderate/severe CD, who are unresponsive to conventional therapies. Correct 
modulation of NF-B-driven gene expression, suitable prohibitin-controlled generation of 
mitochondrial ROS, plus a similarly adequate quenching of NOX-dependent ROS generation and 
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membrane lipid oxidation, should result in better, and perhaps more personalized, management of this 
very common disease process. A therapeutic approach that is unlikely to eradicate the disease per se 
but will, in the not-too-distant future, undoubtedly limit its progression and expansion (Figure 11).  
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List of abbreviations 
7-OH: 7α-hydroxycholesterol 
7-OH: 7β-hydroxycholesterol 
7K: 7-ketocholesterol 
8-OHdG: 8-hydroxy-2′-deoxyguanosine 
AA: arachidonic acid 
AJ: adherens junction 
AJC: apical junctional complex  
AP-1: activator protein-1 
ATG: autophagy-related protein 
ATL: aspirin-triggered lipoxin 
Bad: Bcl-xL/Bcl-2 associated death promoter 
Bcl-2: B-cell lymphoma 2 anti-apoptotic protein 
Bim: Bcl-2 interacting mediator of cell death 
CARD: caspase activation and recruitment domain 
CAT: catalase 
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CD: Crohn’s disease 
COX: cyclooxygenase 
CpG: cytosine nucleotide next to guanine separated by a phosphate 
DAMP: danger associated molecular patterns 
DC: dendritic cells 
DHA: docosahexaenoic acid 
DSS: dextran sodium sulfate 
DUOX: Dual Oxidase 
EC: endothelial cells 
EGF: epidermal growth factor 
eNOS: endothelial nitric oxide synthase 
EPA: eicosapentanoic acid 
ERK: extracellular signal regulated kinase 
FADD: Fas-associated death domain protein 
FGF: fibroblast growth factor 
FLIP: flice-like inhibitory protein 
FOXP3: forkhead box protein 3 
GC: goblet cell 
GM-CSF: granulocyte-macrophage colony-stimulating factor 
Gpx: glutathione peroxidase 
GSH: reduced glutathione 
GSSG: glutathione disulfide 
HBD: human β-defensin 
HD:  human α-defensin 
HLA: human leukocyte antigen 
HNE: 4-hydroxynonenal 
IB: inhibitor of B 
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IAP: inhibitor of apoptosis protein  
IBD: Inflammatory bowel disease 
ICAM: intercellular adhesion molecule 
IEC: intestinal epithelial cell 
IFN: interferon 
IKK: IB kinase 
IL: interleukin 
iL: intraepithelial lymphocyte 
iNOS: inducible nitric oxide synthase 
IPAF: IL-1β converting enzyme-protease activating factor 
IRF: interferon regulatory factor 
IRGM: immunity-related guanosine triphosphatase M 
JAK: just another kinase 
JAM: junctional adhesion molecule 
JNK: c-Jun N-terminal kinase  
L
.
: lipid radical 
LO
.
: alkoxy radical 
LOO
.
:
 
peroxy radical 
LOX: lipoxygenase 
LPS: lipopolysaccharide 
LRRK2: leucine-rich repeat kinase 2 
LRRs: leucine-rich repeats 
LT: leukotriene 
LX: lipoxin  
M: macrophage 
MAMPs: microbe-associated molecular patterns  
MAPK: mitogen activated protein kinase 
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MC: microfold cells 
MCP-1: monocyte chemotactic protein-1 
MDA5: melanoma differentiation-associated gene 5 
MIP: macrophage inflammatory protein 
MLCK: myosin light-chain kinase 
MMP: matrix metalloproteinase 
MPO: myeloperoxidase 
MUC: mucin  
MYD88: myeloid differentiation primary-response gene 88 
NAC: N-acetyl-cysteine 
NEMO: NF-B essential modulator 
NF-B: nuclear factor-B 
NLR: NOD-like receptor 
NLRP: nucleotide-binding oligomerization domain, leucine rich repeat and pyrin domain 
NO: nitric oxide 
NOD: nucleotide-binding oligomerization domain 
NOX: NADPH oxidase 
Nrf2: nuclear factor-erythroid 2-related factor 2 
NSAID: nonsteroidal anti-inflammatory drugs 
Ox-PLs: oxidized phospholipids 
PAMPs:  pathogen-associated molecular patterns  
PC: Paneth cell 
PDGF: platelet-derived growth factor 
PG: prostaglandin 
PHB: prohibitin 
PI3K: phosphatidylinositol 3 kinase 
PKC: protein kinase C 
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Plase A2: phospholipase A2 
PMN: polymorphonuclear cells 
PRRs:  pathogen recognition receptors 
PUFA: polyunsaturated fatty acid 
PUMA: p53 upregulated modulator of apoptosis 
PYK2: proline-rich tyrosine kinase 2 
RANTES: regulated upon activation, normal T cell expressed and secreted 
RELMβ: resistin-like molecules beta 
RICK: RIP-like interacting caspase-like apoptosis regulatory protein kinase 
RIG-I: retinoic acid inducible gene I 
RIP: receptor-interacting protein 
RLRs: RIG-I-like receptors 
RNS: reactive nitrogen species 
ROS: reactive oxygen species 
Rv: resolvin 
SOD: superoxide dismutase 
STAT: signal transducer and activator of transcription 
TFF: trefoil factor 
TGFβ: transforming growth factor beta 
Th: T helper 
TIR: Toll–IL-1–resistance 
TJ: tight junction 
TLR: toll-like receptor 
TNBS: trinitrobenzene sulfonic acid 
TNF-R: tumor necrosis factor receptor  
TNFα: tumor necrosis factor α 
TRADD: tumor necrosis factor receptor type 1-associated death domain 
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TRAF2: TNF-receptor-associated factor 2 
Tregs: regulatory T lymphocytes 
TRIF: TIR-domain-containing adapter-inducing interferon beta 
Trx: thioredoxin 
Trxip: thioredoxin Trx-interacting protein 
TrxSS: 
UC: ulcerative colitis 
VCAM: vascular cell adhesion molecule 
VEGF: vascular endothelial growth factor 
ZO-1: zonula occludens-1 
Biasi 
62 
 
References 
1. Aggarwal BB, Vijayalekshmi RV, and Sung B. Targeting inflammatory pathways for 
prevention and therapy of cancer: short-term friend, long-term foe. Clin Cancer Res 15: 425-
430, 2009. 
2. Aghdassi E, Wendland BE, Steinhart AH, Wolman SL, Jeejeebhoy K, and Allard JP. 
Antioxidant vitamin supplementation in Crohn's disease decreases oxidative stress. A 
randomized controlled trial. Am J Gastroenterol 98: 348-353, 2003. 
3. Akira S, Uematsu S, and Takeuchi O. Pathogen recognition and innate immunity. Cell 124: 
783-801, 2006. 
4. Allen IC, TeKippe EM, Woodford RM, Uronis JM, Holl EK, Rogers AB, Herfarth HH, Jobin 
C, and Ting JP. The NLRP3 inflammasome functions as a negative regulator of tumorigenesis 
during colitis-associated cancer. J Exp Med 207: 1045-1056, 2010. 
5. Anand PK, Tait SW, Lamkanfi M, Amer AO, Nunez G, Green DR, and Kanneganti TD. TLR2 
and RIP2 pathways mediate autophagy of Listeria monocytogenes via ERK activation. J Biol 
Chem 286: 42981-42991, 2011. 
6. Anderson CA, Boucher G, Lees CW, Franke A, D'Amato M, Taylor KD, Lee JC, Goyette P, 
Imielinski M, Latiano A, Lagacé C, Scott R, Amininejad L, Bumpstead S, Baidoo L, 
Baldassano RN, Barclay M, Bayless TM, Brand S, Büning C, Colombel JF, Denson LA, De 
Vos M, Dubinsky M, Edwards C, Ellinghaus D, Fehrmann RS, Floyd JA, Florin T, 
Franchimont D, Franke L, Georges M, Glas J, Glazer NL, Guthery SL, Haritunians T, Hayward 
NK, Hugot JP, Jobin G, Laukens D, Lawrance I, Lémann M, Levine A, Libioulle C, Louis E, 
McGovern DP, Milla M, Montgomery GW, Morley KI, Mowat C, Ng A, Newman W, Ophoff 
RA, Papi L, Palmieri O, Peyrin-Biroulet L, Panés J, Phillips A, Prescott NJ, Proctor DD, 
Roberts R, Russell R, Rutgeerts P, Sanderson J, Sans M, Schumm P, Seibold F, Sharma Y, 
Simms LA, Seielstad M, Steinhart AH, Targan SR, van den Berg LH, Vatn M, Verspaget H, 
Walters T, Wijmenga C, Wilson DC, Westra HJ, Xavier RJ, Zhao ZZ, Ponsioen CY, Andersen 
V, Torkvist L, Gazouli M, Anagnou NP, Karlsen TH, Kupcinskas L, Sventoraityte J, Mansfield 
Biasi 
63 
 
JC, Kugathasan S, Silverberg MS, Halfvarson J, Rotter JI, Mathew CG, Griffiths AM, Gearry 
R, Ahmad T, Brant SR, Chamaillard M, Satsangi J, Cho JH, Schreiber S, Daly MJ, Barrett JC, 
Parkes M, Annese V, Hakonarson H, Radford-Smith G, Duerr RH, Vermeire S, Weersma RK, 
and Rioux JD. Meta-analysis identifies 29 additional ulcerative colitis risk loci, increasing the 
number of confirmed associations to 47. Nat Genet 43: 246-252, 2011.  
7. Andresen L, Jorgensen VL, Perner A, Hansen A, Eugen-Olsen J, and Rask-Madsen J. 
Activation of nuclear factor kappaB in colonic mucosa from patients with collagenous and 
ulcerative colitis. Gut 54: 503-509, 2005. 
8. Ardite E, Sans M, Panés J, Romero FJ, Piqué JM, and Fernández-Checa JC.Replenishment of 
glutathione levels improves mucosal function in experimental acute colitis. Lab Invest 80: 735-
744, 2000. 
9. Ariel A, Chiang N, Arita M, Petasis NA, and Serhan CN. Aspirin-triggered lipoxin A4 and B4 
analogs block extracellular signal-regulated kinase-dependent TNF-alpha secretion from human 
T cells. J Immunol 170: 6266-6272, 2003. 
10. Arita M, Yoshida M, Hong S, Tjonahen E, Glickman JN, Petasis NA, Blumberg RS, and 
Serhan CN. Resolvin E1, an endogenous lipid mediator derived from omega-3 
eicosapentaenoic acid, protects against 2,4,6 trinitrobenzene sulfonic acid-induced colitis. Proc 
Natl Acad Sci U S A 102: 7671-7676, 2005. 
11. Artal-Sanz M and Tavernarakis N. Prohibitin and mitochondrial biology. Trends Endocrinol 
Metab 20: 394-401, 2009. 
12. Asehnoune K, Strassheim D, Mitra S, Kim JY, and Abraham E. Involvement of reactive 
oxygen species in Toll-like receptor 4-dependent activation of NF-kappa B. J Immunol 172: 
2522-2529, 2004. 
13. Balkis Budin S, Othman F, Louis SR, Abu Bakar M, Radzi M, Osman K, Das S, and Mohamed 
J. Effect of alpha lipoic acid on oxidative stress and vascular wall of diabetic rats. Rom J 
Morphol Embryol 50: 23-30, 2009. 
Biasi 
64 
 
14. Banan A, Choudhary S, Zhang Y, Fields JZ, anf Keshavarzian A. Oxidant-induced intestinal 
barrier disruption and its prevention by growth factors in a human colonic cell line: role of the 
microtubule cytoskeleton. Free Radic Biol Med 28: 727-738, 2000. 
15. Baregamian N, Song J, Bailey CE, Papaconstantinou J, and Evers BM, Chung DH. Tumor 
necrosis factor-alpha and apoptosis signal-regulating kinase 1 control reactive oxygen species 
release, mitochondrial autophagy, and c-Jun N-terminal kinase/p38 phosphorylation during 
necrotizing enterocolitis. Oxid Med Cell Longev 2: 297-306, 2009. 
16. Barksby HE, Lea SR, Preshaw PM, and Taylor JJ. The expanding family of interleukin-1 
cytokines and their role in destructive inflammatory disorders. Clin Exp Immunol 149: 217-225, 
2007. 
17. Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, Silverberg MS, 
Taylor KD, Barmada MM, Bitton A, Dassopoulos T, Datta LW, Green T, Griffiths AM, 
Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, Targan SR, 
Xavier RJ; NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop M, Belaiche J, 
Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, Zelenika D, 
Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, the Belgian-French IBD 
Consortium, the Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, 
Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, 
Bumpstead S, Gwilliam R, Tremelling M, Deloukas P, Mansfield J, Jewell D, Satsangi J, 
Mathew CG, Parkes M, Georges M, and Daly MJ. Genome-wide association defines more than 
30 distinct susceptibility loci for Crohn's disease. Nat Genet 40: 955-962, 2008. 
18. Baud V and Karin M. Signal transduction by tumor necrosis factor and its relatives. Trends Cell 
Biol 11: 372-377, 2001. 
19. Bauer C, Duewell P, Mayer C, Lehr HA, Fitzgerald KA, Dauer M, Tschopp J, Endres S, Latz 
E, and Schnurr, M. Colitis induced in mice with dextran sulfate sodium  (DSS) is mediated by 
the NLRP3 inflammasome. Gut 59: 1192-1199, 2010. 
Biasi 
65 
 
20. Begue B, Verdier J, Rieux-Laucat F, Goulet O, Morali A, Canioni D, Hugot JP, Daussy C, 
Verkarre V, Pigneur B, Fischer A, Klein C, Cerf-Bensussan N, and Ruemmele FM. Defective 
IL10 Signaling Defining a Subgroup of Patients With Inflammatory Bowel Disease. Am J 
Gastroenterol 106: 1544-1555, 2011. 
21. Beltrán B, Nos P, Dasí F, Iborra M, Bastida G, Martínez M, O'Connor JE, Sáez G, Moret I, and 
Ponce J. Mitochondrial dysfunction, persistent oxidative damage, and catalase inhibition in 
immune cells of naïve and treated Crohn's disease. Inflamm Bowel Dis 16: 76-86, 2010. 
22. Bento AF, Claudino RF, Dutra RC, Marcon R, and Calixto JB. Omega-3 fatty acid-derived 
mediators 17(R) hydroxy docosahexaenoic acid, aspirin-triggered resolvin D1 and resolvin D2 
prevent experimental colitis in mice. J Immunol 187: 1957-1969, 2011. 
23. Bernstein CN, Fried M, Krabshuis JH, Cohen H, Eliakim R, Fedail S, Gearry R, Goh KL, 
Hamid S, Khan AG, LeMair AW, Malfertheiner P, Ouyang Q, Rey JF, Sood A, Steinwurz F, 
Thomsen OO, Thomson A, and Watermeyer G. World Gastroenterology Organization Practice 
Guidelines for the diagnosis and management of IBD in 2010. Inflamm Bowel Dis 16: 112-124, 
2010.  
24. Biasi F, Astegiano M, Maina M, Leonarduzzi G, and Poli G. Polyphenol supplementation as a 
complementary medicinal approach to treating inflammatory bowel disease. Curr Med Chem 
18: 4851-4865, 2011. 
25. Biasi F, Tessitore L, Zanetti D, Cutrin JC, Zingaro B, Chiarpotto E, Zarkovic N, Serviddio G, 
and Poli G. Associated changes of lipid peroxidation and transforminggrowth factor beta1 
levels in human colon cancer during tumour progression. Gut 50: 361-367, 2002.  
26. Biasi F, Vizio B, Mascia C, Gaia E, Zarkovic N, Chiarpotto E, Leonarduzzi G, and Poli G. c-
Jun N-terminal kinase upregulation as a key event in the proapoptotic interaction between 
transforming growth factor-beta1 and 4-hydroxynonenal in colon mucosa. Free Radic Biol Med 
41: 443-454, 2006.  
27. Biasi F, Mascia C, Astegiano M, Chiarpotto E, Nano M, Vizio B, Leonarduzzi G, and Poli G. 
Pro-oxidant and proapoptotic effects of cholesterol oxidation products on human colonic 
Biasi 
66 
 
epithelial cells: a potential mechanism of inflammatory bowel disease progression. Free Radic 
Biol Med 47: 1731-1741, 2009.  
28. Binion DG, Rafiee P, Ramanujam KS, Fu S, Fisher PJ, Rivera MT, Johnson CP, Otterson MF, 
Telford GL, and Wilson KT. Deficient iNOS in inflammatory bowel disease intestinal 
microvascular endothelial cells results in increased leukocyte adhesion. Free Radic Biol Med 
29: 881-888, 2000. 
29. Bochkov VN, Philippova M, Oskolkova O, Kadl A, Furnkranz A, Karabeg E, Afonyushkin T, 
Gruber F, Breuss J, Minchenko A, Mechtcheriakova D, Hohensinner P, Rychli K, Wojta J, 
Resink T, Erne P, Binder BR, and Leitinger N. Oxidized phospholipids stimulate angiogenesis 
via autocrine mechanisms, implicating a novel role for lipid oxidation in the evolution of 
atherosclerotic lesions. Circ Res 99: 900-908, 2006. 
30. Brown AJ and Jessup W. Oxysterols: Sources, cellular storage and metabolism, and new 
insights into their roles in cholesterol homeostasis. Mol Aspects Med 30: 111-122, 2009. 
31. Brown SJ, Gianni D, Bokoch G, Mercer BA, Hodder P, and Rosen HR. Probe report for  NOX1 
inhibitors. Probe Reports from the NIH Molecular Libraries Program [Internet]. Bethesda 
(MD): National Center for Biotechnology Information (US); 2010. Bookshelf ID: 
NBK47342PMID:21433358. 
32. Bruewer M, Luegering A, Kucharzik T, Parkos CA, Madara JL, Hopkins AM, and Nusrat A. 
Proinflammatory cytokines disrupt epithelial barrier function by apoptosis-independent 
mechanisms. J Immunol 171: 6164-6172, 2003.  
33. Burke JP, Mulsow JJ, O'Keane C, Docherty NG, Watson RW, and O'Connell PR. Fibrogenesis 
in Crohn's disease. Am J Gastroenterol 102: 439-448, 2007. 
34. Burrin DG, and Stoll B. Emerging aspects of gut sulfur amino acid metabolism. Curr Opin Clin 
Nutr Metab Care 10: 63-68, 2007. 
35. Calder PC. Omega-3 polyunsaturated fatty acids and inflammatory processes: Nutrition or 
pharmacology? Br J Clin Pharmacol 2012, Jul 6. Epub ahead of print. 
Biasi 
67 
 
36. Cao W, Fiocchi C, and Pricolo VE. Production of IL-1beta, hydrogen peroxide, and nitric oxide 
by colonic mucosa decreases sigmoid smooth muscle contractility in ulcerative colitis. Am J 
Physiol Cell Physiol 289: C1408-C1416, 2005. 
37. Carroll IM, Andrus JM, Bruno-Bárcena JM, Klaenhammer TR, Hassan HM, and Threadgill 
DS. Anti-inflammatory properties of Lactobacillus gasseri expressing manganese superoxide 
dismutase using the interleukin 10-deficient mouse model of colitis. Am J Physiol Gastrointest 
Liver Physiol 293: G729-G738, 2007. 
38. Chaparro M, Burgueño P, Iglesias E, Panés J, Muñoz F, Bastida G, Castro L, Jiménez C, 
Mendoza JL, Barreiro-de Acosta M, Senent SG, Gomollón F, Calvet X, García-Planella E, 
Gómez M, Hernández V, Hinojosa J, Mañosa M, Nyssen OP, and Gisbert JP. Infliximab 
salvage therapy after failure of ciclosporin in corticosteroid-refractory ulcerative colitis: a 
multicentre study.  Aliment Pharmacol Ther 35: 275-283, 2012. 
39. Chiva-Blanch G, Urpi-Sarda M, Llorach R, Rotches-Ribalta M, Guillén M, Casas R, Arranz S, 
Valderas- Martinez P, Portoles O, Corella D, Tinahones F, Lamuela-Raventos RM, Andres-
Lacueva C, and Estruch R. Differential effects of polyphenols and alcohol of red wine on the 
expression of adhesion molecules and inflammatory cytokines related to atherosclerosis: a 
randomized clinical trial. Am J Clin Nutr 95: 326-334, 2012. 
40. Choi YJ, Seelbach MJ, Pu H, Eum SY, Chen L, Zhang B, Hennig B, and Toborek M. 
Polychlorinated biphenyls disrupt intestinal integrity via NADPH oxidase-induced alterations 
of tight junction protein expression. Environ Health Perspect 118: 976-981, 2010. 
41. Chouchana L, Narjoz C, Beaune P, Loriot MA, and Roblin X. Review article: benefits of 
pharmacogenetics for improving thiopurine therapy in inflammatory bowel disease. Aliment 
Pharmacol Ther 35: 15-36, 2012. 
42. Circu ML and Aw TY. Redox biology of the intestine. Free Radic Res 45: 1245-1266, 2011. 
43. Clevers H. At the crossroads of inflammation and cancer. Cell 118: 671-674, 2004. 
44. Collingwood S and Witherington J. Therapeutic approaches towards the treatment of 
gastroinstestinal disorders. Drug News Perspect 20: 139-144, 2007. 
Biasi 
68 
 
45. Colombel JF, Sandborn WJ, Reinisch W, Mantzaris GJ, Kornbluth A, Rachmilewitz  D, 
Lichtiger S, D'Haens G, Diamond RH, Broussard DL, Tang KL, van der Woude CJ, and 
Rutgeerts P; SONIC Study Group. Infliximab, azathioprine, or combination therapy for Crohn's 
disease. N Engl J Med 362: 1383-1395, 2010. 
46. Coombes JL, Siddiqui KR, Arancibia-Cárcamo CV, Hall J, Sun CM, Belkaid Y, and Powrie F. 
A functionally specialized population of mucosal CD103+ DCs induces Foxp3+ regulatory T 
cells via a TGF-beta and retinoic acid-dependent mechanism. J Exp Med 204: 1757-1764, 2007. 
47. Cordero Ruiz P, Castro Márquez C, Méndez Rufián V, Castro Laria L, Caunedo Álvarez A, 
Romero Vázquez J, and Herrerías Gutiérrez JM. Efficacy of adalimumab in patients with 
Crohn's disease and failure to infliximab therapy: a clinical series. Rev Esp Enferm Dig 
103:294-298, 2011. 
48. Corleto VD, Pagnini C, Margagnoni G, Guagnozzi D, Torre MS, Martorelli M, Latiano A, 
Annese V, Caprilli R, and Delle Fave G. IL-1beta-511 and IL-1RN*2 polymorphisms in 
inflammatory bowel disease: An Italian population study and meta-analysis of European 
studies. Dig Liver Dis 42: 179-184, 2010.  
49. Cosnes J, Gower-Rousseau C, Seksik P, and Cortot A. Epidemiology and natural history of 
inflammatory bowel diseases. Gastroenterology 140: 1785-1794, 2011. 
50. Cruz CM, Rinna A, Forman HJ, Ventura AL, Persechini PM, and Ojcius DM. ATP activates a 
reactive oxygen species-dependent oxidative stress response and secretion of proinflammatory 
cytokines in macrophages. J Biol Chem 282: 2871-2879, 2007.  
51. Damiani CR, Benetton CA, Stoffel C, Bardini KC, Cardoso VH, Di Giunta G, Pinho RA, Dal-
Pizzol F, and Streck EL. Oxidative stress and metabolism in animal model of colitis induced by 
dextran sulfate sodium. J Gastroenterol Hepatol 22: 1846-1851, 2007. 
52. Danese S, Sans M, and Fiocchi C. The CD40/CD40L costimulatory pathway in inflammatory 
bowel disease. Gut 53: 1035-1043, 2004. 
53. Danese S and Mantovani A. Inflammatory bowel disease and intestinal cancer: a paradigm of 
the Yin-Yang interplay between inflammation and cancer. Oncogene 29: 3313-3323, 2010. 
Biasi 
69 
 
54. Danese S, Fiorino G, and Reinisch W. Review article: Causative factors and the clinical 
management of patients with Crohn's disease who lose response to anti-TNF-α therapy. Aliment 
Pharmacol Ther 34: 1- 10, 2011. 
55. Danesi F, Philpott M, Huebner C, Bordoni A, and Ferguson LR. Food-derived bioactives as 
potential regulators of the IL-12/IL-23 pathway implicated in inflammatory bowel diseases. 
Mutat Res 690: 139-144, 2010. 
56. De Bacquer D, Clays E, Delanghe J, and De Backer G. Epidemiological evidence for an 
association between habitual tea consumption and markers of chronic inflammation. 
Atherosclerosis 189: 428–435, 2006. 
57. D'Haens GR, Panaccione R, Higgins PD, Vermeire S, Gassull M, Chowers Y, Hanauer SB, 
Herfarth H, Hommes DW, Kamm M, Löfberg R, Quary A, Sands B, Sood A, Watermeyer G, 
Lashner B, Lémann M, Plevy S, Reinisch W, Schreiber S, Siegel C, Targan S, Watanabe M, 
Feagan B, Sandborn WJ, Colombel JF, and Travis S. The London Position Statement of the 
World Congress of Gastroenterology on Biological Therapy for IBD with the European Crohn's 
and Colitis Organization: when tostart, when to stop, which drug to choose, and how to predict 
response? Am J Gastroenterol 106: 199-212, 2011. 
58. D'Incà R, Cardin R, Benazzato L, Angriman I, Martines D, and Sturniolo GC.Oxidative DNA 
damage in the mucosa of ulcerative colitis increases with disease duration and dysplasia. 
Inflamm Bowel Dis 10: 23-27, 2004. 
59. Dincer Y, Erzin Y, Himmetoglu S, Gunes KN, Bal K, and Akcay T. Oxidative DNA damage 
and antioxidant activity in patients with inflammatory bowel disease. Dig Dis Sci 52: 1636-
1641, 2007. 
60. Dionne S, D'Agata ID, Hiscott J, Vanounou T, and Seidman EG. Colonic explant production of 
IL-1and its receptor antagonist is imbalanced in inflammatory bowel disease (IBD). Clin Exp 
Immunol 112: 435-442, 1998.  
Biasi 
70 
 
61. Dostert C, Pétrilli V, Van Bruggen R, Steele C, Mossman BT, and Tschopp J. Innate  immune 
activation through Nalp3 inflammasome sensing of asbestos and silica. Science 320: 674-677, 
2008.  
62. Elrod JW, Laroux FS, Houghton J, Carpenter A, Ando T, Jennings MH, Grisham M, Walker N, 
and Alexander JS. DSS-induced colitis is exacerbated in STAT-6 knockout mice. Inflamm 
Bowel Dis 11: 883-889, 2005. 
63. Engler MB and Engler MM. The emerging role of flavonoid-rich cocoa and chocolate in 
cardiovascular health and disease. Nutr Rev 64: 109–118, 2006. 
64. Farhadi A, Keshavarzian A, Van de Kar LD, Jakate S, Domm A, Zhang L, Shaikh M, Banan A, 
and Fields JZ. Heightened responses to stressors in patients with inflammatory bowel disease. 
Am J Gastroenterol 100: 1796-1804, 2005. 
65. Fava F and Danese S. Intestinal microbiota in inflammatory bowel disease: friend of foe? 
World J Gastroenterol 17:557-566, 2011. 
66. Feagins LA, Souza RF, and Spechler SJ. Carcinogenesis in IBD: potential targets for the 
prevention of colorectal cancer. Nat Rev Gastroenterol Hepatol 6: 297-305, 2009. 
67. Ferguson LR. Chronic inflammation and mutagenesis. Mutat Res 690: 3-11, 2010. 
68. Fernando MM, Stevens CR, Walsh EC, De Jager PL, Goyette P, Plenge RM, Vyse TJ, and 
Rioux JD. Defining the role of the MHC in autoimmunity: a review and pooled analysis. PLoS 
Genet 4: e1000024, 2008. 
69. Fichtner-Feigl S, Fuss IJ, Preiss JC, Strober W, and Kitani A. Treatment of murine Th1- and 
Th2-mediated inflammatory bowel disease with NF-kappa B decoy oligonucleotides. J Clin 
Invest 115: 3057-3071, 2005. 
70. Filippi J, Al-Jaouni R, Wiroth JB, Hébuterne X, and Schneider SM. Nutritional deficiencies in 
patients with Crohn's disease in remission. Inflamm Bowel Dis 12: 185-191, 2006. 
71. Fiorucci S, Wallace JL, Mencarelli A, Distrutti E, Rizzo G, Farneti S, Morelli A, Tseng JL, 
Suramanyam B, Guilford WJ, and Parkinson JF. A beta-oxidation-resistant lipoxin A4 analog 
Biasi 
71 
 
treats hapten-induced colitis by attenuating inflammation and immune dysfunction. Proc Natl 
Acad Sci U S A  101: 15736- 15741, 2004. 
72. Förstermann U and Münzel T. Endothelial nitric oxide synthase in vascular disease: from 
marvel to menace. Circulation 113: 1708-1714, 2006. 
73. Fraga CG, Galleano M, Verstraeten SV, and Oteiza PI. Basic biochemical mechanisms behind 
the health benefits of polyphenols. Mol Aspects Med 31: 435-445, 2010. 
74. Franchi L, Park JH, Shaw MH, Marina-Garcia N, Chen G, Kim YG, and Núñez G. Intracellular 
NOD-like receptors in innate immunity, infection and disease. Cell Microbiol 10: 1-8, 2008. 
75. Franchimont D, Vermeire S, El Housni H, Pierik M, Van Steen K, Gustot T, Quertinmont E, 
Abramowicz M, Van Gossum A, Devière J, and Rutgeerts P. Deficient host-bacteria 
interactions in inflammatory bowel disease? The toll-like receptor (TLR)-4 Asp299gly 
polymorphism is associated with Crohn’s disease and ulcerative colitis. Gut 53: 987-992, 2004. 
76. Franke A, Balschun T, Karlsen TH, Sventoraityte J, Nikolaus S, Mayr G, Domingues FS, 
Albrecht M, Nothnagel M, Ellinghaus D, Sina C, Onnie CM, Weersma RK, Stokkers PC, 
Wijmenga C, Gazouli M, Strachan D, McArdle WL, Vermeire S, Rutgeerts P, Rosenstiel P, 
Krawczak M, Vatn MH, the IBSEN study group, Mathew CG, and Schreiber S. Sequence 
variants in IL10, ARPC2 and multiple other loci contribute to ulcerative colitis susceptibility. 
Nat Genet 40: 1319-1323, 2008. 
77. Garat C and Arend WP. Intracellular IL-1Ra type 1 inhibits IL-1-induced IL-6 and IL-8 
production in Caco-2 intestinal epithelial cells through inhibition of p38 mitogen-activated 
protein kinase and NF-kappaB pathways. Cytokine  23: 31-40, 2003. 
78. Garenc C, Julien P, and Levy E. Oxysterols in biological systems: the gastrointestinal tract, 
liver, vascular wall and central nervous system. Free Radic Res 44: 47-73, 2010. 
79. Garrett WS, Lord GM, Punit S, Lugo-Villarino G, Mazmanian SK, Ito S, Glickman JN, and 
Glimcher LH. Communicable ulcerative colitis induced by T-bet deficiency in the innate 
immune system. Cell 131: 33-45, 2007. 
Biasi 
72 
 
80. Gelbmann CM, Leeb SN, Vogl D, Maendel M, Herfarth H, Scholmerich J, Falk W, and Rogler 
G. Inducible CD40 expression mediates NFkappaB activation and cytokine secretion in human 
colonic fibroblasts. Gut 52: 1448-1456, 2003. 
81. Gewirtz AT, Collier-Hyams LS, Young AN, Kucharzik T, Guilford WJ, Parkinson JF, Williams 
IR, Neish AS, and Madara JL. Lipoxin a4 analogs attenuate induction of intestinal epithelial 
proinflammatory gene expression and reduce the severity of dextran sodium sulfate-induced 
colitis. J Immunol 168: 5260-7, 2002. 
82. Glocker EO, Kotlarz D, Boztug K, Gertz EM, Schäffer AA, Noyan F, Perro M, Diestelhorst J, 
Allroth A, Murugan D, Hätscher N, Pfeifer D, Sykora KW, Sauer M, Kreipe H, Lacher M, 
Nustede R, Woellner C, Baumann U, Salzer U, Koletzko S, Shah N, Segal AW, Sauerbrey A, 
Buderus S, Snapper SB, Grimbacher B, and Klein C. Inflammatory bowel disease and mutations 
affecting the interleukin-10 receptor. N Engl J Med 361: 2033-2045, 2009. 
83. Halliwell B. Oxygen and nitrogen are pro-carcinogens. Damage to DNA by reactive oxygen, 
chlorine and nitrogen species: measurement, mechanism and the effects of nutrition. Mutat Res 
443: 37-52, 1999. 
84. Hanai H, Iida T, Takeuchi K, Watanabe F, Maruyama Y, Andoh A, Tsujikawa T, Fujiyama Y, 
Mitsuyama K, Sata M, Yamada M, Iwaoka Y, Kanke K, Hiraishi H, Hirayama K, Arai H, 
Yoshii S, Uchijima M, Nagata T, and Koide Y. Curcumin maintenance therapy for ulcerative 
colitis: randomized, multicenter, double-blind, placebo-controlled trial. Clin Gastroenterol 
Hepatol 4: 1502-1506, 2006. 
85. Hanai H, Iida T, Takeuchi K, Arai H, Arai O, Abe J, Tanaka T, Maruyama Y, Ikeya K, 
Sugimoto K, Nakamura T, Nakamura K, and Watanabe F. Nutritional therapy versus 6-
mercaptopurine as maintenance therapy in patients with Crohn's disease. Dig Liver Dis 44: 649-
654, 2012. 
86. Hanauer SB, Feagan BG, Lichtenstein GR, Mayer LF, Schreiber S, Colombel JF, Rachmilewitz 
D, Wolf DC, Olson A, Bao W, Rutgeerts P and ACCENT I Study Group. Maintenance 
infliximab for Crohn's disease: the ACCENT I randomised trial. Lancet 359: 1541-1549, 2002. 
Biasi 
73 
 
87. Harizi H, Corcuff JB, and Gualde N. Arachidonic-acid-derived eicosanoids: roles in biology 
and immunopathology. Trends Mol Med 14: 461-469, 2008. 
88. Hatoum OA, Binion DG, Otterson MF, and Gutterman DD. Acquired microvascular 
dysfunction in inflammatory bowel disease: Loss of nitric oxide-mediated vasodilation. 
Gastroenterology 125: 58-69, 2003. 
89. Hausmann M, Kiessling S, Mestermann S, Webb G, Spöttl T, Andus T, Schölmerich J, 
Herfarth H, Ray K, Falk W, and Rogler G. Toll-like receptors 2 and 4 are up-regulated during 
intestinal inflammation. Gastroenterology 122: 1987-2000, 2002. 
90. Heazlewood CK, Cook MC, Eri R, Price GR, Tauro SB, Taupin D, Thornton DJ, Png CW, 
Crockford TL, Cornall RJ, Adams R, Kato M, Nelms KA, Hong NA, Florin TH, Goodnow CC, 
and McGuckin MA. Aberrant mucin assembly in mice causes endoplasmic reticulum stress and 
spontaneous inflammation resembling ulcerative colitis. PloS Med 5(3): e54, 2008. 
91. Heidemann J, Domschke W, Kucharzik T, and Maaser C. Intestinal microvascular endothelium 
and innate immunity in inflammatory bowel disease: a second line of defense? Infect Immun 
74: 5425-5432, 2006.  
92. Heller F, Florian P, Bojarski C, Richter J, Christ M, Hillenbrand B, Mankertz  J, Gitter AH, 
Bürgel N, Fromm M, Zeitz M, Fuss I, Strober W, Schulzke JD. Interleukin-13 is the key 
effector Th2 cytokine in ulcerative colitis that affects epithelial tight junctions, apoptosis, and 
cell restitution. Gastroenterology 129: 550-564, 2005. 
93. Hengstermann S, Valentini L, Schaper L, Buning C, Koernicke T, Maritschnegg M, Buhner S, 
Tillinger W, Regano N, Guglielmi F, Winklhofer-Roob BM, and Lochs H. Altered status of 
antioxidant vitamins and fatty acids in patients with inactive inflammatory bowel disease. Clin 
Nutr 27: 571-578, 2008. 
94. Higashikubo A, Tanaka N, Noda N, Maeda I, Yagi K, Mizoguchi T, Nanri H. Increase in 
thioredoxin activity of intestinal epithelial cells mediated by oxidative stress. Biol Pharm Bull 
22: 900-903, 1999. 
Biasi 
74 
 
95. Hirota SA, Ng J, Lueng A, Khajah M, Parhar K, Li Y, Lam V, Potentier MS, Ng K, Bawa M, 
McCafferty DM, Rioux KP, Ghosh S, Xavier RJ, Colgan SP, Tschopp J, Muruve D, 
MacDonald JA, and Beck PL. NLRP3 inflammasome plays a key role in the regulation of 
intestinal homeostasis. Inflamm Bowel Dis 17: 1359-1372, 2011. 
96. Holtmann MH and Neurath MF. Anti-TNF strategies in stenosing and fistulizing Crohn's 
disease. Int J Colorectal Dis 20: 1-8, 2005. 
97. Hsieh SY, Shih TC, Yeh CY, Lin CJ, Chou YY, and Lee YS. Comparative proteomic studies 
on the pathogenesis of human ulcerative colitis. Proteomics 6: 5322-5331, 2006. 
98. Huang J, Canadien V, Lam GY, Steinberg BE, Dinauer MC, Magalhaes MA, Glogauer M, 
Grinstein S, and Brumell JH. Activation of antibacterial autophagy by NADPH oxidases. Proc 
Natl Acad Sci U S A 106: 6226-6231, 2009. 
99. Hudert CA, Weylandt KH, Lu Y, Wang J, Hong S, Dignass A, Serhan CN, and Kang JX. 
Transgenic mice rich in endogenous omega-3 fatty acids are protected from colitis. Proc Natl 
Acad Sci U S A 103: 11276-11281, 2006. 
100. Hussain SP, Amstad P, Raja K, Ambs S, Nagashima M, Bennett WP, Shields PG, Ham AJ, 
Swenberg JA, Marrogi AJ, and Harris CC. Increased p53 mutation load in noncancerous colon 
tissue from ulcerative colitis: a cancer-prone chronic inflammatory disease. Cancer Res 60: 
3333-3337, 2000. 
101. Iborra M, Moret I, Rausell F, Bastida G, Aguas M, Cerrillo E, Nos P, and Beltrán B. Role of 
oxidative stress and antioxidant enzymes in Crohn's disease. Biochem Soc Trans 39: 1102-
1106, 2011. 
102. Iimura M, Gallo RL, Hase K, Miyamoto Y, Eckmann L, and Kagnoff MF. Cathelicidin 
mediates innate intestinal defense against colonization with epithelial adherent bacterial 
pathogens. J Immunol 174: 4901-4907, 2005. 
103. Imielinski M, Baldassano RN, Griffiths A, Russell RK, Annese V, Dubinsky M, Kugathasan S, 
Bradfield JP, Walters TD, Sleiman P, Kim CE, Muise A, Wang K, Glessner JT, Saeed S, Zhang 
H, Frackelton EC, Hou C, Flory JH, Otieno G, Chiavacci RM, Grundmeier R, Castro M, 
Biasi 
75 
 
Latiano A, Dallapiccola B, Stempak J, Abrams DJ, Taylor K, McGovern D; Western Regional 
Alliance for Pediatric IBD, Silber G, Wrobel I, Quiros A, the International IBD Genetics 
Consortium, Barrett JC, Hansoul S, Nicolae DL, Cho JH, Duerr RH, Rioux JD, Brant SR, 
Silverberg MS, Taylor KD, Barmuda MM, Bitton A, Dassopoulos T, Datta LW, Green T, 
Griffiths AM, Kistner EO, Murtha MT, Regueiro MD, Rotter JI, Schumm LP, Steinhart AH, 
Targan SR, Xavier RJ, the NIDDK IBD Genetics Consortium, Libioulle C, Sandor C, Lathrop 
M, Belaiche J, Dewit O, Gut I, Heath S, Laukens D, Mni M, Rutgeerts P, Van Gossum A, 
Zelenika D, Franchimont D, Hugot JP, de Vos M, Vermeire S, Louis E, the Belgian-French 
IBD Consortium, the Wellcome Trust Case Control Consortium, Cardon LR, Anderson CA, 
Drummond H, Nimmo E, Ahmad T, Prescott NJ, Onnie CM, Fisher SA, Marchini J, Ghori J, 
Bumpstead S, Gwillam R, Tremelling M, Delukas P, Mansfield J, Jewell D, Satsangi J, Mathew 
CG, Parkes M, Georges M, Daly MJ, Heyman MB, Ferry GD, Kirschner B, Lee J, Essers J, 
Grand R, Stephens M, Levine A, Piccoli D, Van Limbergen J, Cucchiara S, Monos DS, 
Guthery SL, Denson L, Wilson DC, Grant SF, Daly M, Silverberg MS, Satsangi J, and 
Hakonarson H. Common variants at five new loci associated with early-onset inflammatory 
bowel disease. Nat Genet 41: 1335-1340, 2009. 
104. Ioannidis O, Varnalidis I, Paraskevas G, and Botsios D. Nutritional modulation of  the 
inflammatory bowel response. Digestion 84: 89-101, 2011. 
105. Ishida T, Yoshida M, Arita M, Nishitani Y, Nishiumi S, Masuda A, Mizuno S, Takagawa T, 
Morita Y, Kutsumi H, Inokuchi H, Serhan CN, Blumberg RS, and Azuma T. Resolvin E1, an 
endogenous lipid mediator derived from eicosapentaenoic acid, prevents dextran sulfate 
sodium-induced colitis. Inflamm Bowel Dis 16: 87-95, 2010. 
106. Ishii Y, Itoh K, Morishima Y, Kimura T, Kiwamoto T, Iizuka T, Hegab A, Hosoya T, Nomura 
A, Sakamoto T, Yamamoto M, and Sekizawa K. Transcription factor Nrf2 plays a pivotal role 
in protection against elastase induced pulmonary inflammation and emphysema. J Immunol 
175: 6968–6975, 2005. 
Biasi 
76 
 
107. Jeong W, Jung Y, Kim H, Park SJ, and Rhee SG. Thioredoxin-related protein 14, a new 
member of the thioredoxin family with disulfide reductase activity: implication in the redox 
regulation of TNF-alpha signaling. Free Radic Biol Med 47: 1294-1303, 2009. 
108. József L, Zouki C, Petasis NA, Serhan CN, and Filep JG. Lipoxin A4 and aspirin-triggered 15-
epi-lipoxin A4 inhibit peroxynitrite formation, NF-kappa B and AP-1 activation, and IL-8 gene 
expression in human leukocytes. Proc Natl Acad Sci U S A 99: 13266-13267, 2002. 
109. Jung Y, Kim H, Min SH, Rhee SG, and Jeong W. Dynein light chain LC8 negatively regulates 
NF-kappaB through the redox-dependent interaction with IkappaBalpha. J Biol Chem 283: 
23863-23871, 2008. 
110. Kader HA, Tchernev VT, Satyaraj E, Lejnine S, Kotler G, Kingsmore SF, and Patel DD. 
Protein microarray analysis of disease activity in pediatric inflammatory bowel disease 
demonstrates elevated serum PLGF, IL-7, TGF-beta1, and IL-12p40 levels in Crohn's disease 
and ulcerative colitis patients in remission versus active disease. Am J Gastroenterol 100: 414-
423, 2005.  
111. Kanner J. Dietary advanced lipid oxidation endproducts are risk factors to human health. Mol 
Nutr Food Res 51: 1094-1101, 2007. 
112. Kaser A, Zeissig S, and Blumberg RS. Genes and environment: how will our concepts on the 
pathophysiology of IBD develop in the future? Dig Dis 28: 395-405, 2010.  
113. Kawanishi S, Hiraku Y, Pinlaor S, and Ma N. Oxidative and nitrative DNA damage in animals 
and patients with inflammatory diseases in relation to inflammation-related carcinogenesis. Biol 
Chem 387: 365-372, 2006. 
114. Kelsall B. Interleukin-10 in inflammatory bowel disease. N Engl J Med 361: 2091-2093, 2009. 
115. Kepp O, Galluzzi L, and Kroemer G. Mitochondrial control of the NLRP3 inflammasome. Nat 
Immunol. 2011 Mar;12(3):199-200; Kepp O, Galluzzi L, Kroemer G. Mitochondrial control of 
the NLRP3 inflammasome. Nat Immunol 12: 199-200, 2011. 
Biasi 
77 
 
116. Keshavarzian A, Banan A, Farhadi A, Komanduri S, Mutlu E, Zhang Y, and Fields JZ. 
Increases in free radicals and cytoskeletal protein oxidation and nitration in the colon of 
patients with inflammatory bowel disease. Gut 52: 720-728, 2003. 
117. Khan KJ, Dubinsky MC, Ford AC, Ullman TA, Talley NJ, and Moayyedi P. Efficacy of 
immunosuppressive therapy for inflammatory bowel disease: a systematic review and meta-
analysis. Am J Gastroenterol 106: 630-642, 2011. 
118. Khan MA, Steiner TS, Sham HP, Bergstrom KS, Huang JT, Assi K, Salh B, Tai IT, Li X, 
Vallance BA. The single IgG IL-1-related receptor controls TLR responses in differentiated 
human intestinal epithelial cells. J Immunol 184: 2305-2313, 2010.  
119. Khor TO, Huang MT, Kwon KH, Chan JY, Reddy BS, and Kong AN. Nrf2-deficient mice have 
an increased susceptibility to dextran sulfate sodium-induced colitis. Cancer Res 66: 11580-
11584, 2006. 
120. Khor TO,  Huang M-T, Prawan A, Liu Y, Hao X, Yu S, Cheung WKL, Chan JY, Reddy BS, 
Yang CS and Kong A-N. Increased Susceptibility of Nrf2 Knockout Mice to Colitis-Associated 
Colorectal Cancer. Cancer Prev Res 1: 187-191, 2008. 
121. Kim GS, Jung JE, Narasimhan P, Sakata H, and Chan PH. Induction of thioredoxin-interacting 
protein is mediated by oxidative stress, calcium, and glucose after brain injury in mice. 
Neurobiol Dis 46: 440-449, 2012. 
122. Kim J, Cha Y-N, and Surh Y-J. A protective role of nuclear factor-erythroid 2-related factor-2 
(Nrf2) in inflammatory disorders. Mut Res 690: 12-23, 2010. 
123. Kim SW, Kim ES, Moon CM, Park JJ, Kim TI, Kim WH, and Cheon JH. Genetic 
polymorphisms of IL-23R and IL-17A and novel insights into their associations with 
inflammatory bowel disease. Gut 60: 1527-1536, 2011. 
124. Kim YS and Ho SB. Intestinal goblet cells and mucins in health and disease: recent insights and 
progress. Curr Gastroenterol Rep 12: 319-330, 2010.  
Biasi 
78 
 
125. Kimura H, Mukaida M, Kuwabara K, Ito T, Hashino K, Uchida K, Matsumoto K, and Yoshida 
K. 4-Hydroxynonenal modifies IgA in rat intestine after lipopolysaccharide injection. Free 
Radic Biol Med 41: 973-978, 2006. 
126. Kjellev S. The trefoil factor family - small peptides with multiple functionalities. Cell Mol Life 
Sci 66: 1350-1369, 2009. 
127. Kobayashi M and Yamamoto M. Molecular mechanisms activating the Nrf2-Keap1 pathway of 
antioxidant gene regulation. Antioxid Redox Signal 7: 385-394, 2005. 
128. Kolios G, Valatas V, and Ward SG. Nitric oxide in inflammatory bowel disease: a universal 
messenger in an unsolved puzzle. Immunology 113: 427–437, 2004. 
129. Kong X, Thimmulappa R, Kombairaju P, and Biswal1 S. NADPH oxidase-dependent reactive 
oxygen species mediate amplified TLR4 signaling and sepsis-induced mortality in Nrf2-
deficient mice. J Immunol 185: 569 577, 2010. 
130. Koslowski MJ, Beisner J, Stange EF, and Wehkamp J. Innate antimicrobial host defense in 
small intestinal Crohn's disease. Int J Med Microbiol 300: 34-40, 2010. 
131. Krieglstein CF, Anthoni C, Cerwinka WH, Stokes KY, Russell J, Grisham MB, and Granger 
DN. Role of Blood- and Tissue-Associated Inducible Nitric-Oxide Synthase in Colonic 
Inflammation. Am J Pathol 170: 490-496, 2007. 
132. Kruidenier L, Kuiper I, van Duijn W, Marklund SL, van Hogezand RA, Lamers CB, and 
Verspaget HW. Differential mucosal expression of three superoxide dismutase isoforms in 
inflammatory bowel disease. J Pathol 201: 7-16, 2003. 
133. Kruidenier L, Kuiper I, Van Duijn W, Mieremet-Ooms MA, van Hogezand RA, Lamers CB, 
and Verspaget HW. Imbalanced secondary mucosal antioxidant response in inflammatory 
bowel disease. J Pathol 201: 17-27, 2003. 
134. Kruidenier L, Kuiper I, Lamers CB, and Verspaget HW. Intestinal oxidative damage in 
inflammatory bowel disease: semi-quantification, localization, and association with mucosal 
antioxidants. J Pathol 201: 28-36, 2003. 
Biasi 
79 
 
135. Krupa LZ, Kennedy HJ, Jamieson CP, Fisher N, and Hart AR. The Reasons for Discontinuation 
of Infliximab Treatment in Patients with Crohn's Disease: A Review of Practice at NHS 
Teaching Hospital. ISRN Gastroenterol 2011: 672017, 2011.  
136. Krzystek-Korpacka M, Neubauer K, Berdowska I, Zielinski B, Paradowski L, and Gamian A. 
Impaired erythrocyte antioxidant defense in active inflammatory bowel disease: impact of 
anemia and treatment. Inflamm Bowel Dis 16: 1467-1475, 2010. 
137. Kucharzik T, Gewirtz AT, Merlin D, Madara JL, and Williams IR. Lateral membrane LXA4 
receptors mediate LXA4's anti-inflammatory actions on intestinal epithelium. Am J Physiol Cell 
Physiol 284: C888-C896, 2003. 
138. Kühn R, Löhler J, Rennick D, Rajewsky K, and Müller W. Interleukin-10-deficient mice 
develop chronic enterocolitis. Cell 75: 263-274, 1993. 
139. Kuiper HC, Bruno RS, Traber MG, and Stevens JF. Vitamin C supplementation lowers urinary 
levels of 4-hydroperoxy-2-nonenal metabolites in humans. Free Radic Biol Med 50: 848-853, 
2011. 
140. Kuwano Y, Tominaga K, Kawahara T, Sasaki H, Takeo K, Nishida K, Masuda K, Kawai T, 
Teshima-Kondo S, and Rokutan K. Tumor necrosis factor alpha activates transcription of the 
NADPH oxidase organizer 1 (NOXO1) gene and upregulates superoxide production in colon 
epithelial cells. Free Radic Biol Med 45: 1642-1652, 2008. 
141. Kwon KH, Ohigashi H, and Murakami A. Dextran sulfate sodium enhances interleukin-1 beta 
release via activation of p38 MAPK and ERK1/2 pathways in murine peritoneal macrophages. 
Life Sci 81: 362-371, 2007. 
142. Landberg R, Sun Q, Rimm EB, Cassidy A, Scalbert A, Mantzoros CS, Hu FB, and van Dam 
RM. Selected dietary flavonoids are associated with markers of inflammation and endothelial 
dysfunction in U.S. women. J Nutr 141: 618-625, 2011. 
143. Leach ST, Messina I, Lemberg DA, Novick D, Rubenstein M, and Day AS. Local and systemic 
interleukin-18 and interleukin-18-binding protein in children with inflammatory bowel disease. 
Inflamm Bowel Dis 2008 14: 68-74, 2008. 
Biasi 
80 
 
144. Lee IA, Bae EA, Hyun YJ, and Kim DH. Dextran sulfate sodium and 2,4,6-trinitrobenzene 
sulfonic acid induce lipid peroxidation by the proliferation of intestinal gram-negative bacteria 
in mice. J Inflamm (Lond) 7: 7, 2010. 
145. Legrand-Poels S, Kustermans G, Bex F, Kremmer E, Kufer TA, and Piette J.Modulation of 
Nod2-dependent NF-kappaB signaling by the actin cytoskeleton. J Cell Sci 120: 1299-1310, 
2007. 
146. Lemaire S, Lizard G, Monier S, Miguet C, Gueldry S, Volot F, Gambert P, and Néel D. 
Different patterns of IL-1beta secretion, adhesion molecule expression and apoptosis induction 
in human endothelial cells treated with 7alpha-,7beta-hydroxycholesterol, or 7-ketocholesterol. 
FEBS Lett 440: 434-439, 1998. 
147. Leonarduzzi G, Scavazza A, Biasi F, Chiarpotto E, Camandola S, Vogel S, Dargel R, and Poli 
G. The lipid peroxidation end product 4-hydroxy-2,3-nonenal up-regulates transforming growth 
factor beta1 expression in the macrophage lineage: a link between oxidative injury and 
fibrosclerosis. FASEB J 11: 851-857, 1997. 
148. Leonarduzzi G, Gamba P, Sottero B, Kadl A, Robbesyn F, Calogero RA, Biasi F, Chiarpotto E, 
Leitinger N, Sevanian A, and Poli G. Oxysterol-induced up-regulation of MCP-1 expression 
and synthesis in macrophage cells. Free Radic Biol Med 39: 1152-1161, 2005. 
149. Leonarduzzi G, Testa G, Sottero B, Gamba P, and Poli G. Design and development of 
nanovehicle based delivery systems for preventive or therapeutic supplementation with 
flavonoids. Curr Med Chem 17: 74-95, 2010. 
150. Li H and Lin X. Positive and negative signaling components involved in TNFalpha-induced 
NF-kappaB activation. Cytokine 41: 1-8, 2008. 
151. Li Q, Spencer NY, Oakley FD, Buettner GR, Engelhardt JF. Endosomal Nox2 facilitates redox-
dependent induction of NF-kappaB by TNF-alpha. Antioxid Redox Signal 11: 1249-1263, 2009. 
152. Li Y, Mao Q, Shen L, Tian Y, Yu C, Zhu WM, and Li JS. Interleukin-23 receptor genetic 
polymorphisms and Crohn's disease susceptibility: a meta-analysis. Inflamm Res 59: 607-614, 
2010. 
Biasi 
81 
 
153. Lin PW, Myers LE, Ray L, Song SC, Nasr TR, Berardinelli AJ, Kundu K, Murthy N, Hansen 
JM, and Neish AS. Lactobacillus rhamnosus blocks inflammatory signaling in vivo via reactive 
oxygen species generation. Free Radic Biol Med 47:1205-1211, 2009. 
154. Lipinski S, Till A, Sina C, Arlt A, Grasberger H, Schreiber S, and Rosenstiel P. DUOX2-
derived reactive oxygen species are effectors of NOD2-mediated antibacterial responses. J Cell 
Sci 122: 3522-3530, 2009. 
155. Liu Y, Hultén LM, and Wiklund O. Macrophages isolated from human atherosclerotic plaques 
produce IL-8, and oxysterols may have a regulatory function for IL-8 production. Arterioscler 
Thromb Vasc Biol 17: 317-323, 1997. 
156. Liu ZJ, Yadav PK, Su JL, Wang JS, and Fei K. Potential role of Th17 cells in the pathogenesis 
of inflammatory bowel disease. World J Gastroenterol 15: 5784-5788, 2009. 
157. Lizard G, Lemaire S, Monier S, Gueldry S, Néel D, and Gambert P. Induction of apoptosis and 
of  interleukin-1beta secretion by 7beta-hydroxycholesterol and 7-ketocholesterol: partial 
inhibition by Bcl-2 overexpression. FEBS Lett 419: 276-280, 1997. 
158. Loguercio C, D'Argenio G, Delle Cave M, Cosenza V, Della Valle N, Mazzacca G, and Del 
Vecchio Blanco C. Glutathione supplementation improves oxidative damage in experimental 
colitis. Dig Liver Dis 35: 635-641, 2003. 
159. Loo YM and Gale M Jr. Immune signaling by RIG-I-like receptors. Immunity 34: 680-692, 
2011. 
160. Mangino MJ, Brounts L, Harms B, and Heise C. Lipoxin biosynthesis in inflammatory bowel 
disease. Prostaglandins Other Lipid Mediat 79: 84-92, 2006. 
161. Marcinkiewicz J, Ciszek M, Bobek M, Strus M, Heczko PB, Kurnyta M, Biedroń R, and 
Chmielarczyk A. Differential inflammatory mediator response in vitro from murine 
macrophages to lactobacilli and pathogenic intestinal bacteria. Int J Exp Pathol 88:155-164, 
2007. 
162. Martinon F. Signaling by ROS drives inflammasome activation. Eur J Immunol 40: 616-619, 
2010. 
Biasi 
82 
 
163. Mascia C, Maina M, Chiarpotto E, Leonarduzzi G, Poli G, and Biasi F. Proinflammatory effect 
of cholesterol and its oxidation products on CaCo-2 human enterocyte-like cells: effective 
protection by epigallocatechin-3-gallate. Free Radic Biol Med 49: 2049-2057, 2010. 
164. McCarroll SA, Huett A, Kuballa P, Chilewski SD, Landry A, Goyette P, Zody MC, Hall JL, 
Brant SR, Cho JH, Duerr RH, Silverberg MS, Taylor KD, Rioux JD, Altshuler D, Daly MJ, and 
Xavier RJ. Deletion polymorphism upstream of IRGM associated with altered IRGM 
expression and Crohn's disease. Nat Genet 40: 1107-1112, 2008. 
165. McGovern DP, Gardet A, Törkvist L, Goyette P, Essers J, Taylor KD, Neale BM, Ong RT, 
Lagacé C, Li C, Green T, Stevens CR, Beauchamp C, Fleshner PR, Carlson M, D'Amato M, 
Halfvarson J, Hibberd ML, Lördal M, Padyukov L, Andriulli A, Colombo E, Latiano A, 
Palmieri O, Bernard EJ, Deslandres C, Hommes DW, de Jong DJ, Stokkers PC, Weersma RK; 
NIDDK IBD Genetics Consortium, Sharma Y, Silverberg MS, Cho JH, Wu J, Roeder K, Brant 
SR, Schumm LP, Duerr RH, Dubinsky MC, Glazer NL, Haritunians T, Ippoliti A, Melmed GY, 
Siscovick DS, Vasiliauskas EA, Targan SR, Annese V, Wijmenga C, Pettersson S, Rotter JI, 
Xavier RJ, Daly MJ, Rioux JD, and Seielstad M. Genome-wide association identifies multiple 
ulcerative colitis susceptibility loci. Nat Genet 42: 332-337, 2010. 
166. Meira LB, Bugni JM, Green SL, Lee CW, Pang B, Borenshtein D, Rickman BH, Rogers AB, 
Moroski-Erkul CA, McFaline JL, Schauer DB, Dedon PC, Fox JG, and Samson LD. DNA 
damage induced by chronic inflammation  contributes to colon carcinogenesis in mice. J Clin 
Invest 118: 2516-2525, 2008. 
167. Merkwirth C, Dargazanli S, Tatsuta T, Geimer S, Löwer B, Wunderlich FT, von Kleist-Retzow 
JC, Waisman A, Westermann B, and Langer T. Prohibitins control cell proliferation and 
apoptosis by regulating OPA1-dependent cristae morphogenesis in mitochondria. Genes Dev 
22: 476-488, 2008. 
168. Miralles-Barrachina O, Savoye G, Belmonte-Zalar L, Hochain P, Ducrotté P, Hecketsweiler B, 
Lerebours E, and Déchelotte P. Low levels of glutathione in endoscopic biopsies of patients 
with Crohn's colitis: the role of malnutrition. Clin Nutr 18: 313-317, 1999. 
Biasi 
83 
 
169. Miroliaee AE, Esmaily H, Vaziri-Bami A, Baeeri M, Shahverdi AR, and Abdollahi M. 
Amelioration of experimental colitis by a novel nanoselenium-silymarin mixture. Toxicol Mech 
Methods 21: 200-208, 2011. 
170. Mishra S, Murphy LC, Nyomba BL, and Murphy LJ. Prohibitin: a potential target for new 
therapeutics. Trends Mol Med 11: 192-197, 2005. 
171. Moehle C, Ackermann N, Langmann T, Aslanidis C, Kel A, Kel-Margoulis O, Schmitz-Madry 
A, Zahn A, Stremmel W, and Schmitz G. Aberrant intestinal expression and allelic variants of 
mucin genes associated with inflammatory bowel disease. J Mol Med (Berl) 84: 1055-1066, 
2006. 
172. Moi P, Chan K, Asunis I, Cao A, and Kan YW. Isolation of NF-E2-related factor 2 (Nrf2), a 
NF-E2-like basic leucine zipper transcriptional activator that binds to the tandem NF-E2/AP1 
repeat of the beta-globin locus control region. Proc Natl Acad Sci USA 91: 9926-9930, 1994. 
173. Monteleone G, Boirivant M, Pallone F, and MacDonald TT. TGF-beta1 and Smad7 in the 
regulation of IBD. Mucosal Immunol 1: S50-53, 2008. 
174. Moore SF and MacKenzie AB. NADPH oxidase NOX2 mediates rapid cellular oxidation 
following ATP stimulation of endotoxin-primed macrophages. J Immunol 183: 3302-3308, 
2009.  
175. Morrison PJ, Ballantyne SJ, and Kullberg MC. Interleukin-23 and T helper 17-type responses 
in intestinal inflammation: from cytokines to T-cell plasticity. Immunology 133: 397-408, 2011. 
176. Mukherjee A, Morosky SA, Shen L, Weber CR, Turner JR, Kim KS, Wang T, and Coyne CB. 
Retinoic acid-induced gene-1 (RIG-I) associates with the actin cytoskeleton via caspase 
activation and recruitment domain-dependent interactions. J Biol Chem 284: 6486-6494, 2009. 
177. Naftali T, Novick D, Gabay G, Rubinstein M,and  Novis B. Interleukin-18 and its binding 
protein in patients with inflammatory bowel disease during remission and exacerbation. Isr 
Med Assoc J 9: 504-508, 2007. 
Biasi 
84 
 
178. Nair J, Gansauge F, Beger H, Dolara P, Winde G, and Bartsch H. Increased etheno-DNA 
adducts in affected tissues of patients suffering from Crohn's disease, ulcerative colitis, and 
chronic pancreatitis. Antioxid Redox Signal 8: 1003-1010, 2006. 
179. Nair MG, Guild KJ, Du Y, Zaph C, Yancopoulos GD, Valenzuela DM, Murphy A, Stevens S, 
Karow M, and Artis D. Goblet cell-derived resistin-like molecule beta augments CD4+ T cell 
production of IFN-gamma and infection-induced intestinal inflammation. J Immunol 181: 
4709-4715, 2008. 
180. Naito Y, Takagi T, Ishikawa T, Handa O, Matsumoto N, Yagi N, Matsuyama K, Yoshida N, 
Yoshikawa T, and Kotake Y. Alpha-Phenyl-N-tert-butylnitrone provides protection from 
dextran sulfate sodium-induced colitis in mice. Antioxid Redox Signal 4: 195-206, 2002. 
181. Naito Y, Takagi, T, and Yoshikawa T. Molecular fingerprints of neutrophil-dependent 
oxidative stress in inflammatory bowel disease. J Gastroenterol 42: 787-798, 2007. 
182. Nakahira K, Haspel JA, Rathinam VA, Lee SJ, Dolinay T, Lam HC, Englert JA, Rabinovitch 
M, Cernadas M, Kim HP, Fitzgerald KA, Ryter SW, and Choi AM. Autophagy proteins 
regulate innate immune responses by inhibiting the release of mitochondrial DNA mediated by 
the NALP3 inflammasome. Nat Immunol 12:222-230, 2011. 
183. Neal MD, Leaphart C, Levy R, Prince J, Billiar TR, Watkins S, Li J, Cetin S, Ford H, Schreiber 
A, and Hackam DJ. Enterocyte TLR4 mediates phagocytosis and translocation of bacteria 
across the intestinal barrier. J Immunol 176: 3070-3079, 2006.  
184. Negre-Salvayre A, Auge N, Ayala V, Basaga H, Boada J, Brenke R, Chapple S, Cohen G, 
Feher J, Grune T, Lengyel G, Mann GE, Pamplona R, Poli G, Portero-Otin M, Riahi Y, 
Salvayre R, Sasson S, Serrano J, Shamni O, Siems W, Siow RC, Wiswedel I, Zarkovic K, and 
Zarkovic N. Pathological aspects of lipid peroxidation. Free Radic Res 44: 1125-1171, 2010. 
185. Neuman MG. Immune dysfunction in inflammatory bowel disease. Transl Res 149: 173-186, 
2007.   
Biasi 
85 
 
186. Nijtmans LG, de Jong L, Artal Sanz M, Coates PJ, Berden JA, Back JW, Muijsers AO, van der 
Spek H, and Grivell LA. Prohibitins act as a membrane-bound chaperone for the stabilization of 
mitochondrial proteins. EMBO J 19: 2444-2451, 2000. 
187. Nijtmans LG, Artal SM, Grivell LA, and Coates PJ. The mitochondrial PHB complex: roles in 
mitochondrial respiratory complex assembly, ageing and degenerative disease. Cell Mol Life 
Sci 59: 143-155, 2002. 
188. Nishikawa M, Oshitani N, Matsumoto T, Nishigami T, Arakawa T, and Inoue M. 
Accumulation of mitochondrial DNA mutation with colorectal carcinogenesis in ulcerative 
colitis. Br J Cancer 93: 331-7, 2005. 
189. Nitti M, Domenicotti C, d'Abramo C, Assereto S, Cottalasso D, Melloni E, Poli G, Biasi F, 
Marinari UM, and Pronzato MA. Activation of PKC-beta isoforms mediates HNE-induced 
MCP-1 release by macrophages. Biochem Biophys Res Commun 294: 547-552, 2002. 
190. Nunes T, Fiorino G, Danese S, and Sans M. Familial aggregation in inflammatory bowel 
disease: is it genes or environment? World J Gastroenterol 17: 2715-2722, 2011. 
191. Ogura Y, Bonen DK, Inohara N, Nicolae DL, Chen FF, Ramos R, Britton H, Moran T, 
Karaliuskas R, Duerr RH, Achkar JP, Brant SR, Bayless TM, Kirschner BS, Hanauer SB, 
Nuñez G, and Cho JH. A frameshift mutation in NOD2 associated with susceptibility to 
Crohn's disease. Nature 411: 603-606, 2001. 
192. Oldenburg B, van Kats-Renaud H, Koningsberger JC, van Berge Henegouwen GP, and van 
Asbeck BS. Chemiluminescence in inflammatory bowel disease patients: a parameter of 
inflammatory activity. Clin Chim Acta 310: 151-156, 2001. 
193. Onizawa M, Nagaishi T, Kanai T, Nagano K, Oshima S, Nemoto Y, Yoshioka A, Totsuka T, 
Okamoto R, Nakamura T, Sakamoto N, Tsuchiya K, Aoki K, Ohya K, Yagita H, and Watanabe 
M. Signaling pathway via TNF-alpha/NF-kappaB in intestinal epithelial cells may be directly 
involved in colitis-associated carcinogenesis. Am J Physiol Gastrointest Liver Physiol 296: 
G850-G859, 2009.  
Biasi 
86 
 
194. Osburn WO, Karim B, Dolan PM, Liu G, Yamamoto M, Huso DL, and Kensler TW. Increased 
colonic inflammatory injury and formation of aberrant crypt foci in Nrf2-deficient mice upon 
dextran sulfate treatment. Int J Cancer 121: 1883-1891, 2007. 
195. Oshima N, Ishihara S, Rumi MA, Aziz MM, Mishima Y, Kadota C, Moriyama I, Ishimura N, 
Amano Y, and Kinoshita Y. A20 is an early responding negative regulator of Toll-like receptor 
5 signalling in intestinal epithelial cells during inflammation. Clin Exp Immunol 159: 185-198, 
2010. 
196. Osman C, Merkwirth C, and Langer T. Prohibitins and the functional compartmentalization of 
mitochondrial membranes. J Cell Sci 122: 3823-3830, 2009. 
197. Otaegui-Arrazola A, Menéndez-Carreño M, Ansorena D, and Astiasarán I. Oxysterols: A world 
to explore. Food Chem Toxicol 48: 3289-3303, 2010.  
198. Pallone F and Monteleone G. Mechanisms of tissue damage in inflammatory bowel disease. 
Curr Opin Gastroenterol 17: 307-312, 2001. 
199. Panaccione R, Loftus EV Jr, Binion D, McHugh K, Alam S, Chen N, Guerette B, Mulani P, and 
Chao J. Efficacy and safety of adalimumab in Canadian patients with moderate to severe 
Crohn's disease: results of the Adalimumab in Canadian SubjeCts with ModErate to Severe 
Crohn's DiseaSe (ACCESS) trial. Can J Gastroenterol 25: 419-425, 2011. 
200. Pasparakis M. IKK/NF-kappaB signaling in intestinal epithelial cells controls immune 
homeostasis in the gut. Mucosal Immunol 1: S54-S57, 2008. 
201. Paul G, Khare V, and Gasche C. Inflamed gut mucosa: downstream of interleukin-10. Eur J 
Clin Invest 42: 95-109, 2012. 
202. Perwez Ussain S, Hofseth LJ, and Harris CC. Radical causes of cancer. Nature Rev Cancer 3: 
276-285, 2003. 
203. Poli G, Schaur RJ, Siems WG, and Leonarduzzi G. 4-hydroxynonenal: a membrane lipid 
oxidation product of medicinal interest. Med Res Rev 28: 569-631, 2008. 
204. Porath D, Riegger C, Drewe J, and Schwager J. Epigallocatechin-3-gallate impairs chemokine 
production in human colon epithelial cell lines. J Pharmacol Exp Ther 315: 1172-1180, 2005. 
Biasi 
87 
 
205. Prasad S, Mingrino R, Kaukinen K, Hayes KL, Powell RM, MacDonald TT, and Collins JE. 
Inflammatory processes have differential effects on claudins 2, 3 and 4 in colonic epithelial 
cells. Lab Invest 85: 1139-1162, 2005. 
206. Pravda J. Radical induction theory of ulcerative colitis. World J Gastroenterol 11: 2371-2384, 
2005. 
207. Preiser JC, Van Gossum A, Berré J, Vincent JL, and Carpentier Y. Enteral feeding with a 
solution enriched with antioxidant vitamins A, C, and E enhances the resistance to oxidative 
stress. Crit Care Med 28: 3828-3832, 2000. 
208. Qiu W, Wu B, Wang X, Buchanan ME, Regueiro MD, Hartman DJ, Schoen RE, Yu J, and 
Zhang L. PUMA-mediated intestinal epithelial apoptosis contributes to ulcerative colitis in 
humans and mice. J Clin Invest 121: 1722-1732, 2011. 
209. Raddatz D, Bockemühl M, and Ramadori G. Quantitative measurement of cytokine mRNA in 
inflammatory bowel disease: relation to clinical and endoscopic activity and outcome. Eur J 
Gastroenterol Hepatol 17: 547-557, 2005.  
210. Ramasundara M, Leach ST, Lemberg DA, and Day AS. Defensins and inflammation: the role 
of defensins in inflammatory bowel disease. J Gastroenterol Hepatol 24: 202-208, 2009. 
211. Rangamani P and Sirovich L. Survival and apoptotic pathways initiated by TNF-alpha: 
modeling and predictions. Biotechnol Bioeng 97: 1216-1229, 2007. 
212. Ravi A, Garg P, and Sitaraman SV. Matrix metalloproteinases in inflammatory bowel disease: 
boon or a bane? Inflamm Bowel Dis 13: 97-107, 2007. 
213. Rezaie A, Parker RD, and Abdollahi M. Oxidative stress and pathogenesis of inflammatory 
bowel disease: an epiphenomenon or the cause? Dig Dis Sci 52: 2015-2021, 2007. 
214. Ricci S, Macchia G, Ruggiero P, Maggi T, Bossù P, Xu L, Medaglini D, Tagliabue A, 
Hammarström L, Pozzi G, and Boraschi D. In vivo mucosal delivery of bioactive human 
interleukin 1 receptor antagonist produced by Streptococcus gordonii. BMC Biotechnol 3: 15, 
2003.  
Biasi 
88 
 
215. Rogler G, Brand K, Vogl D, Page S, Hofmeister R, Andus T, Knuechel R, Baeuerle PA, 
Scholmerich J, and Gross V. Nuclear factor kappaB is activated in macrophages and epithelial 
cells of inflamed intestinal mucosa. Gastroenterology 115: 357-369, 1998. 
216. Rokutan K, Kawahara T, Kuwano Y, Tominaga K, Nishida K, and Teshima-Kondo S. Nox 
enzymes and oxidative stress in the immunopathology of the gastrointestinal tract. Semin 
Immunopathol 30: 315-327, 2008. 
217. Romier B, Schneider YJ, Larondelle Y, and During A. Dietary polyphenols can modulate the 
intestinal inflammatory response. Nutr Rev 67: 363-378, 2009. 
218. Ryu JH, Kim SH, Lee HY, Bai JY, Nam YD, Bae JW, Lee DG, Shin SC, Ha EM, and Lee WJ. 
Innate immune homeostasis by the homeobox gene caudal and commensal-gut mutualism in 
Drosophila. Science 319: 777-782, 2008. 
219. Saitoh T, Fujita N, Jang MH, Uematsu S, Yang BG, Satoh T, Omori H, Noda T, Yamamoto N, 
Komatsu M, Tanaka K, Kawai T, Tsujimura T, Takeuchi O, Yoshimori T, and Akira S. Loss of 
the autophagy protein Atg16L1 enhances endotoxin-induced IL-1beta production. Nature 456: 
264-268, 2008. 
220. Sands BE, Blank MA, Diamond RH, Barrett JP, and Van Deventer SJ. Maintenance infliximab 
does not result in increased abscess development in fistulizing Crohn's disease: results from the 
ACCENT II study. Aliment Pharmacol Ther 23: 1127-1136, 2006. 
221. Sasaki M, Bharwani S, Jordan P, Elrod JW, Grisham MB, Jackson TH, Lefer DJ, and 
Alexander JS. Increased disease activity in eNOS-deficient mice in experimental colitis. Free 
Radic Biol Med 35: 1679-1687, 2003. 
222. Scharlau D, Borowicki A, Habermann N, Hofmann T, Klenow S, Miene C, Munjal U, Stein K, 
and Glei M. Mechanisms of primary cancer prevention by butyrate and other products formed 
during gut flora-mediated fermentation of dietary fibre. Mutat Res 682: 39-53, 2009. 
223. Scherz-Shouval R, Shvets E, Fass E, Shorer H, Gil L, and Elazar Z. Reactive oxygen species 
are essential for autophagy and specifically regulate the activity of Atg4. EMBO J 26:1749-
1760, 2007. 
Biasi 
89 
 
224. Schlee M, Harder J, Köten B, Stange EF, Wehkamp J, and Fellermann K. Probiotic lactobacilli 
and VSL#3 induce enterocyte beta-defensin 2. Clin Exp Immunol 151: 528-535, 2008. 
225. Seidelin JB and Nielsen OH. Continuous cytokine exposure of colonic epithelial cells induces 
DNA damage. Eur J Gastroenterol Hepatol 17: 363-369, 2005. 
226. Serhan CN. The resolution of inflammation: the devil in the flask and in the details. FASEB J  25: 1441-
1448, 2011. 
227. Serhan CN and Savill J. Resolution of inflammation: the beginning programs the end. Nat Immunol 6: 
1191-1197, 2005. 
228. Serhan CN, Clish CB, Brannon J, Colgan SP, Chiang N, and Gronert K. Novel functional sets 
of lipid-derived mediators with antiinflammatory actions generated from omega-3 fatty acids 
via cyclooxygenase 2-nonsteroidal antiinflammatory drugs and transcellular processing. J Exp 
Med 192: 1197-1204, 2000. 
229. Seth RB, Sun L, Ea CK, and Chen ZJ. Identification and characterization of MAVS, a 
mitochondrial antiviral signaling protein that activates NF-kappaB and IRF 3. Cell 122: 669-
682, 2005. 
230. Sharma A and Qadri A. Vi polysaccharide of Salmonella typhi targets the prohibitin family of 
molecules in intestinal epithelial cells and suppresses early inflammatory responses. Proc Natl 
Acad Sci U S A 101: 17492-17497, 2004. 
231. Sheng YH, Hasnain SZ, Florin TH and McGuckin MA. Mucins in inflammatory bowel diseases 
and colorectal cancer. J Gastroenterol Hepatol  27: 28-38, 2012. 
232. Shibata W, Maeda S, Hikiba Y, Yanai A, Ohmae T, Sakamoto K, Nakagawa H, Ogura K, and 
Omata M. Cutting edge: The IkappaB kinase (IKK) inhibitor, NEMO-binding domain peptide, 
blocks inflammatory injury in murine colitis. J Immunol 179: 2681-2685, 2007. 
233. Shimozawa M, Naito Y, Manabe H, Uchiyama K, Kuroda M, Katada K, Yoshida N, and 
Yoshikawa T. 7-Ketocholesterol enhances the expression of adhesion molecules on human 
aortic endothelial cells by increasing the production of reactive oxygen species. Redox Rep 9: 
370-375, 2004. 
Biasi 
90 
 
234. Sido B, Hack V, Hochlehnert A, Lipps H, Herfarth C, and Dröge W. Impairment of intestinal 
glutathione synthesis in patients with inflammatory bowel disease. Gut 42: 485-492, 1998. 
235. Siegmund B, Fantuzzi G, Rieder F, Gamboni-Robertson F, Lehr HA, Hartmann G, Dinarello 
CA, Endres S, and Eigler A. Neutralization of interleukin-18 reduces severity in murine colitis 
and intestinal IFN-gamma and TNF-alpha production. Am J Physiol Regul Integr Comp Physiol 
281: R1264-R1273, 2001. 
236. Silverberg MS, Cho JH, Rioux JD, McGovern DP, Wu J, Annese V, Achkar JP, Goyette P, 
Scott R, Xu W, Barmada MM, Klei L, Daly MJ, Abraham C, Bayless TM, Bossa F, Griffiths 
AM, Ippoliti AF, Lahaie RG, Latiano A, Paré P, Proctor DD, Regueiro MD, Steinhart AH, 
Targan SR, Schumm LP, Kistner EO, Lee AT, Gregersen PK, Rotter JI, Brant SR, Taylor KD, 
Roeder K, and Duerr RH. Ulcerative colitis-risk loci on chromosomes 1p36 and 12q15 found 
by genome-wide association study. Nat Genet 41: 216-220, 2009. 
237. Slavova N, Drescher A, Visekruna A, Dullat S, Kroesen AJ, Ritz JP, and Buhr HJ. NALP 
expression in Paneth cells provides a novel track in IBD signaling. Langenbecks Arch Surg 
395: 351-357, 2010. 
238. Song YA, Park YL, Yoon SH, Kim KY, Cho SB, Lee WS, Chung IJ, and Joo YE. Black tea 
polyphenol theaflavin suppresses LPS-induced ICAM-1 and VCAM-1 expression via blockage 
of NF-κB and JNK activation in intestinal epithelial cells. Inflamm Res 60: 493-500, 2011. 
239. Sono K, Yamada A, Yoshimatsu Y, Takada N, and Suzuki Y. Factors associated with the loss 
of response to infliximab in patients with Crohn's disease. Cytokine 59: 410-416, 2012. 
240. Sorbara MT and Girardin SE. Mitochondrial ROS fuel the inflammasome. Cell Res 21: 558-
560, 2011. 
241. Sottero B, Gamba P, Gargiulo S, Leonarduzzi G, and Poli G. Cholesterol oxidation products 
and disease: an emerging topic of interest in medicinal chemistry. Curr Med Chem 16: 685-705, 
2009. 
Biasi 
91 
 
242. Sripathi SR, He W, Atkinson CL, Smith JJ, Liu Z, Elledge BM,  and Jahng WJ. Mitochondrial-
nuclear communication by prohibitin shuttling under oxidative stress. Biochemistry 50: 8342-
8351, 2011. 
243. Stables MJ and Gilroy DW. Old and new generation lipid mediators in acute inflammation and 
resolution. Prog Lipid Res 50: 35-51, 2011. 
244. Steglich G, Neupert W, and Langer T. Prohibitins regulate membrane protein degradation by 
the m-AAA protease in mitochondria. Mol Cell Biol 19: 3435-3442, 1999. 
245. Sung SC, Kim K, Lee KA, Choi KH, Kim SM, Son YH, Moon YS, Eo SK, and Rhim BY. 7-
Ketocholesterol upregulates interleukin-6 via mechanisms that are distinct from those of tumor 
necrosis factor-alpha, in vascular smooth muscle cells. J Vasc Res 46: 36-44, 2009. 
246. Surh J, Lee S, and Kwon H. 4-hydroxy-2-alkenals in polyunsaturated fatty acids-fortified infant 
formulas and other commercial food products. Food Addit Contam 24: 1209-1218, 2007. 
247. Suzuki K, Sugimura K, Hasegawa K, Yoshida K, Suzuki A, Ishizuka K, Ohtsuka K, Honma T, 
Narisawa R, and Asakura H. Activated platelets in ulcerative colitis enhance the production of 
reactive oxygen species by polymorphonuclear leukocytes. Scand J Gastroenterol 36: 1301-
1306, 2001. 
248. Szanto I, Rubbia-Brandt L, Kiss P, Steger K, Banfi B, Kovari E, Herrmann F, Hadengue A, and 
Krause KH. Expression of NOX1, a superoxide-generating NADPH oxidase, in colon cancer 
and inflammatory bowel disease. J Pathol 207: 164-176, 2005. 
249. Tai EK, Wu WK, Wong HP, Lam EK, Yu L, and Cho CH. A new role for cathelicidin in 
ulcerative colitis in mice. Exp Biol Med (Maywood) 232: 799-808, 2007. 
250. Takagi S, Utsunomiya K, Kuriyama S, Yokoyama H, Takahashi S, Iwabuchi M, Takahashi H, 
Takahashi S, Kinouchi Y, Hiwatashi N, Funayama Y, Sasaki I, Tsuji I, and Shimosegawa T. 
Effectiveness of an 'half elemental diet' as maintenance therapy for Crohn's disease: A 
randomized-controlled trial. Aliment Pharmacol Ther 24: 1333-1340, 2006. 
Biasi 
92 
 
251. Takahashi Y, Masuda H, Ishii Y, Nishida Y, Kobayashi M, and Asai S. Decreased expression 
of thioredoxin interacting protein mRNA in inflamed colonic mucosa in patients with ulcerative 
colitis. Oncol Rep 18:531-535, 2007. 
252. Tamaki H, Nakamura H, Nishio A, Nakase H, Ueno S, Uza N, Kido M, Inoue S, Mikami S, 
Asada M, Kiriya K, Kitamura H, Ohashi S, Fukui T, Kawasaki K, Matsuura M, Ishii Y, 
Okazaki K, Yodoi J, and Chiba T. Human thioredoxin-1 ameliorates experimental murine 
colitis in association with suppressed macrophage inhibitory factor production. 
Gastroenterology 131: 1110-1121, 2006. 
253. Tardieu D, Jaeg JP, Cadet J, Embvani E, Corpet DE, and Petit C. Dextran sulfate enhances the 
level of an oxidative DNA damage biomarker, 8-oxo-7,8-dihydro-2'-deoxyguanosine, in rat 
colonic mucosa. Cancer Lett 134: 1-5, 1998. 
254. Tardieu D, Jaeg JP, Deloly A, Corpet DE, Cadet J, and Petit CR. The COX-2 inhibitor 
nimesulide suppresses superoxide and 8-hydroxy-deoxyguanosine formation, and stimulates 
apoptosis in mucosa during early colonic inflammation in rats. Carcinogenesis 21: 973-976, 
2000. 
255. Targan SR and Karp LC. Defects in mucosal immunity leading to ulcerative colitis. Immunol 
Rev 206: 296-305, 2005. 
256. te Velde AA, Pronk I, de Kort F, and Stokkers PCF. Glutathione peroxidase 2 and aquaporin 8 
as new markers for colonic inflammation in experimental colitis and inflammatory bowel 
diseases: an important role for H2O2? Eur J Gastroenterol Hepatol 20: 555-560, 2008. 
257. Tebbutt NC, Giraud AS, Inglese M, Jenkins B, Waring P, Clay FJ, Malki S, Alderman BM, 
Grail D, Hollande F, Heath JK, and Ernst M. Reciprocal regulation of gastrointestinal 
homeostasis by SHP2 and STAT-mediated trefoil gene activation in gp130 mutant mice. Nat 
Med 8: 1089-1097, 2002. 
258. Teng X, Xu LF, Zhou P, Sun HW, and Sun M. Effects of trefoil peptide 3 on expression of 
TNF-alpha, TLR4, and NF-kappaB in trinitrobenzene sulphonic acid induced colitis mice. 
Inflammation 32: 120-129, 2009. 
Biasi 
93 
 
259. Theiss AL and Sitaraman SV. The role and therapeutic potential of prohibitin in disease. 
Biochim Biophys Acta 1813: 1137-1143, 2011. 
260. Theiss AL, Idell RD, Srinivasan S, Klapproth JM, Jones DP, Merlin D, and Sitaraman SV. 
Prohibitin protects against oxidative stress in intestinal epithelial cells. FASEB J 21: 197-206, 
2007. 
261. Theiss AL, Obertone TS, Merlin D, and Sitaraman SV. Interleukin-6 transcriptionally regulates 
prohibitin expression in intestinal epithelial cells. J Biol Chem 282: 12804-12812, 2007. 
262. Theiss AL, Jenkins AK, Okoro NI, Klapproth JM, Merlin D, and Sitaraman SV. Prohibitin 
inhibits tumor necrosis factor alpha-induced nuclear factor-kappa B nuclear translocation via 
the novel mechanism of decreasing importin alpha3 expression. Mol Biol Cell 20: 4412-4423, 
2009. 
263. Theiss AL, Vijay-Kumar M, Obertone TS, Jones DP, Hansen JM, Gewirtz AT, Merlin D, and 
Sitaraman SV. Prohibitin is a novel regulator of antioxidant response that attenuates colonic 
inflammation in mice. Gastroenterology 137: 199-208, 2009. 
264. Theiss AL, Laroui H, Obertone TS, Chowdhury I, Thompson WE, Merlin D, and Sitaraman 
SV. Nanoparticle-based therapeutic delivery of prohibitin to the colonic epithelial cells 
ameliorates acute murine colitis. Inflamm Bowel Dis 17: 1163-1176, 2011. 
265. Thiele K, Bierhaus A, Autschbach F, Hofmann M, Stremmel W, Thiele H, Ziegler R, and 
Nawroth PP. Cell specific effects of glucocorticoid treatment on the NF-
kappaBp65/IkappaBalpha system in patients with Crohn's disease. Gut 45: 693-704, 1999. 
266. Thimmulappa R, Lee H, Rangasamy T, Reddy S, Yamamoto M, Kensler T, and Biswal S. Nrf2 
is a critical regulator of the innate immune response and survival during experimental sepsis. J 
Clin Invest 116: 984-995, 2006.  
267. Tong Y, Yamaguchi H, Giaime E, Boyle S, Kopan R, Kelleher RJ 3rd, and Shen J. Loss of 
leucine-rich repeat kinase 2 causes impairment of protein degradation pathways, accumulation 
of alpha-synuclein, and apoptotic cell death in aged mice. Proc Natl Acad Sci U S A 107: 9879-
9884, 2010. 
Biasi 
94 
 
268. Toruner M, Loftus EV Jr, Harmsen WS, Zinsmeister AR, Orenstein R, Sandborn WJ, Colombel 
JF, and Egan LJ. Risk factors for opportunistic infections in patients with inflammatory bowel 
disease. Gastroenterology 134: 929-936, 2008. 
269. Ullman TA and Itzkowitz SH. Intestinal inflammation and cancer. Gastroenterology 140: 
1807–1816, 2011. 
270. Van der Sluis M, De Koning BA, De Bruijn AC, Velcich A, Meijerink JP, Van Goudoever JB, 
Büller HA, Dekker J, Van Seuningen I, Renes IB, and Einerhand AW. Muc2-deficient mice 
spontaneously develop colitis, indicating that MUC2 is critical for colonic protection. 
Gastroenterology 131: 117-129, 2006. 
271. Van Limbergen J, Russell RK, Nimmo ER, and Satsangi J. The genetics of inflammatory bowel 
disease. Am J Gastroenterol 102: 2820-2831, 2007. 
272. Vetrano S, Rescigno M, Cera MR, Correale C, Rumio C, Doni A, Fantini M, Sturm A, Borroni 
E, Repici A, Locati M, Malesci A, Dejana E, and Danese S. Unique role of junctional adhesion 
molecule-a in maintaining mucosal homeostasis in inflammatory bowel disease. 
Gastroenterology 135: 173-184, 2008.  
273. Villani AC, Lemire M, Fortin G, Louis E, Silverberg MS, Collette C, Baba N, Libioulle C, 
Belaiche J, Bitton A, Gaudet D, Cohen A, Langelier D, Fortin PR, Wither JE, Sarfati M, 
Rutgeerts P, Rioux JD, Vermeire S, Hudson TJ, and Franchimont D. Common variants in the 
NLRP3 region contribute to Crohn's disease susceptibility. Nat Genet 41: 71-76, 2009. 
274. Visekruna A, Joeris T, Seidel D, Kroesen A, Loddenkemper C, Zeitz M, Kaufmann SH, 
Schmidt-Ullrich R, and Steinhoff U. Proteasome-mediated degradation of IkappaBalpha and 
processing of p105 in Crohn disease and ulcerative colitis. J Clin Invest 116: 3195-3203, 2006. 
275. Vladykovskaya E, Ozhegov E, Hoetker JD, Xie Z, Ahmed Y, Suttles J, Srivastava S, Bhatnagar 
A,  and Barski OA. Reductive metabolism increases the proinflammatory activity of aldehyde 
phospholipids. J Lipid Res 52: 2209-2225, 2011. 
Biasi 
95 
 
276. Vong L, Ferraz JG, Dufton N, Panaccione R, Beck PL, Sherman PM, Perretti M, and Wallace 
JL. Up-regulation of annexin-A1 and lipoxin a(4) in individuals with ulcerative colitis may 
promote mucosal homeostasis. PLoS One 7: e39244, 2012.  
277. Vora P, Youdim A, Thomas LS, Fukata M, Tesfay SY, Lukasek K, Michelsen KS, Wada A, 
Hirayama T, Arditi M, and Abreu MT. Beta-defensin-2 expression is regulated by TLR 
signaling in intestinal epithelial cells. J Immunol 173: 5398-5405, 2004.  
278. Voss E, Wehkamp J, Wehkamp K, Stange EF, Schröder JM, and Harder J. NOD2/CARD15 
mediates induction of the antimicrobial peptide human beta-defensin-2. J Biol Chem 281: 2005-
2011, 2006.  
279. Walter E Cromer, J Michael Mathis, Daniel N Granger, Ganta V Chaitanya, and J Steven 
Alexander. Role of the endothelium in inflammatory bowel diseases. World J Gastroenterol 17: 
578-593, 2011. 
280. Wang K, Zhang H, Kugathasan S, Annese V, Bradfield JP, Russell RK, Sleiman PM, 
Imielinski M, Glessner J, Hou C, Wilson DC, Walters T, Kim C, Frackelton EC, Lionetti P, 
Barabino A, Van Limbergen J, Guthery S, Denson L, Piccoli D, Li M, Dubinsky M, Silverberg 
M, Griffiths A, Grant SF, Satsangi J, Baldassano R, and Hakonarson H. Diverse genome-wide 
association studies associate the IL12/IL23 pathway with Crohn Disease. Am J Hum Genet 84: 
399-405, 2009. 
281. Wang Y and Bogenhagen DF. Human mitochondrial DNA nucleoids are linked to protein 
folding machinery and metabolic enzymes at the mitochondrial inner membrane. J Biol Chem 
281: 25791-25802, 2006. 
282. Weber CK, Liptay S, Wirth T, Adler G, and Schmid RM. Suppression of NF-kappaB activity by 
sulfasalazine is mediated by direct inhibition of IkappaB kinases alpha and beta. 
Gastroenterology 119: 1209-1218, 2000. 
283. Wehkamp J, Salzman NH, Porter E, Nuding S, Weichenthal M, Petras RE, Shen B, Schaeffeler 
E, Schwab M, Linzmeier R, Feathers RW, Chu H, Lima H Jr, Fellermann K, Ganz T, Stange 
Biasi 
96 
 
EF, and Bevins CL. Reduced Paneth cell alpha-defensins in ileal Crohn’s disease. Proc Natl 
Acad Sci U S A 102: 18129-18134, 2005. 
284. Wehkamp J, Schmid M, Fellermann K, and Stange EF. Defensin deficiency, intestinal 
microbes, and the clinical phenotypes of Crohn's disease. J Leukoc Biol 77: 460-465, 2005. 
285. Wells JM, Rossi O, Meijerink M, and van Baarlen P. Epithelial crosstalk at the microbiota-
mucosal interface. Proc Natl Acad Sci U S A 108: 4607-4614, 2011. 
286. West AP, Brodsky IE, Rahner C, Woo DK, Erdjument-Bromage H, Tempst P, Walsh MC, Choi 
Y, Shadel GS, and Ghosh S. TLR signalling augments macrophage bactericidal activity through 
mitochondrial ROS. Nature 472: 476-480, 2011. 
287. Weylandt KH, Kang JX, Wiedenmann B, and Baumgart DC. Lipoxins and resolvins in 
inflammatory bowel disease. Inflamm Bowel Dis 13: 797-799, 2007. 
288. Wullaert A, Bonnet MC, and Pasparakis M. NF-κB in the regulation of epithelial homeostasis 
and inflammation. Cell Res 21: 146-158, 2011. 
289. Xu Y, Jagannath C, Liu XD, Sharafkhaneh A, Kolodziejska KE, and Eissa NT. Toll-like 
receptor 4 is a sensor for autophagy associated with innate immunity. Immunity 27: 135-144, 
2007. 
290. Yamamoto M, Sato S, Mori K, Hoshino K, Takeuchi O, Takeda K, and Akira S. Cutting edge: 
a novel Toll/IL-1 receptor domain-containing adapter that preferentially activates the IFN-beta 
promoter in the Toll-like receptor signaling. J Immunol 169: 6668-6672, 2002.  
291. Yamamoto-Furusho JK, Santiago-Hernández JJ, Pérez-Hernández N, Ramírez-Fuentes S, 
Fragoso JM, and Vargas-Alarcón G. Interleukin 1 β (IL-1B) and IL-1 antagonist receptor (IL-
1RN) gene polymorphisms are associated with the genetic susceptibility and steroid 
dependence in patients with ulcerative colitis. J Clin Gastroenterol 45: 531-535, 2011. 
292. Ye D and Ma TY. Cellular and molecular mechanisms that mediate basal and tumour necrosis 
factor-alpha-induced regulation of myosin light chain kinase gene activity. J Cell Mol Med 12: 
1331-1346, 2008. 
Biasi 
97 
 
293. Yoshida H, Russell J, Senchenkova EY, Almeida Paula LD, and Granger DN. Interleukin-1beta 
mediates the extra-intestinal thrombosis associated with experimental colitis. Am J Pathol 177: 
2774-2781, 2010. 
294. You Y, Fu JJ, Meng J, Huang GD, and Liu YH.  Effect of N-acetylcysteine on the murine 
model of colitis induced by dextran sodium sulfate through up-regulating PON1 activity. Dig 
Dis Sci 54: 1643-1650, 2009. 
295. Yu QT, Saruta M, Avanesyan A, Fleshner PR, Banham AH, and Papadakis KA. Expression and 
functional characterization of FOXP3+ CD4+ regulatory T cells in ulcerative colitis. Inflamm 
Bowel Dis 13: 191-199, 2007. 
296. Zaki MH, Boyd KL, Vogel P, Kastan MB, Lamkanfi M, and Kanneganti TD. The NLRP3 
inflammasome protects against loss of epithelial integrity and mortality during experimental 
colitis. Immunity 32: 379-391, 2010. 
297. Zhou L, Lopes JE, Chong MM, Ivanov II, Min R, Victora GD, Shen Y, Du J, Rubtsov YP, 
Rudensky AY, Ziegler SF, and Littman DR. TGF-beta-induced Foxp3 inhibits T(H)17 cell 
differentiation by antagonizing RORgammat function. Nature 453: 236-240, 2008.  
298. Zhou R, Tardivel A, Thorens B, Choi I, and Tschopp J. Thioredoxin-interacting protein links 
oxidative stress to inflammasome activation. Nat Immunol 11: 136-140, 2010. 
299. Zhou R, Yazdi AS, Menu P, and Tschopp J. A role for mitochondria in NLRP3 inflammasome 
activation. Nature 469: 221-225, 2011. 
300. Zhu LJ, Landolt-Marticorena C, Li T, Yang X, Yu XQ, Gladman DD, Urowitz MB, Fortin PR, 
and Wither JE. Altered expression of TNF-alpha signaling pathway proteins in systemic lupus 
erythematosus. J Rheumatol 37: 1658-1666, 2010. 
 
Biasi 
98 
 
 
Table 1. Antioxidant status in human IBD patients. 
 
Antioxidant enzymes/molecules whose activity/levels decrease with the severity of IBD  
Molecule    Localization   Reference 
Reduced glutathione  intestinal mucosa      234  
Superoxide dismutase-1 intestinal mucosa      132  
Superoxide dismutase-1 red cells       136 
Catalase   red cells       136  
Glutathione-peroxidase-1 red cells       136 
Glutathione-peroxidase-2 intestinal mucosa      256  
Carotenoids   plasma          93  
Vitamin C   plasma          93  
 
Antioxidant enzymes/molecules whose activity/levels increase with the severity of IBD 
Thioredoxin    intestinal mucosa     252 
Aquaporin    intestinal mucosa     256  
Biasi 
99 
 
Table 2. Enhanced synthesis of inflammatory cytokines, chemokines and adhesion molecules, 
induced by lipid oxidation products relevant to IBD progression. 
Lipid oxidation  Cell type      Induced molecule/s  Reference    
product/s 
 
7K macrophages   IL-1     157  
7K, 7-OH macrophages   IL-8    155  
 
7K endothelial cells  adhesion molecules  233  
7K/7-, 7-OH endothelial cells  adhesion molecules/IL-1 146 
      
7-OH endothelial cells  MCP-1    148  
 
7K smooth muscle cells IL-6    245  
 
7-OH colon epithelial cells IL-8    163  
        
HNE macrophages   TGF1    147  
HNE  macrophages  MCP-1    189  
 
Ox-PLs macrophages  VEGF/IL-8/COX-2      29  
Ox-PLs macrophages GM-CSF/IL-1β,            275  
IL-6/IL-8/MCP-1/TNFα     
________________________________________________________________________________ 
7K: 7-ketocholesterol; 7-OH: 7α-hydroxycholesterol; 7-OH: 7β-hydroxycholesterol;  
HNE: 4-hydroxynonenal; Ox-PLs: oxidized phospholipids; IL: interleukin; TGF1: transforming 
growth factor beta1; MCP-1: monocyte chemotactic protein-1; MIP-1: Macrophage inflammatory 
protein 1; VEGF: vascular endothelial growth factor; COX-2: cyclooxygenase-2; GM-CSF: 
Granulocyte-macrophage colony-stimulating factor; TNFα: Tumor necrosis factor-alpha. 
Biasi 
100 
 
Legends to Figures 
 
Figure 1. Inappropriate response of the mucosa-associated immune system to commensal and 
pathogenic microbiota in IBD. NLRs: NOD-like receptors recognizing bacteria-derived 
peptidoglycan; TLRs: Toll-like receptors recognizing bacteria-derived lipopolysaccharide, flagellin or 
unmethylated CpG. 
 
Figure 2. Cell types involved in Ulcerative Colitis 
EC: endothelial cell; IEC: intestinal epithelial cells; iL: intraepithelial lymphocyte; M: macrophage; 
PMN: polymorphonuclear cells; Th: T helper lymphocyte. To see this illustration in color the reader is 
referred to the web version of this article at www.liebertonline.com/ars 
 
Figure 3. Cell types involved in Crohn’s disease 
DC: dendritic cell; EC: endothelial cell; GC: goblet cell; MC: Microfold cell; PC: Paneth cell; Th: T 
helper lymphocyte. To see this illustration in color the reader is referred to the web version of this 
article at www.liebertonline.com/ars 
 
Figure 4. Histological evidence of Crohn’s disease in colonic biopsy.  
Diffuse inflammation involves the greater part of the tissue section. Giant cells, histiocytes and a large 
number of intraepithelial lymphocytes are present. Glands appear normal but hyperplastic. 
The specimen was stained with Hematoylin and Eosin (20X magnification) and viewed using a 
microscope equipped with a LEICA Photocamera. To see this illustration in color the reader is 
referred to the web version of this article at www.liebertonline.com/ars 
 
Figure 5. Primary contribution of the pleiotropic cytokine TGFβ1 to the chronicization of IBD 
process.  
Reactive oxygen species, as well as lipid oxidation products such as oxysterols and HNE, contribute 
to regulate the activity of TGFβ1. This cytokine is a crucial molecule produced during inflammatory 
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reactions. TGFβ1 is the “crossroads” for cell fate: it is responsible for enterocyte differentiation and 
aging, with consequent induction of cell death. In parallel, it also activates intestinal wound healing, 
inducing angiogenesis and fibrosis, this last mainly involved in Crohn’s disease pathogenesis. 
L
.
: lipid radical; LO
.
: alkoxy radical; LOO
.
:
 
peroxy radical; H2O2: hydrogen peroxide; O2
-.
: 
superoxide; HNE: 4-hydroxynonenal. 
 
Figure 6. Intracellular production of reactive oxygen species in intestinal epithelial cells. 
ROS production was visualized in colon intestinal CaCo-2 cells using the fluorescent probe 2’,7’-
dichlorofluorescein derived from the cleavage and oxidation of its reduced form, dichlorofluorescin. 
The fluorescence, shown in green, was monitored directly by laser scanning confocal microscopy 
(microscope Zeiss LSM 510, Carl Zeiss SpA, Arese, Milan, Italy) equipped with a plan neofluar lens 
20×/0.75. A: untreated cells; B: CaCo-2 cells treated with 1 mM H2O2. To see this illustration in color 
the reader is referred to the web version of this article at www.liebertonline.com/ars 
 
Figure 7. Role of oxysterols in regulating cell signaling pathways related to oxidative reactions.  
Among various signaling pathways induced by oxysterols, the activation of Ca
2+
-dependent 
phospholipase A2, followed by arachidonic acid release and NADPH oxidase up-regulation, has been 
hypothesized. The consequent ROS generation induces a complex network of cellular signals, which 
can lead to inflammation through NF-B or to cell death by activating mitochondrial apoptotic 
pathway.  
Plase A2: phospholipase A2; AA: arachidonic acid; PYK2: proline-rich tyrosine kinase 2; PKC: 
protein kinase C; ERK1,2: extracellular signal-regulated kinase1,2; ROS: reactive oxygen species; 
NF-B: nuclear factor kappaB; Bim:  Bcl-2 interacting mediator of cell death;  Bad: Bcl-xL/Bcl-2 
associated death promoter. 
 
Figure 8. IL-1β induction in enterocytes stimulated with oxysterols. 
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Stimulation of CaCo-2 enterocyte-like cells with a mixture of dietary oxysterols comprising: 42.96% 
7-ketocholesterol, 32.3% 5α,6α-epoxycholesterol, 5.76% 5β,6β-epoxycholesterol, 4.26% 7α-
hydroxycholesterol, 14.71% 7β-hydroxycholesterol. A: untreated cells; B: oxysterol-treated cells. 
IL-1β production was detected by red immunefluorescence, using a confocal microscope Zeiss  LSM  
510 (Carl Zeiss SpA, Arese, Milan, Italy ) with a plan neofluar lens 40×/0.5. To see this illustration in 
color the reader is referred to the web version of this article at www.liebertonline.com/ars 
 
Figure 9. NF-kB target genes likely implicated in the development of IBD.  
IL: interleukin; TNF: tumor necrosis factor; ICAM: intercellular adhesion molecule; VCAM: vascular 
cell adhesion molecule; MCP-1: monocyte chemotactic protein-1; MIP-1: macrophage inflammatory 
protein 1; RANTES: regulated upon activation, normal T cell expressed and secreted;  
PDGF: platelet-derived growth factor; EGF: epidermal growth factor; IAP: inhibitor of apoptosis, 
FLIP: flice-like inhibitory protein; MLCK: myosin light-chain kinase; VEGF: vascular endothelial 
growth factor; TGFβ1, transforming growth factor β1; MMP: metalloproteinases; COX-2: 
cycloxygenase-2; MnSOD: manganese superoxide dismutase; iNOS: inducible nitric oxide synthase. 
 
Figure 10. Current therapeutic approaches to IBD 
 
Figure 11. Main cellular sites of production of reactive oxygen species targeted by IBD therapy. 
Membrane NADPH oxidase (NOX) and mitochondria are the two main sources of ROS generation, 
which target pathogen recognition pathways and activate the inflammatory response mediated by NF-
kB activation. The use of molecules to control oxidative and inflammatory reactions by interfering in 
different ROS production sites is the most probable future approach to treating IBD, or at least 
delaying its progression. 
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